NZ619873B2 - Methods and compositions for treating asthma using anti-il-13 antibodies - Google Patents
Methods and compositions for treating asthma using anti-il-13 antibodies Download PDFInfo
- Publication number
- NZ619873B2 NZ619873B2 NZ619873A NZ61987312A NZ619873B2 NZ 619873 B2 NZ619873 B2 NZ 619873B2 NZ 619873 A NZ619873 A NZ 619873A NZ 61987312 A NZ61987312 A NZ 61987312A NZ 619873 B2 NZ619873 B2 NZ 619873B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- antigen
- binding portion
- dose
- seq
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract description 578
- 108090001123 antibodies Proteins 0.000 title claims abstract description 578
- 239000000203 mixture Substances 0.000 title claims abstract description 147
- 208000006673 Asthma Diseases 0.000 title claims description 171
- 230000027455 binding Effects 0.000 claims abstract description 323
- 239000000427 antigen Substances 0.000 claims abstract description 282
- 102000038129 antigens Human genes 0.000 claims abstract description 281
- 108091007172 antigens Proteins 0.000 claims abstract description 281
- 230000000275 pharmacokinetic Effects 0.000 claims abstract description 64
- 230000001747 exhibiting Effects 0.000 claims abstract description 28
- 241000282414 Homo sapiens Species 0.000 claims description 139
- 239000003814 drug Substances 0.000 claims description 126
- 230000037242 Cmax Effects 0.000 claims description 100
- 238000001990 intravenous administration Methods 0.000 claims description 71
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 238000007920 subcutaneous administration Methods 0.000 claims description 49
- 102000018358 Immunoglobulins Human genes 0.000 claims description 41
- 108060003951 Immunoglobulins Proteins 0.000 claims description 41
- 229940079593 drugs Drugs 0.000 claims description 37
- 210000002966 Serum Anatomy 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 34
- 230000035700 Clearance Rate Effects 0.000 claims description 29
- 230000003042 antagnostic Effects 0.000 claims description 28
- 230000035513 volume of distribution Effects 0.000 claims description 28
- 239000005557 antagonist Substances 0.000 claims description 26
- 230000035852 Tmax Effects 0.000 claims description 24
- 230000003442 weekly Effects 0.000 claims description 22
- 230000036499 Half live Effects 0.000 claims description 20
- 230000036912 Bioavailability Effects 0.000 claims description 18
- 230000035514 bioavailability Effects 0.000 claims description 18
- 230000037165 Serum Concentration Effects 0.000 claims description 17
- 239000003246 corticosteroid Substances 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 16
- 230000001809 detectable Effects 0.000 claims description 15
- 150000003431 steroids Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 12
- 239000002254 cytotoxic agent Substances 0.000 claims description 10
- 238000002649 immunization Methods 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
- 238000010606 normalization Methods 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 7
- 239000003589 local anesthetic agent Substances 0.000 claims description 7
- 229960000485 methotrexate Drugs 0.000 claims description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 7
- 229960002930 sirolimus Drugs 0.000 claims description 7
- 230000003444 anaesthetic Effects 0.000 claims description 6
- 230000002682 anti-psoriatic Effects 0.000 claims description 6
- 230000000561 anti-psychotic Effects 0.000 claims description 6
- 230000001506 immunosuppresive Effects 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 5
- 108010051696 Growth Hormone Proteins 0.000 claims description 5
- 229940088597 Hormone Drugs 0.000 claims description 5
- 239000003263 anabolic agent Substances 0.000 claims description 5
- 230000000202 analgesic Effects 0.000 claims description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 5
- 229940121369 angiogenesis inhibitors Drugs 0.000 claims description 5
- 230000003092 anti-cytokine Effects 0.000 claims description 5
- 230000000845 anti-microbial Effects 0.000 claims description 5
- 230000003356 anti-rheumatic Effects 0.000 claims description 5
- 239000003435 antirheumatic agent Substances 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 239000000430 cytokine receptor antagonist Substances 0.000 claims description 5
- 229960005139 epinephrine Drugs 0.000 claims description 5
- 239000000122 growth hormone Substances 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 239000003158 myorelaxant agent Substances 0.000 claims description 5
- 230000003533 narcotic Effects 0.000 claims description 5
- 239000012217 radiopharmaceutical Substances 0.000 claims description 5
- 230000002799 radiopharmaceutical Effects 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 230000001430 anti-depressive Effects 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 4
- 230000001624 sedative Effects 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 229940035295 Ting Drugs 0.000 claims description 3
- 239000000842 neuromuscular blocking agent Substances 0.000 claims description 3
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- 210000003205 Muscles Anatomy 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 99
- 230000035492 administration Effects 0.000 description 72
- 201000010099 disease Diseases 0.000 description 55
- 230000000694 effects Effects 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 49
- -1 166Ho Chemical compound 0.000 description 38
- 239000000902 placebo Substances 0.000 description 35
- 229940068196 placebo Drugs 0.000 description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 34
- 238000000034 method Methods 0.000 description 32
- 102000024070 binding proteins Human genes 0.000 description 31
- 108091007650 binding proteins Proteins 0.000 description 31
- 229920001184 polypeptide Polymers 0.000 description 31
- 102000019207 human interleukin-13 Human genes 0.000 description 30
- 108091018136 human interleukin-13 Proteins 0.000 description 30
- 150000002500 ions Chemical class 0.000 description 30
- 230000001225 therapeutic Effects 0.000 description 29
- 101710038213 AKR1C4 Proteins 0.000 description 28
- 101700073818 CDR1 Proteins 0.000 description 28
- 102100009178 RUNX1T1 Human genes 0.000 description 28
- 101710034060 RUNX1T1 Proteins 0.000 description 28
- 230000003899 glycosylation Effects 0.000 description 27
- 238000006206 glycosylation reaction Methods 0.000 description 27
- 238000001802 infusion Methods 0.000 description 27
- 210000004408 Hybridomas Anatomy 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 238000004166 bioassay Methods 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 210000004369 Blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 238000001647 drug administration Methods 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 108010045030 monoclonal antibodies Proteins 0.000 description 15
- 102000005614 monoclonal antibodies Human genes 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000894007 species Species 0.000 description 14
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000002685 pulmonary Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000035693 Fab Effects 0.000 description 10
- 102100009534 TNF Human genes 0.000 description 10
- 101710040537 TNF Proteins 0.000 description 10
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000004602 germ cell Anatomy 0.000 description 10
- 230000000051 modifying Effects 0.000 description 10
- 229960000060 monoclonal antibodies Drugs 0.000 description 10
- 230000003472 neutralizing Effects 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 201000008937 atopic dermatitis Diseases 0.000 description 9
- 108091006028 chimera Proteins 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000036231 pharmacokinetics Effects 0.000 description 9
- 229920000023 polynucleotide Polymers 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 230000002459 sustained Effects 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 8
- 229960001334 Corticosteroids Drugs 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000000069 prophylaxis Effects 0.000 description 8
- 238000003259 recombinant expression Methods 0.000 description 8
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 8
- 210000004072 Lung Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000001131 transforming Effects 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 108090001124 Immunoglobulin E Proteins 0.000 description 6
- 229920001850 Nucleic acid sequence Polymers 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000240 adjuvant Effects 0.000 description 6
- 230000001058 adult Effects 0.000 description 6
- 230000001627 detrimental Effects 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- 229940020899 hematological Enzymes Drugs 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000000172 allergic Effects 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 230000013595 protein glycosylation Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000035841 AUCt Effects 0.000 description 4
- 102100019494 CCL17 Human genes 0.000 description 4
- 101700084100 CCL17 Proteins 0.000 description 4
- 230000037250 Clearance Effects 0.000 description 4
- 229920000453 Consensus sequence Polymers 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- 206010014950 Eosinophilia Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 229940102223 Injectable Solution Drugs 0.000 description 4
- 241000229754 Iva xanthiifolia Species 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229960002329 Methacholine Drugs 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 206010038683 Respiratory disease Diseases 0.000 description 4
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 4
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 4
- 206010047924 Wheezing Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002730 additional Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000035512 clearance Effects 0.000 description 4
- 230000000295 complement Effects 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002255 enzymatic Effects 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000003147 glycosyl group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 238000004450 types of analysis Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000003612 virological Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 206010006334 Breathing abnormality Diseases 0.000 description 3
- 102100003729 CD40LG Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 3
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108010002335 Interleukin-9 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 231100000494 adverse effect Toxicity 0.000 description 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091005600 glycosylated proteins Proteins 0.000 description 3
- 102000035362 glycosylated proteins Human genes 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000002818 protein evolution Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 229940023808 Albuterol Drugs 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010071919 Bispecific Antibodies Proteins 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 101700070842 CCR3 Proteins 0.000 description 2
- 102100005861 CCR3 Human genes 0.000 description 2
- 101710003804 CD40LG Proteins 0.000 description 2
- 108060001945 CRK Proteins 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N Chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 101710007887 DHFR Proteins 0.000 description 2
- 102100005838 DHFR Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229920001272 Exogenous DNA Polymers 0.000 description 2
- 102100014838 FCGRT Human genes 0.000 description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 102100008842 GH1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229960002885 Histidine Drugs 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 102000001974 Hyaluronidase Human genes 0.000 description 2
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 description 2
- 102100006815 IL2RA Human genes 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 230000036917 MEAN CMAX Effects 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 2
- 210000003097 Mucus Anatomy 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- 229950010131 PUROMYCIN Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229940055729 Papain Drugs 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 229940071643 Prefilled Syringe Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 210000003802 Sputum Anatomy 0.000 description 2
- 210000001179 Synovial Fluid Anatomy 0.000 description 2
- 101700057652 TYK2 Proteins 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000840 anti-viral Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001082 cryoprotectant Effects 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 230000035510 distribution Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- 230000002538 fungal Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000069 poly(p-phenylene sulfide) Polymers 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory Effects 0.000 description 2
- 231100000817 safety factor Toxicity 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000003248 secreting Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000934 spermatocidal agent Substances 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 229940026754 topical Antivirals Drugs 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- DTYZSEFHBLCMTE-HDIZBSAMSA-N (2R)-2-[[(2S)-6-amino-2-[[(4R)-5-amino-4-[[(2S)-2-[2-[(3R,4R,5S,6R)-3-(carboxyamino)-5-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(2-oxopropyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-5-oxopentanoyl]am Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NC(O)=O)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](CC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DTYZSEFHBLCMTE-HDIZBSAMSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-Diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- 101710039984 9.1 Proteins 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101700043710 ACTPC Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100000269 AIMP2 Human genes 0.000 description 1
- 229940069428 ANTACIDS Drugs 0.000 description 1
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 description 1
- 230000036364 AUCinf Effects 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- 229940090167 Advair Drugs 0.000 description 1
- 206010001584 Alcohol abuse Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010052737 Atopic disease Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 230000036868 Blood Concentration Effects 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N Boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100019487 CCL11 Human genes 0.000 description 1
- 101700074178 CCL11 Proteins 0.000 description 1
- 102100019485 CCL13 Human genes 0.000 description 1
- 101700034979 CCL13 Proteins 0.000 description 1
- 102100016449 CCL5 Human genes 0.000 description 1
- 102100005862 CCR2 Human genes 0.000 description 1
- 101700024589 CCR4 Proteins 0.000 description 1
- 102100019461 CD28 Human genes 0.000 description 1
- 101700033362 CD28 Proteins 0.000 description 1
- 102100013077 CD4 Human genes 0.000 description 1
- 101700022938 CD4 Proteins 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100005832 CD69 Human genes 0.000 description 1
- 101700080416 CD69 Proteins 0.000 description 1
- 102100019451 CD80 Human genes 0.000 description 1
- 101700080477 CD80 Proteins 0.000 description 1
- 102100008191 CD8A Human genes 0.000 description 1
- 101700054655 CD8A Proteins 0.000 description 1
- 108010034751 CDP 571 Proteins 0.000 description 1
- 230000036261 CLT Effects 0.000 description 1
- 101700078818 CNOT6 Proteins 0.000 description 1
- 101700072812 COX2 Proteins 0.000 description 1
- 108060001122 CRTISO Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100002212 CXCR4 Human genes 0.000 description 1
- 101710003734 CXCR4 Proteins 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229950006073 Cotinine Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229940009997 Cromolyn Drugs 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000036472 DOSE NORMALIZED AUC Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229940073621 Enbrel Drugs 0.000 description 1
- 102400000792 Endothelial monocyte-activating polypeptide 2 Human genes 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 101710003421 FGF Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102100010474 GATA3 Human genes 0.000 description 1
- 101700021558 GATA3 Proteins 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 description 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- IUAYMJGZBVDSGL-UHFFFAOYSA-N Gramicidin Chemical compound N1C(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 IUAYMJGZBVDSGL-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108090000065 HIV Antibodies Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 101710002882 IKBKB Proteins 0.000 description 1
- 102100008724 IKBKB Human genes 0.000 description 1
- 102100004549 IL13RA2 Human genes 0.000 description 1
- 101700036616 IL16 Proteins 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 241000188250 Idas Species 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 206010051792 Infusion related reaction Diseases 0.000 description 1
- 206010053483 Infusion site pain Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 229940028885 Interleukin-4 Drugs 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102100002581 KAT5 Human genes 0.000 description 1
- 101700057035 KAT5 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229950002183 Lebrikizumab Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229950007278 Lenercept Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 108009000252 Lung fibrosis Proteins 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 206010061232 Lymphoproliferative disease Diseases 0.000 description 1
- 101710039067 MAP3K8 Proteins 0.000 description 1
- 102100002306 MAP3K8 Human genes 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 102100008860 MAPKAPK2 Human genes 0.000 description 1
- 101710034449 MT-CO2 Proteins 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 230000035750 Mean Tmax Effects 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N Mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 1
- 102100012067 NOCT Human genes 0.000 description 1
- 101700014192 NOCT Proteins 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 108091005503 Nucleic proteins Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 101710029802 PLA2G4A Proteins 0.000 description 1
- 101710040930 PTGS2 Proteins 0.000 description 1
- 102100015381 PTGS2 Human genes 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 108060002038 Pde4 Proteins 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000011587 Polyproteins Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940077718 Proton pump inhibitors for peptic ulcer and GORD Drugs 0.000 description 1
- 230000036028 QTc interval Effects 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 229940120723 Recombinant human hyaluronidase Drugs 0.000 description 1
- 206010057190 Respiratory tract infection Diseases 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 101700021612 STAT6 Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940074404 Sodium succinate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100008333 THY1 Human genes 0.000 description 1
- 101700026084 THY1 Proteins 0.000 description 1
- 102100009538 TNFRSF8 Human genes 0.000 description 1
- 101710040533 TNFRSF8 Proteins 0.000 description 1
- 102100016864 TYK2 Human genes 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229950000835 Tralokinumab Drugs 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229940044953 Vaginal Ring Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 208000000697 Vocal Cord Dysfunction Diseases 0.000 description 1
- 230000036872 Vsst Effects 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- 229940099073 Xolair Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- YYAZJTUGSQOFHG-RZFXJYHSSA-N [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino] Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-RZFXJYHSSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000367 adverse event profile Toxicity 0.000 description 1
- 201000003082 alcohol use disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 108010049535 anti-IgE antibodies Proteins 0.000 description 1
- 230000001458 anti-acid Effects 0.000 description 1
- 230000003510 anti-fibrotic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000002612 cardiopulmonary Effects 0.000 description 1
- 101710014509 celF Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic Effects 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drugs Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L disodium butanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 108010010776 lebrikizumab Proteins 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000032476 lymphotoxin A production Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000001254 nonsecretory Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000003482 proton pump inhibitor Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 230000001359 rheumatologic Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 231100000247 serious adverse effect Toxicity 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000001150 spermicidal Effects 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940065721 systemic for obstructive airway disease Xanthines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 108010037465 tralokinumab Proteins 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 230000001173 tumoral Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
Abstract
Disclosed is an isolated composition comprising an anti-IL-13 antibody, or antigen binding portion thereof, wherein, when administered intravenously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting any of the pharmacokinetic parameters set forth in the specification, Tables or Figures. Also disclosed is an isolated composition comprising an anti-IL-13 antibody, or antigen binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg or 3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting any of the pharmacokinetic parameters set forth in the specification, Tables or Figures. of the pharmacokinetic parameters set forth in the specification, Tables or Figures. Also disclosed is an isolated composition comprising an anti-IL-13 antibody, or antigen binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg or 3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of exhibiting any of the pharmacokinetic parameters set forth in the specification, Tables or Figures.
Description
S AND COMPOSITIONS FOR TREATING ASTHMA USING
ANTI-IL-13 ANTIBODIES
RELATED APPLICATIONS
This application claims priority to US. Provisional Application No. 61/507,347,
filed on July 13, 2011, the entire contents of which are hereby incorporated herein by
nce.
BACKGROUND OF THE INVENTION
Asthma is a c inflammatory disorder of the airways characterized by
wheezing, lessness, chest tightness, and cough. Asthma s approximately 20
million people in the US, and about 75% of asthma patients are adults. Of the adult
asthma patients, approximately 60% of asthma patients have mild disease, about 20%
have moderate disease and the remaining 20% have severe disease.
Interleukin-13 ) is thought to be pivotal in the pathogenesis of human
asthma, in that elevated levels of IL-13 are present in the lungs of asthma patients, and
these levels correlate with disease severity e 1). Likewise, increased IL-13 is
present in both sputum and in lung biopsies of patients with moderate to severe asthma
who are treated with inhaled corticosteroids (ICS) or systemic corticosteroids and
2O continue to be symptomatic. Moreover, human IL-13 genetic polymorphisms are
associated with asthma and atopy (allergic hypersensitivity). IL-13 binds to two
receptors, IL-13R0t1 and IL-13R0t2. IL-13 is a alidated target for asthma as
efficacy has been demonstrated using various means of IL-13 antagonism in multiple,
pre-clinical models of asthma.
Due to the role of human IL-13 in a variety of human disorders, eutic
strategies have been designed to inhibit or counteract IL-13 activity. In particular,
antibodies that bind to, and neutralize, IL-13 have been sought as a means to inhibit IL-13
activity. However, there exists a need in the art for ed antibodies capable of binding IL-
13 for treating asthma.
SUMMARY OF THE INVENTION
The present invention provides methods and compositions for treating asthma, e.g., mild or
moderate , using an anti-IL-13 antibody, or n-binding portion thereof.
ing to a first aspect of the present invention, there is provided use of an isolated
composition sing an anti-IL-13 antibody, or antigen-binding portion thereof, in the
preparation of a medicament for treating asthma in a human subject by intravenous
administration of the antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg,
wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy
chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein, the antibody, or antigen-binding portion thereof, is capable of exhibiting:
(a) an area under the curve (AUC) of between about 1,500 and about 2,700 µgh/ml;
(b) a volume of distribution of between about 65 and 125 mL/kg;
(c) a peak concentration (Cmax) of between about 5 and about 8 µg/ml; and
(d) a clearance rate of n about 0.1 and about 0.2 ml/h/kg.
According to a second aspect of the t invention, there is provided use of an isolated
composition sing an anti-IL-13 antibody, or antigen-binding portion thereof, in the
preparation of a medicament for treating asthma in a human subject by intravenous
administration of the dy, or antigen-binding portion thereof, at a dose of about 3 mg/kg,
wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy
chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein the antibody, or antigen-binding portion thereof, is capable of exhibiting:
(a) an area under the curve (AUC) of n about 21,000 and about 33,500 ;
(b) a volume of distribution of between about 55 and about 100 mL/kg;
(c) a peak concentration (Cmax) of between about 55 and about 90 µg/ml; and
(d) a clearance rate of between about 0.08 and about 0.15 ml/h/kg.
According to a third aspect of the present invention, there is provided use of an ed
composition comprising an L-13 antibody, or antigen-binding portion thereof, in the
preparation of a medicament for treating asthma in a human t by intravenous
administration of the antibody, or antigen-binding portion thereof, at a dose of about 10 mg/kg,
AH26(11205451_1):JJC
n the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy
chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
n the antibody, or antigen-binding n thereof, is capable of exhibiting:
(a) an area under the curve (AUC) of between about 75 and about 100 µgh/ml;
(b) a volume of distribution of between about 90 and about130 mL/kg;
(c) a peak concentration (Cmax) of between about 185 and about 250 µg/ml; and
(d) a clearance rate of between about 0.1 and about 0.15 ml/h/kg.
According to a fourth aspect of the present invention, there is provided use of an ed
composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, in the
preparation of a medicament for ng asthma in a human subject by subcutaneous
administration of the antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg,
n the anti-IL-13 antibody, or antigen binding portion thereof, ses the heavy
chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein the antibody, or antigen-binding portion thereof, is capable of exhibiting:
(a) an area under the curve (AUC) of between about 125 and about 800 µgh/ml; and
(b) a peak tration (Cmax) of between about 1.0 and about 6.0 µg/ml.
According to a fifth aspect of the present invention, there is provided use of an isolated
composition comprising an anti-IL-13 antibody, or antigen-binding portion f, in the
preparation of a medicament for treating asthma in a human subject by subcutaneous
administration of the antibody, or antigen-binding portion thereof, at a dose of about 3 mg/kg,
wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy
chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein the antibody, or antigen-binding portion thereof, is e of exhibiting:
(a) an area under the curve (AUC) of n about 1,100 and about 8,500 µgh/ml; and
(b) a peak concentration (Cmax) of between about 12 and about 60 µg/ml.
According to a sixth aspect of the present ion, there is provided use of an anti-IL-13
antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating
asthma in a human subject by intravenous stration of the antibody, or antigen-binding
portion f, at a dose of about 0.3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding
portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain
variable region of SEQ ID NO:3, and
wherein at least one pharmacokinetic characteristic selected from the group consisting of:
(a) a m serum concentration (Cmax) of between about 5 and about 235 µg/mL, and
AH26(11269199_1):JJC
(b) an area under the serum concentration-time curve (AUC) of between about 1,500 and
about 98,000 ,
is achieved following administration of the antibody, or antigen-binding portion
thereof to said subject.
According to a seventh aspect of the present invention, there is provided use of an anti-IL-
13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating
asthma in a human subject by intravenous administration of the antibody, or antigen-binding
portion thereof, at a dose of about 3 mg/kg,
wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy
chain variable region of SEQ ID NO:2 and the light chain le region of SEQ ID
NO:3, and
wherein at least one pharmacokinetic characteristic selected from the group consisting of:
(a) a m serum concentration (Cmax) of between about 5 and about 235 µg/mL, and
(b) an area under the serum tration-time curve (AUC) of between about 1,500 and
about 98,000 µgh/mL,
is achieved following administration of the dy, or n-binding portion thereof to
said subject.
ing to an eighth aspect of the present invention, there is ed use of an anti-IL-
13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating
asthma in a human subject by intravenous administration of the antibody, or antigen-binding
portion thereof, at a dose of about 10 mg/kg,
wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy
chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID
NO:3, and
wherein at least one pharmacokinetic characteristic selected from the group consisting of:
(a) a maximum serum concentration (Cmax) of n about 5 and about 235 µg/mL, and
(b) an area under the serum concentration-time curve (AUC) of between about 1,500 and
about 98,000 µgh/mL,
is achieved following administration of the antibody, or antigen-binding portion thereof to
said subject.
According to a ninth aspect of the present invention, there is provided use of an anti-IL-13
antibody, or antigen-binding portion thereof, in the preparation of a ment for treating
asthma in a human subject by aneous stration at a dose of about 0.3 mg/kg, wherein
the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable
AH26(11269199_1):JJC
region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, n at least one
pharmacokinetic characteristic selected from the group consisting of:
(a) a maximum serum concentration (Cmax) of between about 1 and about 60 µg/mL, and
(b) an area under the serum concentration-time curve (AUC) of between about 125 and
about 8,100 µgh/mL,
is achieved following administration of the antibody, or antigen-binding n
thereof to said t.
According to a tenth aspect of the present ion, there is provided use of an anti-IL-13
antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating
asthma in a human subject by subcutaneous administration at a dose of about 3 mg/kg, wherein
the anti-IL-13 dy, or antigen binding portion thereof, comprises the heavy chain variable
region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, wherein at least one
pharmacokinetic characteristic selected from the group consisting of:
(a) a maximum serum concentration (Cmax) of between about 1 and about 60 µg/mL, and
(b) an area under the serum concentration-time curve (AUC) of between about 125 and
about 8,100 µgh/mL,
is achieved following administration of the antibody, or antigen-binding portion thereof to said
According to an eleventh aspect of the present invention, there is ed use of an anti-
IL-13 antibody, or antigen-binding portion thereof, in the ation of a medicament for
treating asthma in a human subject by subcutaneous administration at a dose of about 0.3 mg/kg,
n the anti-IL-13 dy, or antigen binding portion thereof, comprises the heavy chain
variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3,
wherein at least one pharmacokinetic characteristic selected from the group consisting of:
(a) a half-life of between about 24 and 31 days;
(b) a Tmax of between about 3 and about 5 days; and
(c) a bioavailability of at least about 60%
is ed following administration of the antibody, or antigen-binding portion
thereof to said subject.
According to a twelfth aspect of the present invention, there is provided use of an L-
13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating
asthma in a human subject by subcutaneous administration at a dose of about 3 mg/kg, wherein
the anti-IL-13 antibody, or antigen binding portion f, comprises the heavy chain variable
region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
AH26(11269199_1):JJC
wherein at least one pharmacokinetic characteristic selected from the group consisting of:
(a) a half-life of between about 23 and 26 days;
(b) a Tmax of less than or equal to about 5 days; and
(c) a bioavailability of at least about 60%
is achieved following administration of the antibody, or antigen-binding portion thereof to said
subject.
According to a thirteenth aspect of the present invention, there is provided use of an anti-
IL-13 antibody, or antigen-binding portion thereof, in the ation of a medicament for
treating asthma in a human subject by intravenous administration at a dose of about 0.3 mg/kg,
wherein the anti-IL-13 antibody, or n binding portion thereof, comprises the heavy chain
variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein at least one cokinetic characteristic selected from the group consisting of:
(a) a clearance rate of between about 0.11 to about 0.19 mL/hr/kg; and
(b) a volume of distribution of between about 70 to about 130 mL/kg
is achieved following administration of the antibody, or antigen-binding portion
thereof to said t.
According to a fourteenth aspect of the present invention, there is provided use of an anti-
IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for
treating asthma in a human subject by intravenous administration at a dose of about 3 mg/kg,
wherein the L-13 antibody, or antigen binding portion thereof, ses the heavy chain
variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein at least one pharmacokinetic characteristic selected from the group consisting of:
(a) a clearance rate of between about 0.08 to about 0.14 kg; and
(b) a volume of bution of between about 55 to about 100 mL/kg
is achieved following administration of the antibody, or antigen-binding portion
thereof to said subject.
According to a fifteenth aspect of the present invention, there is provided use of an L-
13 antibody, or antigen-binding portion f, in the preparation of a medicament for treating
asthma in a human subject by intravenous administration at a dose of about 10 mg/kg, wherein
the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable
region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and
wherein at least one pharmacokinetic characteristic ed from the group consisting of:
(a) a clearance rate of between about 0.09 to about 0.13 mL/hr/kg; and
(b) a volume of distribution of between about 85 to about 130 mL/kg
AH26(11269199_1):JJC
is achieved following administration of the antibody, or antigen-binding portion
thereof to said subject.
According to a sixteenth aspect of the present invention, there is provided use of an anti-
IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for
treating asthma in a human subject by intravenous administration at a dose of about 0.3 mg/kg, 1
mg/kg, 3 mg/kg or 10 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion
thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable
region of SEQ ID NO:3, and wherein at least one of the pharmacokinetic characteristics set forth
in the ication, Tables or Figures is achieved following stration of the dy, or
antigen-binding n thereof, to said subject.
According to a eenth aspect of the present invention, there is provided use of an anti-
IL-13 antibody, or antigen-binding portion thereof, in the ation of a medicament for
treating asthma in a human subject by subcutaneous administration at a dose of about 0.3 mg/kg,
1 mg/kg, 3 mg/kg or 10 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion
thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable
region of SEQ ID NO:3, and wherein at least one of the pharmacokinetic characteristics set forth
in the specification, Tables or Figures is achieved ing administration of the antibody, or
antigen-binding portion f, to said t.
In one aspect, the invention es an isolated composition comprising an anti-IL-13
antibody, or antigen-binding portion thereof, wherein, when administered intravenously to a
subject at a dose of about 0.3 mg/kg, the dy, or antigen-binding portion thereof, is e
of exhibiting: (a) an area under the curve (AUC) of between about 1,500 and about 2,700
µgh/ml; (b) a volume of distribution of between about 65 and 125 mL/kg; (c) a peak
tration (Cmax) of between about 5 and about 8 µg/ml; and (d) a clearance rate of between
about 0.1 and about 0.2 ml/h/kg.
In another aspect, the invention provides an isolated composition comprising an anti-IL-
13 antibody, or antigen-binding portion thereof, wherein, when administered intravenously to a
subject at a dose of about 3 mg/kg, the antibody, or antigen-binding portion thereof, is capable of
exhibiting: (a) an area under the curve (AUC) of between about 21,000 and about 33,500
µgh/ml; (b) a volume of distribution of between about 55 and about 100 mL/kg; (c) a peak
concentration (Cmax) of between about 55 and about 90 µg/ml; and (d) a clearance rate of
between about 0.08 and about 0.15 g.
In another aspect, the invention provides an isolated composition comprising an anti-IL-
13 antibody, or antigen-binding portion thereof, wherein, when administered intravenously to a
AH26(11269199_1):JJC
subject at a dose of about 10 mg/kg, the antibody, or antigen-binding portion thereof, is capable
of exhibiting: (a) an area under the curve (AUC) of n about 75 and about 100 µgh/ml; (b)
a volume of distribution of between about 90 and
AH26(11269199_1):JJC
about130 mL/kg; (c) a peak concentration (Cmax) of between about 185 and about 250
ug/ml; and (d) a clearance rate of between about 0.1 and about 0.15 ml/h/kg.
In yet another aspect, the invention provides an isolated composition comprising
an anti-IL-13 antibody, or antigen-binding portion thereof, wherein, when administered
subcutaneously to a subject at a dose of about 0.3 mg/kg, the antibody, or antigen-
binding portion thereof, is e of exhibiting: (a) an area under the curve (AUC) of
n about 125 and about 800 ; and (b) a peak concentration (Cmax) of
between about 1.0 and about 6.0 ug/ml.
In another aspect, the invention provides an isolated composition comprising an
anti-IL-13 antibody, or n-binding portion thereof, wherein, when administered
subcutaneously to a subject at a dose of about 3 mg/kg, the antibody, or antigen-binding
portion thereof, is e of exhibiting: (a) an area under the curve (AUC) of between
about 1,100 and about 8,500 ugh/ml; and (b) a peak tration (Cmax) of n
about 12 and about 60 ug/ml.
In one embodiment, the anti-IL-13 antibody, or antigen-binding portion thereof,
is 13C5.5, or an antigen-binding portion thereof. In another embodiment, the
composition is a pharmaceutical composition.
In another aspect, the invention provides methods of treating or preventing
asthma in a subject by administering a composition of the invention to the t,
2O thereby treating or preventing asthma. In one embodiment, the composition is
administered once. In another ment, the composition is administered weekly. In
yet another embodiment, the composition is administered for about 3 weeks.
In one embodiment, the asthma is mild to te asthma. In another
embodiment, the subject is a human.
In another embodiment, the method further comprises the administration of an
additional agent. In one embodiment, the onal agent is selected from the group
consisting of: a therapeutic agent, an g agent, a cytotoxic agent, an angiogenesis
tor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule
blocker, an anti-cytokine antibody or functional fragment thereof; methotrexate, a
porin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an
anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug
, an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular
blocker, an crobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an
opoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth
hormone, a hormone replacement drug, a harmaceutical, an antidepressant, an
antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an
oral steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.
In another aspect, the invention provides methods of treating asthma in a subject
by intravenously administering to the subject an L-13 antibody, or antigen-binding
portion thereof, wherein at least one pharmacokinetic characteristic selected from the
group consisting of: (a) a maximum serum tration (Cmax) of between about 5 and
about 235 ug/mL, and (b) an area under the serum concentration-time curve (AUC) of
between about 1,500 and about 98,000 ugh/mL, is achieved following administration of
the antibody, or antigen-binding portion thereof to the subject.
In one embodiment, the antibody, or n-binding portion thereof, is
stered at a dose of about 0.3 mg/kg. In one embodiment, the Cmax is between
2O about 5 and about 10 ug/mL. In one embodiment, the AUC is between about 1,500 and
about 2,700 .
In another embodiment, the antibody, or antigen-binding portion thereof, is
administered at a dose of about 3 mg/kg. In one embodiment, the Cmax is n about
55 and about 90 ug/mL. In another embodiment, the AUC is between about 20,000 and
about 34,000 ugh/mL.
In another embodiment, the antibody, or antigen-binding portion thereof, is
administered at a dose of about 10 mg/kg. In one embodiment, the Cmax is between
about 190 and about 235 ug/mL. In one embodiment, the AUC is between about 75,000
and about 100,000 ugh/mL.
In another embodiment, the Cmax value is between about 20 and about 30
(ug/mL)/(mg/kg) after dose normalization. In another embodiment, the AUC is between
about 6,000 and about 10,000 (ugh/mL)/(mg/kg) after dose normalization.
In another aspect, the invention provides s of treating asthma in a subject
by subcutaneously administering to the t an anti-IL-13 antibody, or antigen-
binding portion thereof, wherein at least one pharmacokinetic characteristic selected
from the group consisting of: (a) a maximum serum concentration (Cmax) of between
about 1 and about 60 ug/mL, and (b) an area under the serum tration-time curve
(AUC) of between about 125 and about 8,100 ugh/mL, is achieved following
administration of the antibody, or antigen-binding portion thereof to the subject.
In one embodiment, the antibody, or antigen-binding portion thereof, is
administered at a dose of about 0.3 mg/kg. In one ment, the Cmax is between
about 1 and about 6 ug/mL. In another embodiment, the AUC is between about 100 and
about 800 .
In another embodiment, the antibody, or antigen-binding portion thereof, is
administered at a dose of about 3 mg/kg. In one embodiment, the Cmax is n about
12 and about 60 ug/mL. In another embodiment, the AUC is n about 1,100 and
about 8,100 ugh/mL.
In one embodiment, the anti-IL-13 antibody, or antigen-binding portion f,
2O is 13C5.5, or an n-binding portion thereof. In another embodiment, the subject is
a human. In another embodiment, the anti-IL-13 antibody, or antigen-binding portion
thereof, is administered once. In another embodiment, the anti-IL—13 antibody, or
antigen-binding portion thereof, is administered weekly. In yet another embodiment, the
anti-IL-13 antibody, or antigen-binding portion thereof, is stered for three weeks.
In one embodiment, the asthma is mild to te asthma.
In another embodiment, the method further comprises the administration of an additional
agent. In one ment, the additional agent is selected from the group consisting of:
a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a
kinase inhibitor, a co-stimulation molecule r, an adhesion molecule blocker, an
ytokine antibody or functional fragment thereof; methotrexate, a cyclosporin, a
rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an anti-
rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug ,
an analgesic, an anesthetic, a sedative, a local anesthetic, a uscular blocker, an
antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an
immunization, an immunoglobulin, an immunosuppressive, a growth e, a
hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a
ant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an
epinephrine or analog, a cytokine, and a cytokine antagonist.
In another aspect, the invention provides methods for treating asthma in a t
by subcutaneously administering to the subject an anti-IL-l3 antibody, or antigenbinding
portion thereof, at a dose of about 0.3 mg/kg, wherein at least one
pharmacokinetic characteristic ed from the group consisting of: (a) a half-life of
between about 24 and 31 days; (b) a Tmax of between about 3 and about 5 days; and (c) a
ilability of at least about 60% is achieved following stration of the
antibody, or antigen-binding portion thereof to the subject. In one embodiment, the
bioavailability is at least about 70%.
In another , the ion provides methods of treating asthma in a subject
by subcutaneously administering to the subject an anti-IL-l3 antibody, or n-
binding portion thereof, at a dose of about 3 mg/kg, wherein at least one
pharmacokinetic characteristic selected from the group consisting of: (a) a half-life of
n about 23 and 26 days; (b) a Tmax of less than or equal to about 5 days; and (c) a
bioavailability of at least about 60% is achieved following administration of the
antibody, or antigen-binding portion thereof to the subject. In one embodiment, the
bioavailability is at least about 70%.
In another aspect, the invention provides methods of treating asthma in a subject
comprising intravenously administering to the subject an anti-IL-l3 antibody, or
antigen-binding portion thereof, at a dose of about 0.3 mg/kg, wherein at least one
pharmacokinetic characteristic selected from the group consisting of: (a) a clearance rate
of between about 0. 11 to about 0.19 kg; and (b) a volume of distribution of
between about 70 to about 130 mL/kg is achieved following administration of the
antibody, or antigen-binding n thereof to the subject.
In another aspect, the invention provides methods treating asthma in a subject by
intravenously administering to the subject an anti-IL-l3 antibody, or antigen-binding
portion thereof, at a dose of about 3 mg/kg, wherein at least one pharmacokinetic
characteristic selected from the group ting of: (a) a clearance rate of between
about 0.08 to about 0.14 mL/hr/kg; and (b) a volume of distribution of between about 55
to about 100 mL/kg is achieved following administration of the antibody, or antigen-
binding portion thereof to the subject.
In r aspect, the invention provides methods of treating asthma in a subject
comprising intravenously administering to the subject an anti-IL-l3 antibody, or
n-binding portion thereof, at a dose of about 10 mg/kg, n at least one
cokinetic characteristic selected from the group consisting of: (a) a clearance rate
of between about 0.09 to about 0. l3 mL/hr/kg; and (b) a volume of distribution of
n about 85 to about 130 mL/kg is achieved ing administration of the
antibody, or antigen-binding portion thereof to the subject.
In one embodiment, the anti-IL-l3 antibody, or antigen-binding portion thereof,
is l3C5.5, or an antigen-binding portion thereof. In another embodiment, the subject is
a human. In one embodiment, the anti-IL-l3 antibody, or antigen-binding portion
thereof, is administered once. In another embodiment, the anti-IL—l3 antibody, or
antigen-binding n thereof, is administered . In yet r embodiment, the
anti-IL-l3 dy, or antigen-binding portion thereof, is administered for 3 weeks.
In one embodiment, the asthma is mild to moderate asthma.
In another embodiment, the methods further comprise the administration of an
additional agent. In one embodiment, the additional agent is selected from the group
consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis
inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule
blocker, an anti-cytokine antibody or functional fragment thereof; methotrexate, a
cyclosporin, a cin, an FK506, a detectable label or er, a TNF antagonist, an
anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug
(NTHE), an sic, an anesthetic, a sedative, a local anesthetic, a neuromuscular
r, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an
erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth
hormone, a hormone replacement drug, a radiopharmaceutical, an pressant, an
antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an
oral steroid, an hrine or , a cytokine, and a cytokine antagonist.
In one ment, the subject is a human.
In another aspect, the invention provides an isolated ition comprising an
anti-IL-l3 antibody, or antigen-binding portion f, wherein, when administered
intravenously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg,
the antibody, or antigen-binding portion thereof, is capable of exhibiting any of the
pharmacokinetic parameters set forth in the specification, Tables or Figures.
In another aspect, the invention provides an ed composition comprising an
anti-IL-l3 antibody, or antigen-binding n thereof, wherein, when administered
subcutaneously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg or 3 mg/kg, the
antibody, or antigen-binding portion thereof, is capable of exhibiting any of the
cokinetic parameters set forth in the specification, Tables or Figures.
In another aspect, the invention provides s of treating or preventing
asthma in a subject by intravenously administering to the subject an anti-IL-l3 antibody,
or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10
mg/kg, wherein at least one of the pharmacokinetic characteristics set forth in the
specification, Tables or Figures is achieved following administration of the antibody, or
antigen-binding portion thereof, to the subject.
In yet another aspect, the invention provides methods of treating or ting
asthma in a subject by subcutaneously administering to the subject an anti-IL-l3
antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, 1 mg/kg, 3
mg/kg or 10 mg/kg, wherein at least one of the pharmacokinetic characteristics set forth
in the specification, Tables or Figures is achieved following administration of the
antibody, or antigen-binding portion thereof, to the subject.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph depicting that IL-13 expression es pulmonary
dysfunction.
Figure 2 depicts that l3C5.5, an anti-IL-l3 antibody, is derived from a
hybridoma with a unique epitope and lineage.
Figure 3 s that l3C5.5, an anti-IL-l3 antibody, neutralizes IL-13 in the
lung.
Figure 4 depicts the schematic of first in human (FIH) dosing used in the Phase I
al Trial.
Figure 5 depicts the mean l3C5.5 serum concentration-time e after single
0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg intravenous infusions of l3C5.5 to healthy
ts on a linear scale.
Figure 6 depicts the pharmacokinetic parameters of l3C5.5, an anti-IL-l3
antibody.
Figure 7 depicts the mean l3C5.5 serum tration-time profile after single
0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg intravenous infusions of l3C5.5 to healthy
and asthma subjects on a linear scale.
Figure 8 depicts the pharmacokinetic parameters of 13C5.5, an anti-IL-l3
antibody.
Figure 9 depicts the pharmacokinetic parameters of 13C5.5, an anti-IL-l3
antibody.
Figure 10 depicts the pharmacokinetic parameters of 13C5.5, an anti-IL-l3
antibody. Bioavailability following subcutaneous administration was estimated to be
about 70%.
Figure 11 s the mean dose normalized Cmax values following three
weekly 0.3 mg/kg (Group 8) and 3 mg/kg (Group 9) subcutaneous injections of l3C5.5
(Part 3 of the al Trial).
Figure 12 depicts the mean dose ized 68 values following three
weekly 0.3 mg/kg (Group 8) and 3 mg/kg (Group 9) aneous injections of l3C5.5
(Part 3 of the Clinical Trial).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides methods and compositions for ng asthma,
e. g., mild or moderate asthma, using an anti-IL—l3 antibody, or antigen-binding portion
thereof.
In order that the present invention may be more readily understood, certain terms
are first defined.
The term "polypeptide" as used herein, refers to any polymeric chain of amino
acids. The terms "peptide" and "protein" are used interchangeably with the term
polypeptide and also refer to a polymeric chain of amino acids. The term "polypeptide"
encompasses native or artificial proteins, protein fragments and ptide analogs of a
protein sequence. A polypeptide may be ric or polymeric.
The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide
that by virtue of its origin or source of derivation is not ated with naturally
associated components that accompany it in its native state; is substantially free of other
ns from the same species; is expressed by a cell from a different species; or does
not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in
a cellular system different from the cell from which it naturally originates will be
"isolated" from its naturally associated components. A protein may also be rendered
substantially free of naturally associated components by isolation, using protein
purification techniques well known in the art.
The term "recovering" as used herein, refers to the process of rendering a
chemical species such as a polypeptide substantially free of naturally associated
components by isolation, e. g., using n cation techniques well known in the
art.
The terms " and "IL-13 wild type" (abbreviated herein as IL-l3, IL-l3 wt),
as used , include a ne that is secreted primarily by T helper 2 cells. The
term includes a monomeric protein of 13 kDa polypeptide. The structure of IL-13 is
described further in, for example, Moy, Diblasio et a1. 2001 J Mol Biol 310 219-30. The
term IL-13 is intended to include recombinant human IL-l3 (rh IL-l3), which can be
prepared by standard recombinant expression methods. The amino acid sequence of
human IL-l3, SEQ ID NO. 1, is known in the art.
Se uence of human IL-l3 - SE ID NO:1
MALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWS
INLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIE
VAQFVKDLLLHLKKLFREGRFN
The term "IL-l3 t" viated herein as IL-l3v), as used herein, includes
a variant of IL-13 wherein amino acid residue 130 of SEQ ID NO:1 is changed from
Arginine to Glutamine (R130Q).
"Biological activity" as used herein, refers to all inherent biological properties of
the cytokine. Biological properties of IL-13 include but are not limited to binding IL-l3
or; (other examples include immunoglobulin e switching to IgE in human B
cells and suppressing inflammatory cytokine production).
The terms "specific binding" or "specifically binding", as used herein, in
reference to the interaction of an dy, a protein, or a e with a second chemical
s, mean that the interaction is dependent upon the presence of a particular
structure (6. g., an antigenic determinant or epitope) on the chemical species; for
example, an antibody recognizes and binds to a specific protein structure rather than to
proteins generally. If an dy is specific for e "A", the presence of a molecule
containing epitope A (or free, unlabeled A), in a reaction containing labeled "A" and the
antibody, will reduce the amount of d A bound to the antibody.
The term "antibody", as used , broadly refers to any immunoglobulin (Ig)
molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L)
chains, or any functional fragment, mutant, variant, or derivation thereof, which retains
the ial epitope binding features of an Ig molecule. Such mutant, variant, or
derivative dy formats are known in the art. Nonlimiting embodiments of which
are discussed herein. In one embodiment, the antibody used in the itions and
methods of the invention is the anti-IL-l3 antibody l3C5.5 described in U.S. Patent No.
7,915,388, orated by reference herein. In r embodiment, the antibody used
in the compositions and methods of the invention is the antibody 6A1, 3G4,
tralokinumab, lebrikizumab, QAZ—576, IMA-638 or IMA-026.
2O In a full-length antibody, each heavy chain is comprised of a heavy chain
variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
Each light chain is comprised of a light chain variable region (abbreviated herein as
LCVR or VL) and a light chain constant region. The light chain constant region is
comprised of one domain, CL. The VH and VL regions can be further subdivided into
regions of hypervariability, termed complementarity determining s (CDR),
interspersed with regions that are more conserved, termed framework regions (FR). Each
VH and VL is composed of three CDRs and four FRs, ed from amino-terminus to
carboxy-terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.
Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY),
class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgAl and IgA2) or subclass.
The term "antigen-binding n" of an antibody (or simply "antibody
n"), as used herein, refers to one or more fragments of an antibody that retain the
ability to specifically bind to an antigen (e.g., IL-13). It has been shown that the
antigen-binding on of an dy can be performed by fragments of a full-length
antibody. Such antibody embodiments may also be ific, dual specific, or multi-
specific formats; specifically binding to two or more different antigens. Examples of
binding nts encompassed within the term "antigen-binding portion" of an
antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH,
CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent nt comprising two Fab
fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting
of the VH and CH1 s; (iv) a Fv fragment consisting of the VL and VH domains
of a single arm of an antibody, (V) a dAb fragment (Ward et al., (1989) Nature 341544-
546, Winter et (11., PCT publication WO 90/05144 A1 herein incorporated by reference),
which comprises a single variable domain; and (vi) an ed complementarity
determining region (CDR). Furthermore, although the two domains of the Fv fragment,
VL and VH, are coded for by separate genes, they can be joined, using recombinant
methods, by a synthetic linker that enables them to be made as a single protein chain in
which the VL and VH regions pair to form monovalent molecules (known as single
chain Fv ; see e.g., Bird et a1. (1988) Science 242:423-426; and Huston et a1.
(1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodies are also
intended to be encompassed within the term "antigen-binding n" of an antibody.
Other forms of single chain antibodies, such as diabodies are also assed.
Diabodies are bivalent, bispecific antibodies in which VH and VL domains are
expressed on a single polypeptide chain, but using a linker that is too short to allow for
pairing between the two domains on the same chain, thereby forcing the domains to pair
with complementary domains of r chain and creating two antigen binding sites
(see e.g., Holliger, P., et a1. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R.
J ., et a1. (1994) Structure 2:1121-1123). Such antibody binding portions are known in
the art (Kontermann and Dubel eds., Antibody Engineering (2001) Springer-Verlag.
New York. 790 pp. (ISBN 341354-5).
The term "antibody construct" as used herein refers to a polypeptide comprising
one or more the antigen binding portions of the ion linked to a linker polypeptide
or an immunoglobulin constant domain. Linker polypeptides comprise two or more
amino acid residues joined by peptide bonds and are used to link one or more antigen
binding portions. Such linker polypeptides are well known in the art (see e. g., Holliger,
P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et a1. (1994)
Structure 2: 1 121-1123). An immunoglobulin constant domain refers to a heavy or light
chain constant domain. Human IgG heavy chain and light chain constant domain amino
acid sequences are known in the art and disclosed in Table 2 of US. Patent No.
7,915,388, the entire contents of which are orated herein by reference.
Still further, an antibody or antigen-binding n thereof may be part of a
larger immunoadhesion molecules, formed by covalent or noncovalent association of the
antibody or antibody portion with one or more other proteins or peptides. Examples of
such immunoadhesion molecules include use of the streptavidin core region to make a
tetrameric scFv molecule yanov, S. M., et a1. (1995) Human Antibodies and
Hybridomas 01) and use of a cysteine residue, a marker peptide and a C-terminal
polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M.,
et al. (1994) Mol. l. 31:1047-1058). Antibody portions, such as Fab and F(ab')2
fragments, can be prepared from whole antibodies using conventional techniques, such
as papain or pepsin ion, respectively, of whole antibodies. Moreover, antibodies,
antibody portions and immunoadhesion molecules can be obtained using standard
recombinant DNA techniques, as described herein.
An "isolated antibody", as used herein, is intended to refer to an antibody that is
substantially free of other antibodies having ent antigenic specificities (e.g., an
ed antibody that specifically binds IL—13 is substantially free of antibodies that
specifically bind antigens other than IL-13). An isolated antibody that specifically binds
IL-13 may, however, have cross-reactivity to other antigens, such as IL-13 molecules
from other species. Moreover, an isolated antibody may be substantially free of other
cellular material and/or chemicals.
The term "human antibody", as used herein, is ed to e antibodies
having variable and constant regions derived from human germline immunoglobulin
sequences. The human antibodies of the invention may include amino acid residues not
encoded by human germline immunoglobulin sequences (e. g., mutations uced by
random or site-specific mutagenesis in vitro or by c mutation in vivo), for
example in the CDRs and in particular CDR3. However, the term "human antibody", as
used herein, is not intended to include antibodies in which CDR sequences derived from
the germline of another mammalian species, such as a mouse, have been grafted onto
human framework sequences.
The term "recombinant human dy", as used herein, is intended to include
all human dies that are prepared, expressed, created or isolated by recombinant
means, such as antibodies sed using a recombinant expression vector ected
into a host cell (described further in U.S. Patent No. 7,915,388, the contents of which are
incorporated herein by reference), dies isolated from a recombinant, combinatorial
human dy library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H.,
and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick
J. W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P. (2000)
Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that
is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992)
Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current
Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today
21:364-370) or antibodies prepared, expressed, created or isolated by any other means
2O that involves splicing of human immunoglobulin gene sequences to other DNA
sequences. Such recombinant human antibodies have variable and constant regions
derived from human germline globulin sequences. In certain embodiments,
however, such recombinant human antibodies are ted to in vitro mutagenesis (or,
when an animal transgenic for human Ig sequences is used, in vivo c mutagenesis)
and thus the amino acid sequences of the VH and VL regions of the recombinant
antibodies are sequences that, while derived from and related to human ne VH
and VL sequences, may not naturally exist within the human antibody germline
repertoire in vivo. One embodiment provides fully human antibodies capable of binding
human IL-13 which can be generated using techniques well known in the art, such as,
but not limited to, using human Ig phage libraries such as those disclosed in Jermutus et
(11., PCT publication No. A2.
2012/045268
The term "chimeric antibody" refers to antibodies which comprise heavy and
light chain variable region sequences from one species and constant region sequences
from another s, such as dies having murine heavy and light chain variable
regions linked to human constant regions.
The term "CDR-grafted dy" refers to antibodies which comprise heavy and
light chain variable region sequences from one species but in which the sequences of
one or more of the CDR regions of VH and/or VL are replaced with CDR sequences of
another species, such as antibodies having murine heavy and light chain variable regions
in which one or more of the murine CDRs (e.g., CDR3) has been replaced with human
CDR sequences.
The term "humanized antibody" refers to antibodies which comprise heavy and
light chain variable region sequences from a non-human species (e. g., a mouse) but in
which at least a portion of the VH and/or VL sequence has been altered to be more
-like", i.e., more similar to human germline variable sequences. One type of
humanized antibody is a CDR-grafted antibody, in which human CDR sequences are
introduced into non-human VH and VL sequences to e the ponding
nonhuman CDR ces. In one embodiment, humanized anti human IL-13 antibodies
and antigen binding portions are provided. Such antibodies were generated by obtaining
murine anti-IL-13 monoclonal antibodies using traditional hybridoma technology
followed by humanization using in vitro genetic engineering, such as those disclosed in
Kasaian et al PCT publication No. WC 2005/123126 A2.
The terms "Kabat numbering", "Kabat definitions and "Kabat labeling" are used
hangeably herein. These terms, which are ized in the art, refer to a system of
numbering amino acid residues which are more variable (Le. hypervariable) than other
amino acid residues in the heavy and light chain variable regions of an antibody, or an
antigen binding portion thereof (Kabat et a1. (1971) Ann. NY Acad, Sci. 190:382-391
and, Kabat, E. A., et a1. (1991) Sequences of Proteins of Immunological Interest, Fifth
Edition, US. Department of Health and Human Services, NIH Publication No. 91-
3242). For the heavy chain variable region, the hypervariable region ranges from amino
acid positions 31 to 35 for CDRl, amino acid positions 50 to 65 for CDR2, and amino
acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable
region ranges from amino acid positions 24 to 34 for CDRl, amino acid positions 50 to
56 for CDR2, and amino acid positions 89 to 97 for CDR3.
As used herein, the terms "acceptor" and "acceptor antibody" refer to the
antibody or nucleic acid sequence providing or encoding at least 80%, at least 85%, at
least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%
of the amino acid sequences of one or more of the framework regions. In some
embodiments, the term "acceptor" refers to the antibody amino acid or nucleic acid
sequence ing or encoding the constant region(s). In yet another embodiment, the
term "acceptor" refers to the antibody amino acid or nucleic acid sequence providing or
encoding one or more of the framework regions and the constant region(s). In a specific
embodiment, the term "acceptor" refers to a human antibody amino acid or nucleic acid
sequence that provides or encodes at least 80%, preferably, at least 85%, at least 90%, at
least 95%, at least 98%, or 100% of the amino acid sequences of one or more of the
ork regions. In accordance with this embodiment, an acceptor may contain at
least 1, at least 2, at least 3, least 4, at least 5, or at least 10 amino acid residues that does
(do) not occur at one or more ic positions of a human antibody. An acceptor
framework region and/or acceptor constant region(s) may be, e. g., derived or obtained
from a germline antibody gene, a mature antibody gene, a functional antibody (e.g.,
antibodies well-known in the art, antibodies in development, or antibodies commercially
ble).
As used herein, the term "CDR" refers to the mentarity determining
region within antibody variable sequences. There are three CDRs in each of the variable
regions of the heavy chain and the light chain, which are designated CDRl, CDR2 and
CDR3, for each of the variable regions. The term "CDR set" as used herein refers to a
group of three CDRs that occur in a single le region capable of binding the
antigen. The exact boundaries of these CDRs have been defined differently according to
different s. The system described by Kabat (Kabat et (1]., ces of Proteins of
Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991))
not only es an unambiguous e numbering system applicable to any variable
region of an antibody, but also es precise residue boundaries defining the three
CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia
&Lesk, J. Mol. Biol. 196:901-917 (1987) and Chothia et al., Nature 342:877-883
(1989)) found that certain sub-portions within Kabat CDRs adopt nearly identical
peptide backbone conformations, despite having great diversity at the level of amino
acid sequence. These sub-portions were designated as L1, L2 and L3 or H1, H2 and H3
where the "L" and the "H" designates the light chain and the heavy chains regions,
respectively. These regions may be ed to as Chothia CDRs, which have boundaries
that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the
Kabat CDRs have been described by Padlan (FASEB J. 9:133-139 (1995)) and
MacCallum (J Mol Biol 262(5):732-45 (1996)). Still other CDR boundary definitions
may not ly follow one of the above systems, but will nonetheless overlap with the
Kabat CDRs, although they may be shortened or lengthened in light of prediction or
experimental gs that particular residues or groups of residues or even entire CDRs
do not icantly impact n binding. The methods used herein may utilize CDRs
defined according to any of these systems, although preferred embodiments use Kabat or
Chothia defined CDRs.
As used herein, the term "canonical" residue refers to a e in a CDR or
framework that defines a particular canonical CDR structure as defined by Chothia et a].
(J. Mol. Biol. 196:901-907 (1987); Chothia et al., J. Mol. Biol. 9 , both are
incorporated herein by reference). According to Chothia et (1]., critical portions of the
2O CDRs of many antibodies have nearly identical peptide ne confirmations despite
great diversity at the level of amino acid sequence. Each canonical structure specifies
primarily a set of peptide backbone torsion angles for a contiguous segment of amino
acid es forming a loop.
As used herein, the terms "donor" and "donor antibody" refer to an antibody
providing one or more CDRs. In a preferred ment, the donor dy is an
antibody from a species different from the antibody from which the framework regions
are obtained or derived. In the context of a humanized antibody, the term "donor
antibody" refers to a non-human antibody providing one or more CDRs.
As used herein, the term work" or "framework sequence" refers to the
remaining sequences of a le region minus the CDRs. Because the exact definition
of a CDR sequence can be determined by different systems, the meaning of a framework
sequence is subject to pondingly different interpretations. The six CDRs (CDR-
Ll, CDR-L2, and CDR-L3 of light chain and CDR-Hl, CDR-H2, and CDR-H3 of heavy
chain) also divide the ork regions on the light chain and the heavy chain into four
sub-regions (FRl, FR2, FR3 and FR4) on each chain, in which CDRl is positioned
between FRl and FR2, CDR2 n FR2 and FR3, and CDR3 between FR3 and FR4.
Without specifying the particular sub-regions as FRl, FR2, FR3 or FR4, a framework
region, as referred by others, represents the ed FR’s within the variable region of
a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one
of the four sub-regions, and FRs represents two or more of the four sub-regions
constituting a framework region.
Human heavy chain and light chain acceptor sequences are known in the art. In
one embodiment of the invention the human heavy chain and light chain acceptor
sequences are selected from the sequences described in Table 3 and Table 4 disclosed in
US. Patent NO. 7,915,388, the contents of which are incorporated herein by reference.
As used herein, the term "germline antibody gene" or "gene fragment" refers to
an immunoglobulin ce encoded by non-lymphoid cells that have not undergone
the maturation process that leads to c rearrangement and mutation for expression
of a particular immunoglobulin. (See, e.g., Shapiro et (1]., Crit. Rev. Immunol. 22(3):
183-200 (2002); Marchalonis et (1]., Adv Exp Med. Biol. 484: 13-30 (2001)). One of the
2O advantages provided by various embodiments of the present invention stems from the
recognition that germline antibody genes are more likely than mature dy genes to
conserve essential amino acid sequence structures characteristic of individuals in the
species, hence less likely to be recognized as from a foreign source when used
therapeutically in that species.
As used herein, the term "key" residues refer to certain residues within the
variable region that have more impact on the binding specificity and/or affinity of an
dy, in particular a humanized antibody. A key residue includes, but is not limited
to, one or more of the following: a residue that is nt to a CDR, a potential
glycosylation site (can be either N- or O-glycosylation site), a rare e, a residue
e of interacting with the antigen, a e capable of interacting with a CDR, a
cal residue, a contact residue between heavy chain variable region and light chain
variable , a residue within the Vernier zone, and a residue in the region that
overlaps between the Chothia definition of a variable heavy chain CDRl and the Kabat
tion of the first heavy chain framework.
As used herein, the term "humanized antibody" is an antibody or a variant,
derivative, analog or fragment thereof which immunospecifically binds to an antigen of
interest and which comprises a framework (FR) region having substantially the amino
acid sequence of a human antibody and a complementary determining region (CDR)
having substantially the amino acid sequence of a non-human dy. As used herein,
the term "substantially" in the context of a CDR refers to a CDR having an amino acid
ce at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 96%,
at least 97%, at least 98% or at least 99% identical to the amino acid ce of a non-
human antibody CDR. A humanized antibody comprises substantially all of at least one,
and typically two, variable domains (Fab, Fab‘, F(ab')2, FabC, Fv) in which all or
substantially all of the CDR regions pond to those of a non-human
immunoglobulin (i.e., donor antibody) and all or substantially all of the framework
regions are those of a human immunoglobulin consensus sequence. ably, a
humanized antibody also comprises at least a portion of an immunoglobulin constant
region (Fc), typically that of a human immunoglobulin. In some ments, a
humanized dy contains both the light chain as well as at least the variable domain
of a heavy chain. The antibody also may include the CH1, hinge, CH2, CH3, and CH4
regions of the heavy chain. In some embodiments, a humanized antibody only contains a
humanized light chain. In some embodiments, a humanized antibody only contains a
zed heavy chain. In specific embodiments, a humanized antibody only contains a
humanized variable domain of a light chain and/or humanized heavy chain.
In one ment of the invention, the humanized anti-IL-13 antibody is
13C5.5. 13C5.5 has the sequences SEQ ID NO:2 (heavy chain variable region) and
SEQ ID NO:3 (light chain variable region). See also U.S. Patent No. 7,915,388, the
entire contents of which are incorporated herein by reference.
SE ID NO:2 - HeaV Chain Variable Re ion 13C5.5
SGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIW
YNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIY
YAMDYWGQGTLVTVSS
SE ID NO:3 - Li ht Chain Variable Re ion 13C5.5
DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLH
SGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK
The humanized antibody can be selected from any class of immunoglobulins,
including IgM, IgG, IgD, IgA and IgE, and any isotype, including t limitation IgG
1, IgG2, IgG3 and IgG4. The humanized antibody may se sequences from more
than one class or isotype, and particular constant domains may be ed to optimize
desired effector functions using techniques well-known in the art.
The ork and CDR regions of a humanized antibody need not correspond
precisely to the parental sequences, e. g., the donor antibody CDR or the consensus
framework may be mutagenized by substitution, insertion and/or deletion of at least one
amino acid residue so that the CDR or framework residue at that site does not
correspond to either the donor antibody or the consensus framework. In a preferred
embodiment, such mutations, however, will not be extensive. Usually, at least 80%,
preferably at least 85%, more ably at least 90%, and most preferably at least 95%
of the humanized antibody residues will correspond to those of the parental FR and CDR
" refers to the framework
sequences. As used herein, the term "consensus framewor
region in the consensus immunoglobulin sequence. As used herein, the term "consensus
immunoglobulin sequence" refers to the sequence formed from the most frequently
occurring amino acids (or nucleotides) in a family of related immunoglobulin sequences
(See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, im, Germany
1987). In a family of immunoglobulins, each position in the consensus sequence is
occupied by the amino acid occurring most frequently at that position in the family. If
two amino acids occur equally frequently, either can be included in the consensus
sequence.
As used herein, "Vernier" zone refers to a subset of ork residues that may
adjust CDR structure and fine-tune the fit to antigen as described by Foote and Winter
(1992, J. Mol. Biol. 224:487-499, which is incorporated herein by reference). Vernier
zone residues form a layer ying the CDRs and may impact on the structure of
CDRs and the affinity of the antibody.
The term "multivalent binding protein" is used in this ication to denote a
binding protein sing two or more n binding sites. The multivalent binding
protein is preferably engineered to have the three or more antigen binding sites, and is
generally not a naturally occurring antibody. The term specific binding protein"
refers to a binding protein capable of binding two or more related or ted targets.
Dual variable domain (DVD) binding proteins as used herein, are binding proteins that
comprise two or more antigen binding sites and are alent or alent binding
proteins. Such DVDs may be monospecific, Le. capable of binding one antigen or
multispecific, Le. capable of binding two or more antigens. DVD binding proteins
comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides
are referred to a DVD Ig. Each half of a DVD Ig comprises a heavy chain DVD
polypeptide, and a light chain DVD polypeptide, and two antigen binding sites. Each
binding site comprises a heavy chain variable domain and a light chain le domain
with a total of 6 CDRs involved in antigen binding per antigen binding site.
As used herein, the term alizing" refers to lization of biological
activity of a cytokine when a binding protein specifically binds the cytokine. ably
a neutralizing binding protein is a neutralizing antibody whose binding to IL-13 and/or
IL-13 results in inhibition of a biological activity of IL-13 and/or IL-13. Preferably the
neutralizing binding protein binds IL-13 and/or IL-13 and reduces a biologically activity
of IL-13 and/or IL-13 by at least about 20%, 40%, 60%, 80%, 85% or more. Inhibition
of a biological activity of IL-13 and/or IL-13 by a neutralizing binding protein can be
assessed by measuring one or more indicators of IL-13 and/or IL-13 ical actiVity
well known in the art. For example, inhibition of human IL-13 induced production of
TARC 7) by A-549 cells can be measured (see Example l.l.C of U.S. Patent No.
7,915,388, the contents of which are incorporated herein by reference).
The term "activity" includes actiVities such as the binding specificity/affinity of
an antibody for an antigen, for e, an anti-IL-13 antibody that binds to an IL-13
antigen and/or the neutralizing potency of an antibody, for example, an anti-IL-13
antibody whose binding to IL-13 inhibits the biological actiVity of IL-13, e. g. For
example inhibition of human IL-13 induced production of TARC (CCL-17) by A-549
cells (see Example l.l.C of U.S. Patent No. 7,915,388, the entire contents of which are
incorporated herein by reference).
The term "epitope" es any polypeptide determinant capable of ic
g to an immunoglobulin or T-cell receptor. In certain ments, epitope
determinants include chemically active surface groupings of molecules such as amino
acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have
specific three dimensional structural characteristics, and/or specific charge
characteristics. An epitope is a region of an antigen that is bound by an antibody. In
2O certain embodiments, an antibody is said to specifically bind an antigen when it
preferentially izes its target antigen in a complex mixture of proteins and/or
macromolecules.
The term "surface plasmon resonance", as used herein, refers to an optical
phenomenon that allows for the analysis of real-time biospecific interactions by
detection of alterations in protein concentrations within a biosensor matrix, for example
using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway,
N.J.). For further ptions, see n, U., et al. (1993) Ann. Biol. Clin. 51:19-26;
Jonsson, U., et al. (1991) Biotechniques 11:620-627; Johnsson, B., et a1. (1995) J. Mol.
it. 8:125-131; and Johnnson, B., et al. (1991) Anal. m. 198:268-277.
The term "km", as used herein, is intended to refer to the on rate constant for
association of an antibody to the n to form the antibody/antigen complex as is
known in the art.
The term ”koff”, as used herein, is intended to refer to the off rate constant for
dissociation of an antibody from the antibody/antigen complex as is known in the art.
The term "KD", as used herein, is intended to refer to the dissociation constant of
a particular antibody-antigen interaction as is known in the art.
The term "labeled binding protein" as used herein, refers to a protein with a label
incorporated that provides for the identification of the binding protein. ably, the
label is a detectable , e.g., incorporation of a radiolabeled amino acid or
attachment to a polypeptide of biotinyl es that can be detected by marked aVidin
(e. g., aVidin ning a fluorescent marker or enzymatic actiVity that can be
detected by optical or metric methods). Examples of labels for polypeptides
include, but are not limited to, the following: radioisotopes or uclides (e. g., 3H,
14C, 358, 90Y, 99Tc, lllIn, 1251, 1311, 177Lu, 166Ho, or 153Sm); fluorescent labels
(e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish
peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl
groups; predetermined polypeptide epitopes recognized by a secondary reporter (e.g.,
leucine zipper pair sequences, binding sites for secondary antibodies, metal binding
domains, epitope tags); and magnetic agents, such as gadolinium chelates.
The term "antibody conjugate" refers to a binding protein, such as an antibody,
chemically linked to a second chemical moiety, such as a therapeutic or cytotoxic agent.
The term "agent" is used herein to denote a chemical compound, a mixture of chemical
compounds, a biological olecule, or an extract made from biological materials.
Preferably the therapeutic or cytotoxic agents e, but are not limited to, pertussis
toxin, taxol, alasin B, gramicidin D, ethidium bromide, emetine, mitomycin,
etoposide, tenoposide, Vincristine, Vinblastine, cin, doxorubicin, daunorubicin,
dihydroxy anthracin dione, ntrone, mithramycin, actinomycin D, 1-
dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and
puromycin and analogs or homologs f.
The terms "crystal", and "crystallized" as used herein, refer to an dy, or
antigen binding portion thereof, that exists in the form of a crystal. Crystals are one form
of the solid state of matter, which is distinct from other forms such as the amorphous
solid state or the liquid crystalline state. ls are composed of regular, repeating,
three-dimensional arrays of atoms, ions, molecules (e.g., proteins such as antibodies), or
molecular assemblies (e.g., antigen/antibody complexes). These three-dimensional
arrays are arranged according to specific mathematical relationships that are well-
understood in the field. The fundamental unit, or building block, that is repeated in a
crystal is called the asymmetric unit. Repetition of the asymmetric unit in an
arrangement that conforms to a given, efined crystallographic symmetry provides
the "unit cell" of the crystal. Repetition of the unit cell by regular translations in all three
dimensions provides the l. See Giege, R. and Ducruix, A. Barrett, Crystallization
of Nucleic Acids and Proteins, a Practical Approach, 2nd ea., pp. 20 1-16, Oxford
University Press, New York, N.Y., (1999)."
The term "polynucleotide" as referred to herein means a polymeric form of two
or more nucleotides, either ribonucleotides or deoxynucleotides or a modified form of
either type of tide. The term includes single and double stranded forms of DNA
but preferably is double-stranded DNA.
The term "isolated polynucleotide" as used herein shall mean a polynucleotide
(e.g., of c, cDNA, or synthetic origin, or some combination thereof) that, by
virtue of its origin, the "isolated polynucleotide": is not ated with all or a portion
of a polynucleotide with which the "isolated polynucleotide" is found in ; is
operably linked to a polynucleotide that it is not linked to in nature; or does not occur in
nature as part of a larger sequence.
The term "vector", as used , is intended to refer to a nucleic acid molecule
capable of transporting another nucleic acid to which it has been linked. One type of
vector is a "plasmid", which refers to a circular double ed DNA loop into which
additional DNA segments may be ligated. Another type of vector is a viral vector,
wherein additional DNA segments may be d into the viral genome. Certain vectors
are capable of autonomous ation in a host cell into which they are introduced (e. g.,
bacterial vectors having a bacterial origin of replication and episomal mammalian
vectors). Other vectors (6. g., isomal mammalian vectors) can be integrated into
the genome of a host cell upon introduction into the host cell, and thereby are replicated
along with the host genome. Moreover, certain s are capable of directing the
expression of genes to which they are ively linked. Such s are referred to
herein as "recombinant expression vectors" (or simply, "expression vectors”). In general,
expression vectors of utility in recombinant DNA techniques are often in the form of
ds. In the present specification, "plasmid" and "vector" may be used
interchangeably as the plasmid is the most commonly used form of vector. However, the
ion is intended to include such other forms of expression vectors, such as viral
vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated
viruses), which serve equivalent functions.
The term "operably linked" refers to a juxtaposition n the components
described are in a relationship permitting them to function in their intended manner. A
control sequence bly linked" to a coding ce is ligated in such a way that
expression of the coding ce is achieved under conditions compatible with the
control sequences. "Operably linked" sequences include both expression control
sequences that are contiguous with the gene of interest and expression control sequences
that act in trans or at a distance to l the gene of st. The term "expression
control sequence" as used herein refers to polynucleotide sequences which are necessary
to effect the expression and processing of coding sequences to which they are ligated.
sion control sequences include appropriate transcription initiation, termination,
promoter and enhancer sequences; efficient RNA processing signals such as splicing and
polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that
e translation efficiency (i.e., Kozak consensus sequence); sequences that enhance
protein stability; and when desired, sequences that enhance protein secretion. The nature
of such control sequences differs ing upon the host organism; in prokaryotes,
such control sequences generally include er, ribosomal g site, and
transcription termination sequence; in eukaryotes, generally, such control sequences
include promoters and transcription termination sequence. The term ol sequences"
is intended to e components whose presence is essential for expression and
processing, and can also include additional components whose presence is
advantageous, for example, leader sequences and fusion partner sequences. Protein
constructs of the present invention may be expressed, and purified using expression
vectors and host cells known in the art, including expression cassettes, vectors,
WO 09521
recombinant host cells and methods for the recombinant expression and proteolytic
processing of recombinant polyproteins and pre-proteins from a single open reading
frame (6. g., , the entire contents of which are incorporated herein by
reference).
"Transformation", as defined herein, refers to any process by which ous
DNA enters a host cell. Transformation may occur under natural or artificial conditions
using various methods well known in the art. Transformation may rely on any known
method for the insertion of foreign c acid sequences into a prokaryotic or
eukaryotic host cell. The method is selected based on the host cell being transformed and
may e, but is not limited to, viral infection, electroporation, lipofection, and
particle bombardment. Such formed" cells include stably ormed cells in
which the inserted DNA is capable of replication either as an autonomously replicating
plasmid or as part of the host chromosome. They also include cells which transiently
express the inserted DNA or RNA for limited s of time.
The term "recombinant host cell" (or simply "host cell"), as used , is
intended to refer to a cell into which exogenous DNA has been introduced. It should be
understood that such terms are intended to refer not only to the particular subject cell,
but, to the progeny of such a cell. Because certain modifications may occur in
succeeding generations due to either mutation or environmental ces, such
2O progeny may not, in fact, be identical to the parent cell, but are still included within the
scope of the term "host cell" as used herein. Preferably host cells e prokaryotic
and eukaryotic cells ed from any of the Kingdoms of life. Preferred eukaryotic
cells include protist, fungal, plant and animal cells. Most preferably host cells include
but are not limited to the prokaryotic cell line E. Coli; mammalian cell lines CHO, HEK
293 and COS; the insect cell line Sf9; and the fungal cell Saccharomyces cerevisiae.
Standard techniques may be used for recombinant DNA, oligonucleotide
synthesis, and tissue culture and transformation (6. g., electroporation, lipofection).
Enzymatic ons and purification techniques may be performed according to
manufacturer's specifications or as commonly accomplished in the art or as described
herein. The foregoing techniques and procedures may be generally performed according
to conventional methods well known in the art and as described in various general and
more specific references that are cited and discussed throughout the present
specification. See e.g., Sambrook et a]. Molecular Cloning: A Laboratory Manual (2d
ed., Cold Spring Harbor tory Press, Cold Spring Harbor, NY. (1989)), which is
incorporated herein by nce for any purpose.
"Transgenic sm", as known in the art and as used herein, refers to an
organism having cells that contain a transgene, wherein the transgene introduced into the
organism (or an ancestor of the organism) expresses a polypeptide not naturally
expressed in the organism. A "transgene" is a DNA construct, which is stably and
operably integrated into the genome of a cell from which a transgenic organism
develops, directing the expression of an encoded gene product in one or more cell types
or tissues of the transgenic organism.
The term "regulate" and "modulate" are used interchangeably, and, as used
herein, refers to a change or an alteration in the activity of a molecule of interest (e.g.,
the biological activity of IL-l3). Modulation may be an increase or a se in the
magnitude of a certain activity or function of the molecule of interest. Exemplary
activities and functions of a molecule include, but are not limited to, binding
characteristics, enzymatic activity, cell or activation, and signal transduction.
Correspondingly, the term "modulator," as used herein, is a compound capable of
changing or altering an activity or function of a le of interest (e. g., the biological
ty of IL-l3). For example, a modulator may cause an increase or decrease in the
ude of a certain activity or function of a le compared to the magnitude of
the activity or function observed in the absence of the modulator. In certain
embodiments, a modulator is an tor, which decreases the magnitude of at least one
ty or function of a le. Exemplary inhibitors include, but are not limited to,
proteins, peptides, antibodies, peptibodies, carbohydrates or small organic molecules.
odies are described, e.g., in WOOl/83525.
The term "agonist", as used herein, refers to a modulator that, when contacted
with a molecule of interest, causes an increase in the magnitude of a certain activity or
function of the molecule compared to the magnitude of the activity or function observed
in the absence of the agonist. Particular agonists of interest may include, but are not
limited to, IL-13 polypeptides or polypeptides, nucleic acids, carbohydrates, or any other
WO 09521
molecules that bind to IL-l3.
The term "antagonist" or "inhibitor", as used , refer to a modulator that,
when contacted with a molecule of interest causes a decrease in the magnitude of a
certain activity or function of the le ed to the ude of the activity or
function observed in the absence of the nist. Particular antagonists of interest
include those that block or modulate the ical or immunological activity of IL-13
and/or IL-l3. Antagonists and inhibitors of IL-13 and/or IL—l3 may include, but are not
limited to, proteins; c acids, carbohydrates, or any other molecules, which bind to
IL-13 and/or IL-l3.
The term it binding to the receptor" refers to the ability of the binding
protein to t the binding of IL-13 to one or more of its receptors. Such inhibition of
binding to the receptor would result in diminishing or abolishing the biological activity
mediated by binding of IL-13 to its receptor or receptors.
As used herein, the term tive amount" refers to the amount of a therapy
which is sufficient to reduce or ameliorate the severity and/or duration of a disorder or
one or more symptoms thereof, prevent the advancement of a disorder, cause regression
of a disorder, prevent the recurrence, development, onset or progression of one or more
symptoms associated with a disorder, detect a disorder, or enhance or improve the
prophylactic or therapeutic effect(s) of another therapy (e. g., prophylactic or therapeutic
agent).
The term "sample", as used herein, is used in its broadest sense. A "biological
sample", as used herein, includes, but is not limited to, any quantity of a nce from
a living thing or formerly living thing. Such living things include, but are not limited to,
humans, mice, rats, monkeys, dogs, rabbits and other animals. Such substances include,
but are not limited to, blood, serum, urine, synovial fluid, cells, organs, tissues, bone
, lymph nodes and spleen.
The term “Cmax” refers to the maximum or peak serum or plasma concentration
of an agent observed in a subject after its administration.
In one embodiment, the anti-IL-l3 antibody, or antigen-binding portion thereof,
of the invention (e. g., a humanized anti-IL-l3 antibody such as l3C5.5, or an antigen-
WO 09521
binding portion thereof) is administered intravenously and exhibits a maximum serum
concentration (Cmax) of between about 5 and about 235 ug/mL; a peak concentration
(Cmax) of n about 5 and about 8 ug/ml; a Cmax of between about 5 and about 10
ug/mL; a peak concentration (Cmax) of between about 55 and about 90 ug/ml; a peak
concentration (Cmax) of between about 185 and about 250 ug/ml; a Cmax of between
about 190 and about 235 ug/mL. In another embodiment, the Cmax is n about 5
and about 50, n about 50 and about 75, between about 75 and about 100, between
about 100 and about 125, between about 125 and about 150, between about 150 and
about 175, between about 175 and about 200, or between about 200 and about 235
ug/mL.
In another embodiment, the anti-IL—13 antibody, or antigen-binding portion
thereof (e. g., a humanized anti-IL—13 antibody such as 13C5.5, or an antigen-binding
portion thereof), is administered intravenously and exhibits a Cmax value of between
about 20 and about 30 (ug/mL)/(mg/kg) after dose normalization. In r
embodiment, the L—13 antibody, or antigen-binding portion thereof, is administered
intravenously and exhibits a Cmax value of about 20, about 21, about 22, about 23, about
24, about 25, about 26, about 27, about 28, about 29 and about 30 (ug/mL)/(mg/kg) after
dose normalization. In another embodiment, the anti-IL-13 antibody, or antigen-binding
portion thereof, is stered intravenously and exhibits a Cmax value of between
2O about 10 and about 40 (ug/mL)/(mg/kg) after dose normalization.
In another embodiment, the L—13 dy, or antigen-binding portion
thereof, of the ion (e.g., a humanized anti-IL-13 antibody such as 13C5.5, or an
antigen-binding portion thereof) is administered subcutaneously and exhibits a
maximum serum concentration (Cmax) of between about 1 and about 60 ug/mL; a peak
concentration (Cmax) of between about 1.0 and about 6.0 ug/ml; a Cmax value of between
about 6 and about 12 ug/ml; a peak concentration (Cmax) of between about 12 and about
60 ug/ml; a Cmax value of between about 1 and about 10, between about 10 and about 20,
between about 20 and about 30, between about 30 and about 40, between about 40 and
about 50, between about 50 and about 60, between about 20 and about 60, or between
about 40 and about 60 ug/ml.
WO 09521
The term “me” refers to the time at which Cmax occurred. In one embodiment,
the anti-IL—13 antibody, or antigen-binding portion thereof, of the invention (e.g., a
humanized anti-IL-13 antibody such as 13C5.5, or an antigen-binding portion thereof) is
stered intravenously or subcutaneously and exhibits a Tmax of between about 1
and about 5 days; a Tmax of between about 3 and about 5 days; a Tmax of less than or
equal to about 5 days; a Tmax of about 1 day, a Tmax of about 2 days, a Tmax of about 3
days, a Tmax of about 4 days, a Tmax of about 5 days, a Tmax of about 6 days, a Tmax of
about 7 days, a Tmax of about 8 days, a Tmax of about 9 days, or a Tmax of about 10 days.
The term “bioavailability” or “F%” refers to a fraction or t of a dose which
is absorbed and enters the systemic circulation after administration of a given dosage
form. The dose of the L-13 antibody, or antigen-binding portion thereof, may be
administered through any route, and, preferably, via intravenous or subcutaneous
injection. In one embodiment, the anti-IL—13 antibody, or antigen-binding portion
thereof, of the invention (e.g., a humanized anti-IL-13 antibody such as 13C5.5, or an
antigen-binding portion thereof) is administered enously or subcutaneously and
ts a bioavailability of at least about 60%. In r embodiment, the antibody, or
antigen-binding portion thereof, exhibits a bioavailability of at least about 35%, at least
about 40%, at least about 45%, at least about 50%, at least about 60%, at least about
65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at
2O least about 90%, at least about 95%, or at least about 100%.
The term “AUC” or “area under the curve” is related to clearance. A higher
clearance rate is d to a smaller AUC, and a lower clearance rate is related to a
larger AUC value. The AUC higher values ent slower clearance rates.
In one embodiment, the anti-IL-13 antibody, or antigen-binding portion thereof,
of the invention (e. g., a humanized anti-IL-13 antibody such as 13C5.5, or an antigen-
binding n thereof) is administered intravenously and exhibits an area under the
curve (AUC) of between about 75 and about 100,000 ugh/mL; an AUC of between
about 75 and about 100; between about 1,500 and about 2,700 ugh/ml; between about
1,500 and about 3,000; between about 21,000 and about 33,500 ugh/ml; between about
1,500 and 98,000; between about 20,000 and about 34,000 ugh/mL; between about
34,000 and about 40,000; between about 40,000 and about ; between about
50,000 and about 60,000; between about 60,000 and about 75,000; between about
75,000 and about 100,000 ugh/mL; about 75, about 100, about 150, about 200, about
250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about
650, about 700, about 750, about 800, about 850, about 900, about 950, about 1,000;
about 1,100; about 1,200; about 1,300; about 1,400; about 1,500; about 1,600; about
1,700; about 1,800; about 1,900; about 2,000; about 2,250; about 2,500; about 2,750;
about 3,000; about 4,000; about 5,000; about 6,000; about 7,000; about 8,000; about
9,000; about 10,000; about 12,000; about 15,000; about 20,000; about 25,000; about
,000; about 35,000; about 40,000; about 45,000; about 50,000; about ; about
60,000; about 65,000; about 70,000; about 75,000; about 80,000, about ; about
90,000; about 95,000 or about 100,000 ugh/mL.
In another embodiment, the AUC is between about 6,000 and about 10,000
L)/(mg/kg) after dose normalization, between about 7,000 and about 9,000; about
6,000; about 6,500; about 7,000; about 7,500; about 8,000; about 8,500; about 9,000;
about 9,500 or about 10,000 (ugh/mL)/(mg/kg) after dose normalization.
In another embodiment, the anti-IL—13 antibody, or antigen-binding portion
thereof, of the invention (e.g., a humanized L-13 antibody such as 13C5.5, or an
2O antigen-binding n thereof) is administered subcutaneously and exhibits an area
under the curve (AUC) of between about 125 and about 8,100 ; between about
125 and about 800 ugh/ml; between about 800 and about 1,100; between about 1,100
and about 8,100; about 100 and about 800 ugh/mL; about 125; about 150; about 175;
about 200; about 250; about 300; about 350; about 400; about 450; about 500; about
550; about 600; about 650; about 700; about 750; about 800; about 850; about 900;
about 950; about 1,000; about 1,100; about 1,200; about 1,300; about 1,400; about
1,500; about 1,600; about 1,700; about 1,800; about 1,900; about 2,000; about 2,250;
about 2,500; about 3,000; about 3,500; about 4,000; about 4,500; about 5,000; about
,500; about 6,000; about 6,500; about 7,000; about 7,500; about 8,000 or about 8,100
ugh/mL.
As used herein, the term “clearance rate” is related to the AUC, or area under the
curve. A higher clearance rate is related to a smaller AUC, and a lower clearance rate is
related to a larger AUC value. The AUC higher values ent slower clearance rates.
In one ment, the anti-IL-13 antibody, or n-binding portion thereof,
of the invention (e. g., a humanized anti-IL-13 antibody such as 13C5.5, or an antigen-
binding portion thereof) is administered intravenously and exhibits a clearance rate of
between about 0.08 and about 0.2 ml/h/kg, between about 0.08 and about 0.15 ml/h/kg;
between about 0.1 and about 0.15 ml/h/kg; between about 0.11 to about 0.19 mL/hr/kg;
between about 0.08 to about 0.14 mL/hr/kg; between about 0.09 to about 0.13 mL/hr/kg;
about 0.08; about 0.09, about 0.1, about 0.11, about 0.12, about 0.13, about 0.14, about
0.15, about 0.16, about 0.17, about 0.18, about 0.19, about 2.0, about 2.1, about 2.2,
about 2.3, about 2.4 or about 2.5 mL/h/kg.
As used herein, the term “volume of distribution” is a term used to quantify the
distribution of a drug, e. g., an anti-IL-13 dy, or antigen-binding portion thereof,
between plasma and the rest of the body after dosing. The volume of distribution is the
theoretical volume in which the total amount of drug would need to be uniformly
bted in order to ed the d blood concentration of the drug.
In one embodiment, the anti-IL-13 antibody, or antigen-binding portion f,
of the invention (e. g., a humanized anti-IL-13 antibody such as 13C5.5, or an antigen-
2O binding portion thereof) is administered intravenously and exhibits a volume of
distribution of n about 55 and about 130 mL/kg; between about 65 and 125
mL/kg; between about 55 and about 100 mL/kg; n about 90 and about 130
mL/kg; between about 70 to about 130 mL/kg; between about 85 to about 130 mL/kg;
between about 100 to about 130; between about 110 to about 120; about 55, about 60,
about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about
105, about 110, about 115, about 120, about 125, about 130 or about 135 mL/kg.
In one embodiment, the anti-IL-13 antibody, or antigen-binding portion thereof,
of the invention (e. g., a humanized anti-IL-13 antibody such as 13C5.5, or an antigen-
binding portion thereof) is administered intravenously or subcutaneously and has a half-
life of between about 24 and 31 days; between about 23 and 26 days; between about 10
and about 40 days, between about 20 and about 30 days, about 10 days, about 15 days,
about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21
days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about
27 days, about 28 days, about 29 days, about 30 days, about 31 days, about 32 days,
about 33 days, about 34 days, about 35 days, about 36 days, about 37 days, about 38
days, about 39 days, or about 40 days.
The term “dosing” or “dose” or “dosage”, as used herein, refers to the
administration of a substance (e.g., an anti-IL-13 antibody, or antigen-binding portion
thereof) to achieve a therapeutic ive (e.g., the treatment of asthma).
In one embodiment, the composition of the invention is administered once. In
another embodiment, the ition of the invention is administered weekly. In
another ment, the composition of the invention is administered for two weeks. In
r embodiment, the composition of the invention is administered for three weeks.
In another embodiment, the composition is administered for four weeks, five weeks, six
weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, three months,
four months, five months, six , seven months, eight months, nine months, ten
, eleven , twelve months, thirteen months, fourteen months, fifteen
months, sixteen months, seventeen months, eighteen months, nineteen months, twenty
2O months, twenty-one months, twenty-two , twenty-three months, two years, three
years, four years, five years, ten years, or for the life of the subject.
The term “combination” as in the phrase “a first agent in combination with a
second agent” includes co-administration of a first agent and a second agent, which for
example may be dissolved or intermixed in the same pharmaceutically acceptable
r, or administration of a first agent, followed by the second agent, or stration
of the second agent, followed by the first agent. The present invention, therefore,
includes methods of combination therapeutic treatment and combination pharmaceutical
compositions.
The term “concomitant” as in the phrase “concomitant therapeutic ent”
includes administering an agent in the presence of a second agent. A concomitant
therapeutic treatment method includes s in which the first, second, third, or
additional agents are co-administered. A concomitant therapeutic treatment method also
es methods in which the first or additional agents are administered in the presence
of a second or additional agents, wherein the second or additional agents, for example,
may have been previously administered. A concomitant therapeutic ent method
may be executed step-wise by different actors. For example, one actor may administer
to a t a first agent and a second actor may to administer to the subject a second
agent, and the administering steps may be executed at the same time, or nearly the same
time, or at distant times, so long as the first agent (and additional agents) are after
administration in the presence of the second agent (and additional agents). The actor
and the subject may be the same entity (e.g., .
The term nation y”, as used herein, refers to the administration of
two or more therapeutic substances, e. g., an anti-IL-l3 antibody and another drug. The
other drug(s) may be administered concomitant with, prior to, or following the
administration of the anti-IL-l3 antibody.
The term "kit" as used herein refers to a packaged product comprising
components with which to administer the anti-IL-l3 antibody of the invention for
treatment of a IL-l3 related disorder. The kit preferably comprises a box or container
that holds the components of the kit. The box or container is affixed with a label or a
Food and Drug Administration approved protocol. The box or container holds
components of the invention which are preferably contained within plastic,
hylene, polypropylene, ethylene, or propylene vessels. The vessels can be capped-
tubes or bottles. The kit can also include instructions for administering an anti-IL-l3
antibody.
Various s of the invention are described in further detail in the following
subsections.
WO 09521
I. dies that Bind IL-13
This invention provides methods and compositions for using anti-IL-13
dies, or antigen-binding ns thereof, for the treatment of asthma. In one
aspect, the present invention provides compositions which include and/or s
which use isolated murine monoclonal antibodies, or n-binding portions thereof,
that bind to IL-13 with high affinity, a slow off rate and high lizing capacity. In a
second aspect, the invention provides compositions which include and/or methods which
use chimeric antibodies that bind IL-13. In a third aspect, the invention provides
compositions which include and/or methods which use humanized antibodies, or
antigen-binding ns thereof, that bind IL-13. Preferably, the antibodies, or portions
thereof, are isolated antibodies. Preferably, the antibodies are neutralizing anti-IL-13
and/or humanized or human anti-IL-13 antibodies.
A. Methods of Making Anti-IL-13 Antibodies
Antibodies to be used in the compositions and/or methods of the present
invention may be made by any of a number of techniques known in the art. For
example, they can be made using the techniques disclosed in US. Patent No. 7,915, 338,
the entire contents of which are incorporated herein by reference.
1. Anti-IL-13 Monoclonal Antibodies Using Hybridoma Technology
Monoclonal antibodies can be prepared using a wide variety of techniques
known in the art including the use of hybridoma, recombinant, and phage display
technologies, or a ation thereof. For example, monoclonal antibodies can be
produced using hybridoma techniques including those known in the art and taught, for
example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor
Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-
Cell Hybridomas 563-681 (Elsevier, N.Y., 1981) (said references incorporated by
reference in their entireties). The term "monoclonal antibody" as used herein is not
limited to antibodies produced through hybridoma technology. The term "monoclonal
antibody" refers to an antibody that is derived from a single clone, including any
eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
Methods for producing and screening for specific antibodies using hybridoma
technology are routine and well known in the art. In one embodiment, the present
invention provides methods of generating monoclonal antibodies as well as antibodies
produced by the method sing culturing a hybridoma cell secreting an antibody of
the invention wherein, preferably, the hybridoma is generated by fusing splenocytes
isolated from a mouse immunized with an antigen of the invention with myeloma cells
and then screening the hybridomas resulting from the fusion for hybridoma clones that
secrete an antibody able to bind a ptide of the invention (See Example 1.2).
Briefly, mice can be zed with an IL—l3 n. In a preferred embodiment, the
IL-l3 antigen is administered with an adjuvant to stimulate the immune response. Such
adjuvants include complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides)
or ISCOM (immunostimulating xes). Such adjuvants may protect the polypeptide
from rapid dispersal by sequestering it in a local deposit, or they may contain substances
that stimulate the host to secrete factors that are chemotactic for macrophages and other
components of the immune system. Preferably, if a polypeptide is being stered,
the immunization le will involve two or more administrations of the polypeptide,
spread out over several weeks.
After immunization of an animal with an IL-l3 antigen, antibodies and/or
antibody-producing cells may be obtained from the animal. An anti-IL-l3 antibody-
containing serum is obtained from the animal by bleeding or sacrificing the animal. The
serum may be used as it is obtained from the animal, an immunoglobulin on may
be obtained from the serum, or the anti-IL-l3 antibodies may be purified from the
serum. Serum or immunoglobulins obtained in this manner are polyclonal, thus having a
heterogeneous array of properties.
Once an immune response is ed, e. g., antibodies specific for the antigen IL-
13 are detected in the mouse serum, the mouse spleen is harvested and splenocytes
isolated. The cytes are then fused by well-known ques to any suitable
myeloma cells, for example cells from cell line SP20 available from the ATCC.
omas are selected and cloned by d dilution. The hybridoma clones are then
assayed by methods known in the art for cells that secrete dies capable of binding
IL-l3. Ascites fluid, which generally contains high levels of dies, can be generated
by immunizing mice with ve hybridoma clones.
In another embodiment, antibody-producing immortalized hybridomas may be
prepared from the immunized animal. After immunization, the animal is sacrificed and
the splenic B cells are fused to alized myeloma cells as is well known in the art.
See, e.g., Harlow and Lane, supra. In a preferred embodiment, the myeloma cells do not
secrete immunoglobulin polypeptides (a non-secretory cell line). After fusion and
antibiotic selection, the hybridomas are screened using IL-l3, or a portion thereof, or a
cell expressing IL-l3. In a preferred ment, the initial ing is performed
using an -linked immunoassay (ELISA) or a radioimmunoassay (RIA),
preferably an ELISA. An example of ELISA ing is provided in WO 00/37504,
herein incorporated by reference.
Anti-IL-l3 antibody-producing hybridomas are selected, cloned and further
screened for desirable characteristics, including robust hybridoma , high dy
production and desirable antibody characteristics, as discussed further below.
Hybridomas may be cultured and expanded in vivo in syngeneic s, in animals that
lack an immune system, e.g., nude mice, or in cell culture in vitro. Methods of selecting,
cloning and ing hybridomas are well known to those of ordinary skill in the art.
In a preferred embodiment, the hybridomas are mouse omas, as described
above. In another preferred embodiment, the hybridomas are produced in a non-human,
non-mouse species such as rats, sheep, pigs, goats, cattle or horses. In another
embodiment, the hybridomas are human hybridomas, in which a human non-secretory
myeloma is fused with a human cell expressing an anti-IL—l3 antibody.
Antibody fragments that recognize ic epitopes may be generated by known
techniques. For example, Fab and F(ab‘)2 fragments of the invention may be produced
by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to
e Fab fragments) or pepsin (to produce F(ab‘)2 fragments). F(ab‘)2 fragments
contain the variable region, the light chain constant region and the CH1 domain of the
heavy chain.
2. Anti-IL-l3 Monoclonal Antibodies Using SLAM
Recombinant antibodies for use in the compositions and/or methods of the
present invention may also be generated from single, isolated lymphocytes using a
procedure referred to in the art as the selected lymphocyte antibody method (SLAM), as
described in US. Pat. Nos. 7,915,388 and 5,627,052, PCT Publication WO 92/02551
and Babcock, J. S. et a1. (1996) Proc. Natl. Acad. Sci. USA 93:7843-7848, the entire
contents of each of which are incorporated herein by nce. Briefly, single cells
secreting antibodies of interest, e. g., lymphocytes derived from any one of the
immunized s described above, are screened using an antigen-specific hemolytic
plaque assay, wherein the antigen IL—13, a subunit of IL-13, or a fragment thereof, is
coupled to sheep red blood cells using a linker, such as biotin, and used to identify single
cells that secrete antibodies with icity for IL—13. Following identification of
antibody-secreting cells of interest, heavy- and light-chain variable region cDNAs are
rescued from the cells by reverse transcriptase-PCR and these variable regions can then
be expressed, in the context of appropriate immunoglobulin nt regions (e. g.,
human constant regions), in mammalian host cells, such as COS or CHO cells. The host
cells transfected with the amplified immunoglobulin sequences, derived from in vivo
selected lymphocytes, can then undergo further analysis and selection in vitro, for
example by panning the transfected cells to isolate cells expressing antibodies to IL-13.
The amplified immunoglobulin sequences further can be manipulated in vitro, such as
2O by in vitro ty maturation s such as those described in PCT ation WO
97/29131 and PCT ation WO 72.
3. Anti-IL-13 Monoclonal Antibodies Using Transgenic Animals
Antibodies for use in the compositions and/or methods of the present invention
may also be produced by zing a non-human animal comprising some, or all, of
the human immunoglobulin locus with an IL-13 antigen. In a preferred embodiment, the
non-human animal is a USE transgenic mouse, an engineered mouse strain
that comprises large fragments of the human immunoglobulin loci and is deficient in
mouse dy production. See, e.g., Green et al. Nature Genetics 7:13-21 (1994) and
US. Pat. Nos. 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181, 6,091,001,
6,114,598 and 6,130,364. See also WO 91/10741, published Jul. 25, 1991, W0
02, published Feb. 3, 1994, WO 96/34096 and WO 96/33735, both published Oct.
31, 1996, WO 98/16654, published Apr. 23, 1998, WO 98/24893, published Jun. 11,
1998, WO 98/50433, published Nov. 12, 1998, WO 99/45031, published Sep. 10, 1999,
WO 99/53049, published Oct. 21, 1999, W0 00 09560, published Feb. 24, 2000 and
WO 00/037504, published Jun. 29, 2000, the entire contents of each of which are
expressly incorporated herein by reference. The XENOMOUSE transgenic mouse
produces an adult-like human repertoire of fully human antibodies, and generates
antigen-specific human Mabs. The XENOMOUSE transgenic mouse contains
imately 80% of the human dy repertoire through introduction of megabase
sized, germline configuration YAC fragments of the human heavy chain loci and x light
chain loci. See Mendez et al., Nature Genetics 15:146-156 (1997), Green and Jakobovits
J. Exp. Med. 188:483-495 (1998), the disclosures of which are hereby incorporated by
nce.
4. Anti-IL-13 Monoclonal dies Using Recombinant Antibody
Libraries
In vitro s also can be used to make the dies for use in the
itions and/or methods of the ion, wherein an antibody library is screened to
identify an antibody haVing the desired binding specificity. Methods for such screening
2O of recombinant antibody libraries are well known in the art and include methods
described in, for example, Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. PCT
Publication No. W0 92/18619; Dower et a]. PCT Publication No. W0 91/17271; Winter
et al. PCT Publication No. WO 91; Markland et a]. PCT Publication No. W0
92/15679; Breitling et a]. PCT Publication No. WO 93/01288; McCafferty et a]. PCT
Publication No. WO 92/01047; Garrard et a]. PCT Publication No. WO 92/09690; Fuchs
et al. (1991) Bio/Technology 9:1370-1372; Hay et a1. (1992) Hum Antibod Hybridomas
3:81-85; Huse et a1. (1989) Science 246:1275-1281; McCafferty et al., Nature (1990)
348:552-554; Griffiths et a1. (1993) EMBO J. 12:725-734; Hawkins et al. (1992) J Mol
Biol 226:889-896; Clackson et a1. (1991) Nature 352:624-628; Gram et a1. (1992) PNAS
6-3580; Garrad et a1. (1991) Bio/Technology 9: 1373-1377; Hoogenboom et a1.
(1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, US
patent application publication 20030186374, and PCT Publication No. WO 97/29131,
the contents of each of which are incorporated herein by reference.
The recombinant antibody library may be from a subject immunized with IL-13
or IL-13, or a portion of IL-13 or IL-13. atively, the recombinant dy library
may be from a naive subject, i.e., one who has not been immunized with IL—13, such as a
human antibody library from a human subject who has not been immunized with human
IL-13. Antibodies of the invention are selected by screening the recombinant antibody
library with the peptide comprising human IL—13 to thereby select those dies that
recognize IL—13. Methods for conducting such screening and selection are well known in
the art, such as bed in the references in the preceding paragraph. To select
antibodies of the invention having particular g affinities for IL-13, such as those
that dissociate from human IL-13 with a particular k.sub.off rate constant, the art-known
method of surface plasmon resonance can be used to select antibodies having the desired
k.sub.off rate constant. To select antibodies of the invention having a particular
neutralizing activity for IL-13, such as those with a particular an IC.sub.50, standard
methods known in the art for assessing the inhibition of IL—13 activity may be used.
In one aspect, the invention pertains to an isolated antibody, or an antigen-
binding portion thereof, that binds human IL-13. Preferably, the antibody is a
lizing antibody. In various embodiments, the antibody is a recombinant antibody
2O or a monoclonal antibody.
For example, the antibodies of the present invention can also be generated using
s phage display methods known in the art. In phage display methods, functional
antibody s are displayed on the e of phage particles which carry the
polynucleotide ces ng them. In a particular, such phage can be ed to
display antigen-binding domains expressed from a oire or combinatorial antibody
library (6. g., human or murine). Phage expressing an antigen binding domain that binds
the antigen of interest can be selected or identified with antigen, e. g., using labeled
n or antigen bound or captured to a solid surface or bead. Phage used in these
methods are typically filamentous phage including fd and M13 binding domains
sed from phage with Fab, Fv or disulfide stabilized Fv antibody domains
recombinantly fused to either the phage gene III or gene VIII protein. Examples of
phage display methods that can be used to make the antibodies of the present invention
include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995);
Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J.
Immunol. 24:952-958 ; Persic et (11., Gene 187 9-18 (1997); Burton et (1].,
Advances in Immunology 57: 191-280 (1994); PCT application No. PCT/GB91/01134;
PCT publications WO 90/02809; W0 91/10737; WO 47; W0 92/18619; WO
93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409;
,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908;
637; 5,780,225; 727; 5,733,743 and 5,969,108; each of which is
incorporated herein by reference in its entirety.
As described in the above references, after phage selection, the antibody coding
regions from the phage can be isolated and used to generate whole antibodies including
human dies or any other d antigen binding fragment, and expressed in any
desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria,
e. g., as described in detail below. For example, techniques to inantly produce
Fab, Fab‘ and F(ab')2 fragments can also be employed using methods known in the art
such as those disclosed in PCT publication WO 24; Mullinax et al.,
BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and
Better et al., Science 240: 1041-1043 (1988) (said references incorporated by reference
2O in their entireties). Examples of techniques which can be used to produce single-chain
Fvs and antibodies include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498;
Huston et (11., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-
7999 (1993); and Skerra et al., Science 240:1038-1040 (1988).
ative to ing of recombinant antibody libraries by phage display,
other methodologies known in the art for screening large combinatorial libraries can be
applied to the identification of dual icity antibodies of the invention. One type of
alternative sion system is one in which the recombinant dy library is
expressed as RNA-protein fusions, as described in PCT Publication No. WO 98/31700
by Szostak and Roberts, and in Roberts, R. W. and Szostak, J. W. (1997) Proc. Natl.
Acad. Sci. USA 94: 12297-12302. In this system, a covalent fusion is created between an
mRNA and the peptide or protein that it encodes by in vitro translation of synthetic
mRNAs that carry puromycin, a peptidyl acceptor antibiotic, at their 3' end. Thus, a
ic mRNA can be ed from a complex mixture of mRNAs (e. g., a
combinatorial y) based on the properties of the encoded peptide or protein, e.g.,
antibody, or n thereof, such as binding of the antibody, or portion f, to the
dual specificity antigen. Nucleic acid sequences encoding dies, or portions thereof,
recovered from screening of such libraries can be expressed by recombinant means as
described above (6. g., in mammalian host cells) and, moreover, can be subjected to
further ty maturation by either additional rounds of screening of mRNA-peptide
fusions in which mutations have been introduced into the originally selected
sequence(s), or by other methods for affinity maturation in vitro of recombinant
antibodies, as described above.
In another approach the antibodies for use in the compositions and/or methods of
the present invention can also be ted using yeast display methods known in the
art. In yeast display methods, genetic methods are used to tether antibody domains to the
yeast cell wall and display them on the surface of yeast. In particular, such yeast can be
utilized to display antigen-binding domains expressed from a repertoire or combinatorial
antibody library (e. g., human or murine). Examples of yeast display methods that can be
used to make the antibodies of the present invention include those disclosed Wittrup, et
a1. U.S. Pat. No. 6,699,658 incorporated herein by reference.
B. Production of Recombinant IL-l3 Antibodies
dies for use in the compositions and/or methods of the present invention
may be produced by any of a number of techniques known in the art. For example,
expression from host cells, wherein expression vector(s) encoding the heavy and light
chains is (are) transfected into a host cell by standard techniques. The various forms of
the term "transfection" are intended to encompass a wide variety of techniques
commonly used for the introduction of exogenous DNA into a prokaryotic or otic
host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran
transfection and the like. Although it is possible to express the antibodies of the
invention in either prokaryotic or eukaryotic host cells, expression of antibodies in
otic cells is preferable, and most preferable in ian host cells, because
such eukaryotic cells (and in particular mammalian cells) are more likely than
prokaryotic cells to assemble and secrete a properly folded and immunologically active
antibody.
Preferred ian host cells for expressing the recombinant antibodies of the
invention include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells,
described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used
with a DHFR selectable marker, e. g., as described in R. J. Kaufman and P. A. Sharp
(1982) Mol. Biol. 159:601-621), NSO myeloma cells, COS cells and SP2 cells. When
recombinant expression s encoding antibody genes are introduced into mammalian
host cells, the antibodies are produced by culturing the host cells for a period of time
sufficient to allow for expression of the antibody in the host cells or, more preferably,
secretion of the antibody into the culture medium in which the host cells are grown.
Antibodies can be recovered from the culture medium using standard protein
purification methods.
Host cells can also be used to produce onal antibody fragments, such as
Fab fragments or scFv molecules. It will be understood that variations on the above
procedure are within the scope of the t invention. For example, it may be desirable
to transfect a host cell with DNA encoding functional fragments of either the light chain
and/or the heavy chain of an antibody of this invention. Recombinant DNA technology
2O may also be used to remove some, or all, of the DNA ng either or both of the light
and heavy chains that is not necessary for binding to the antigens of interest. The
molecules expressed from such truncated DNA molecules are also encompassed by the
antibodies of the invention. In on, bifunctional antibodies may be produced in
which one heavy and one light chain are an antibody of the ion and the other
heavy and light chain are specific for an n other than the antigens of interest by
crosslinking an antibody of the invention to a second antibody by standard chemical
inking s.
In a preferred system for recombinant expression of an antibody, or antigen-
binding portion thereof, of the invention, a recombinant expression vector encoding both
the antibody heavy chain and the antibody light chain is introduced into dhfr-CHO cells
by calcium phosphate-mediated transfection. Within the recombinant sion vector,
the antibody heavy and light chain genes are each ively linked to CMV
enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of
the genes. The recombinant sion vector also carries a DHFR gene, which allows
for selection of CHO cells that have been transfected with the vector using methotrexate
selection/amplification. The selected transformant host cells are cultured to allow for
expression of the antibody heavy and light chains and intact antibody is recovered from
the culture medium. Standard lar biology techniques are used to prepare the
recombinant expression vector, transfect the host cells, select for ormants, culture
the host cells and recover the antibody from the culture medium. Still further the
invention provides a method of synthesizing a recombinant antibody of the invention by
culturing a host cell of the invention in a suitable culture medium until a recombinant
antibody of the invention is synthesized. The method can further comprise isolating the
recombinant antibody from the e medium.
1. Anti IL-13 Antibodies
Table 5 of U.S. Patent No. 7,195,388 (the contents of which are incorporated
herein by nce) is a list of amino acid sequences of VH and VL regions of preferred
anti-IL-13 antibodies to be used in the compositions and/or methods of the invention.
These isolated anti-IL-13 antibody CDR sequences establish a family of IL-13 binding
proteins, isolated in accordance with this invention, and comprising polypeptides that
include the CDR ces listed in Table 6 of U.S. Patent No. 7,195,388 (the ts
of which are orated herein by reference). To generate and to select CDRs of the
invention having preferred IL-13 binding and/or neutralizing activity with respect to IL-
13 and/or IL-13, standard methods known in the art for generating binding ns of
the present ion and assessing the IL—13 and or IL-13 binding and/or neutralizing
characteristics of those binding protein may be used, including but not limited to those
specifically described herein.
In one embodiment, the antibody used in the compositions and/or s of the
invention is the antibody 13C5.5 (see US Patent No. 388, the entire contents of
which are incorporated herein by reference). 13C5.5 is a humanized antibody that binds
with great affinity to helices A and D of interleukin 13 (IL-13) (see Figure 1). The
heavy and light chain variable region sequences of 13C5.5 are set forth above as SEQ ID
N02 and SEQ ID NO:3, respectively.
2. Anti IL-13 Chimeric Antibodies
A chimeric antibody is a molecule in which different portions of the antibody are
derived from different animal species, such as dies having a variable region
derived from a murine monoclonal antibody and a human immunoglobulin constant
region. Methods for producing chimeric antibodies are known in the art and sed in
detail in e 2.1. See e.g., Morrison, Science 229:1202 (1985); Oi et al.,
BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202;
US. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by
reference in their entireties. In addition, techniques developed for the production of
"chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. -855;
Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454
which are incorporated herein by reference in their entireties) by splicing genes from a
mouse antibody molecule of appropriate antigen specificity er with genes from a
human dy molecule of appropriate biological activity can be used.
In one embodiment, the chimeric antibodies for use in the compositions and/or
2O methods of the invention are produced by replacing the heavy chain constant region of
the murine monoclonal anti human IL—13 antibodies described in section 1 with a human
IgG1 nt region. In a ic embodiment the chimeric antibody of the invention
ses a heavy chain variable region (VH) comprising the amino acid sequence of
SEQ ID NO: 34; SEQ ID NO: 36; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 46
and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID
NO: 35; SEQ ID NO: 37; SEQ ID NO: 40; SEQ ID NO: 43; or SEQ ID NO: 47
disclosed in US. Patent No. 388.
3. Anti IL-13 Humanized Antibodies
Humanized antibodies are antibody molecules from non-human species antibody
that binds the desired antigen having one or more complementarity determining regions
WO 09521
(CDRs) from the non-human species and framework regions from a human
immunoglobulin molecule. Known human Ig sequences are disclosed, e. g., Kabat et al.,
Sequences of Proteins of Immunological st, U.S. Dept. Health (1983), entirely
incorporated herein by reference. Such imported sequences can be used to reduce
immunogenicity or reduce, e or modify binding, affinity, on-rate, off-rate,
avidity, specificity, half-life, or any other suitable characteristic, as known in the art.
ork residues in the human framework regions may be substituted with
the ponding residue from the CDR donor antibody to alter, preferably improve,
n binding. These framework substitutions are identified by methods well known in
the art, e.g., by modeling of the interactions of the CDR and framework residues to
identify framework residues important for antigen binding and sequence comparison to
fy l framework residues at particular positions. (See, e.g., Queen et al., U.S.
Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated
herein by reference in their entireties.) Three-dimensional immunoglobulin models are
commonly available and are familiar to those skilled in the art. Computer programs are
available which illustrate and display probable three-dimensional mational
structures of selected candidate immunoglobulin ces. Inspection of these displays
permits is of the likely role of the residues in the functioning of the candidate
immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the
2O ate immunoglobulin to bind its antigen. In this way, FR residues can be selected
and combined from the consensus and import sequences so that the desired antibody
characteristic, such as increased affinity for the target antigen(s), is ed. In l,
the CDR residues are directly and most substantially involved in influencing antigen
binding. Antibodies can be humanized using a variety of techniques known in the art,
such as but not limited to those described in Jones et al., Nature 321 :522 (1986);
Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol. 151: 2296 (1993);
Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl. Acad. Sci.
USA. 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993), Padlan, Molecular
Immunology ):489-498 (1991); Studnicka et (11., Protein Engineering 7(6):805-
814 (1994), Roguska. et al., PNAS 91:969-973 (1994); PCT publication WO 91/09967,
PCT/: US98/16280, US96/18978, US91/09630, US91/05939, US94/01234,
GB89/01334, GB91/01134, GB92/01755; WO90/14443, WO90/14424, WO90/14430,
EP 229246, EP 592,106; EP 519,596, EP 239,400, U.S. Pat. Nos. 5,565,332, 5,723,323,
862, 5,824,514, 5,817,483, 5,814,476, 5,763,192, 323, 5,766886, 5,714,352,
6,204,023, 6,180,370, 5,693,762, 5,530,101, 5,585,089, 5,225,539; 4,816,567, each
entirely incorporated herein by reference, included references cited therein.
C. Production of Antibodies and Antibody-producing Cell Lines
Preferably, L-13 antibodies for use in the compositions and/or methods of
the present invention exhibit a high capacity to reduce or to neutralize IL-13 activity,
e.g., as assessed by any one of several in vitro and in vivo assays known in the art (e.g.,
see Example 1.1.C of US. Patent No. 388, the entire contents of which are
incorporated herein by reference.). For example, these antibodies neutralize IL
d production of TARC by A-549 cells with IC50 values in the range of at least
about 10'8 M, about 10'9 M, or about 10'10 M.
In preferred embodiments, the isolated antibody, or antigen-binding n
thereof, binds human IL-13, wherein the antibody, or n-binding portion thereof,
dissociates from human IL-13 with a koff rate constant of about 0.1s'1 or less, as
determined by surface plasmon resonance, or which inhibits human IL—13 and/or human
IL-13 activity with an IC50 of about 1x10.sup.-6M or less. Alternatively, the antibody, or
2O an antigen-binding portion thereof, may dissociate from human IL—13 with a koff rate
constant of about 1x10'2s'1 or less, as determined by surface plasmon resonance, or may
inhibit human IL—13 and/or human IL-13 activity with an IC50 of about 1x10'7M or less.
Alternatively, the antibody, or an n-binding portion thereof, may dissociate from
human IL-13 with a koff rate constant of about 1x10'3s'1 or less, as determined by surface
plasmon resonance, or may inhibit human IL—13 and/or human IL-13 with an IC50 of
about 1x10'8M or less. Alternatively, the dy, or an antigen-binding portion thereof,
may dissociate from human IL—13 with a koff rate constant of about 1x104s'1 or less, as
determined by surface plasmon resonance, or may inhibit IL— 13 and/or human L-13
ty with an IC50 of about M or less. Alternatively, the antibody, or an antigen-
binding portion thereof, may dissociate from human IL—13 with a koff rate nt of
about s'1 or less, as determined by surface plasmon nce, or may inhibit IL-
13 and/or human IL—13 activity with an IC50 of about 1x10'10M or less. Alternatively, the
antibody, or an antigen-binding portion thereof, may dissociate from human IL-13 with
a koff rate constant of about s'1 or less, as determined by surface n
resonance, or may inhibit IL-13 and/or human IL-13 activity with an IC50 of about
M or less.
IL-13 exerts its actions by binding to the IL-13 receptor R) on the cell
surface, the heterodimer comprised of the IL-13R0t1 chain (IL-13R0t1) and the IL—4R
chain (IL-4R). IL-13 binds to 0t1 first with low affinity (KD=2'10 nM) and then
recruits IL-4R to the complex, generating a high affinity receptor (KD=0.03-0.4 nM)
(Aman, M. J., et al. 1996 J. Biol. Chem. 271, 29265-29270; Miloux, et al. 1997 FEBS
Lett. 401, 163-166; Andrews, et al 2002 J. Biol. Chem. 277, 46073-46078).
Heterodimerization of IL-13R causes activation of Janus kinases, TYK2 and JAKl,
constitutively associated with IL-13R0t1 and IL-4R, respectively, followed by activation
of the signal transducer and activator of transcription 6 (STAT6) (Izuhara, K., and
Arima, K. 2004 Drug News Perspect. 17, 91-98). There is another ILbinding unit,
the IL-13R0t2 chain (IL-13R0t2), which binds to IL-13 with high affinity (0.25-1.2 nM)
(Caput, et al 1996J. Biol. Chem. 271, 16921-16926; Donaldson et al 1998 J. l.
161, 2317-2324). No other receptor molecule is known to be involved in the IL-13IL-
13R2 complex. 2 is initially t to act as a nonsignaling " receptor.
2O However, it was later discovered that it can bind to IL-13 and signals through AP-l
pathway, leading to TNF-beta production in certain cell types including hages,
which in turn leads to lung fibrosis (Fichtner-Feigl, 2006 Nat Med 12:99-106).
Therefore both IL-13R0t1/IL-4R0t and IL-13R0t2 ys contribute to the overall
pathophysiology of asthma and other pulmonary inflammatory conditions. Therefore, a
therapeutic anti-IL-13 antibody that blocks IL-13 binding to both receptors will be more
effective that those that blocks only one receptor.
In one , the instant invention provides compositions and/or methods which
use monoclonal antibodies that block IL—13 binding to both IL-13R0t1 and IL-13R0t2.
Both ELISA-based receptor binding assay and 125-I-labeled IL-13 g assay on cell
surface demonstrated that 13C5, both murine version and humanized version (i.e.,
13C5.5), were able to effective block IL-13 binding to both receptors. Antibodies in the
same lineage as 13C5, including 25C8 and 33C3, were also able to block IL-13 binding
to both receptors. Epitope mapping of 13C5 indicated that its binding site(s) included the
C-terminal Helix D region of human IL-13 (residues VRDTK IEVAQ FVKDL LLHLK
KLFRE GR, corresponding to amino acid 104-130 of SEQ ID NO. 1). The c-terminal
helix D region has been proposed to be involved in interactions with the IL-13 receptor
(Zuegg et al 2001 Immunol Cell Biol. 79:332-9). Crystal structure of human IL-13
complexed with the Fab portion of 13C5.5 dy indicated that 13C5.5 binds the C-
al Helix D region as well as the N-terminal Helix A region of human IL-13.
Preferably the antibody, or antigen binding fragment thereof binds human IL-13 such
that IL-13 with said antibody, or antigen binding fragment thereof, bound to the epitope
defined by the topographic regions Ser26-Thr27-Ala28-Leu29-Arg30-Glu31-Leu32-
Ile33-Glu34-Glu35-Leu36-Val37-A- sn38 and Lys123-Lys124-Leu125-Phe126-Arg127-
GluGly129-Arg130 of SEQ ID No. 1 is inhibited from binding to the IL-13
receptor. Preferably the antibody, or n g fragment thereof binds human IL-
13 such that IL-13 with said dy, or antigen binding fragment f, bound to the
epitope defined by the topographic regions Arg30-Glu3'—Leu32-Ile33-Glu34-Glu35-
Leu36-Val37-Asn38 and -Lys124-Leu125-Phe126-Arg127 of SEQ ID No. 1 is
inhibited from binding to the IL-13.alpha.2 receptor.
In n embodiments, the antibody comprises a heavy chain constant region,
2O such as an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region. Preferably,
the heavy chain nt region is an IgGl heavy chain constant region or an IgG4
heavy chain constant region. Furthermore, the dy can comprise a light chain
constant region, either a kappa light chain constant region or a lambda light chain
nt region. Preferably, the antibody comprises a kappa light chain constant region.
Alternatively, the antibody portion can be, for example, a Fab fragment or a single chain
Fv fragment.
ements of amino acid residues in the Fc portion to alter antibody effector
function are known in the art (Winter, et al. US. Pat. Nos. 5,648,260; 5,624,821). The
Fc portion of an antibody mediates several important effector functions e. g. cytokine
ion, ADCC, phagocytosis, complement dependent cytotoxicity (CDC) and half-
life/clearance rate of antibody and antigen-antibody complexes. In some cases these
WO 09521
effector functions are desirable for therapeutic antibody but in other cases might be
unnecessary or even deleterious, depending on the therapeutic objectives. Certain human
IgG es, particularly IgG1 and IgG3, mediate ADCC and CDC via binding to
Fc.gamma.Rs and complement Clq, respectively. Neonatal Fc receptors (FcRn) are the
critical components determining the circulating half-life of antibodies. In still another
embodiment at least one amino acid e is replaced in the constant region of the
antibody, for example the Fc region of the antibody, such that effector functions of the
antibody are altered.
In one embodiment, the methods and compositions of the invention use a labeled
binding protein wherein an antibody or antibody portion of the invention is derivatized
or linked to another onal molecule (e.g., another peptide or protein). For example,
a labeled binding protein of the invention can be derived by onally linking an
dy or dy portion of the invention (by chemical coupling, genetic fusion,
noncovalent association or otherwise) to one or more other molecular entities, such as
another antibody (e.g., a ific antibody or a diabody), a detectable agent, a
cytotoxic agent, a pharmaceutical agent, and/or a n or peptide that can mediate
associate of the antibody or antibody portion with another molecule (such as a
streptavidin core region or a polyhistidine tag).
Useful detectable agents with which an antibody or antibody portion of the
invention may be tized include fluorescent compounds. Exemplary fluorescent
detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-
dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin and the like. An antibody
may also be derivatized with detectable enzymes, such as alkaline phosphatase,
horseradish peroxidase, glucose oxidase and the like. When an antibody is derivatized
with a detectable , it is detected by adding onal reagents that the enzyme
uses to produce a detectable reaction product. For example, when the detectable agent
horseradish peroxidase is t, the addition of en peroxide and
diaminobenzidine leads to a colored reaction product, which is detectable. An antibody
may also be tized with biotin, and detected h indirect measurement of
avidin or streptavidin binding.
In another embodiment, the compositions and methods of the invention use a
crystallized g protein. Preferably the invention relates to crystals of whole anti-IL-
13 dies and fragments thereof as disclosed herein, and formulations and
compositions comprising such crystals. In one embodiment the crystallized binding
protein has a greater ife in vivo than the soluble counterpart of the binding protein.
In another embodiment the binding protein retains biological activity after
crystallization.
Crystallized binding protein of the invention may be produced according
methods known in the art and as disclosed in WO 02072636, incorporated herein by
reference.
In yet another ment, the compositions and/or methods of the invention
use a glycosylated binding protein wherein the antibody or n-binding portion
thereof comprises one or more carbohydrate residues. t in vivo protein production
may undergo further processing, known as post-translational modification. In particular,
sugar syl) residues may be added enzymatically, a process known as
glycosylation. The resulting proteins bearing covalently linked oligosaccharide side
chains are known as glycosylated proteins or glycoproteins. Antibodies are
glycoproteins with one or more carbohydrate es in the Fc domain, as well as the
variable domain. Carbohydrate residues in the Fc domain have important effect on the
effector function of the Fc domain, with minimal effect on antigen g or half-life of
2O the antibody (R. Jefferis, Biotechnol. Prog. 21 (2005), pp. 11-16). In contrast,
glycosylation of the variable domain may have an effect on the antigen binding activity
of the antibody. Glycosylation in the variable domain may have a negative effect on
antibody binding affinity, likely due to steric hindrance (Co, M. S., et (1]., Mol. Immunol.
(1993) 30:1361-1367), or result in increased affinity for the n (Wallick, S. C., et
al., Exp. Med. (1988) 99-1109; Wright, A., et al., EMBO J. (1991) 10:2717
2723).
One aspect of the present invention is directed to generating glycosylation site
mutants in which the O- or N-linked glycosylation site of the binding protein has been
mutated. One d in the art can generate such s using standard nown
technologies. Glycosylation site mutants that retain the biological activity, but have
increased or decreased g activity, are another object of the present invention.
2012/045268
In still another embodiment, the glycosylation of the antibody or antigen-binding
portion of the invention is modified. For example, an aglycoslated antibody can be made
(i.e., the antibody lacks glycosylation). Glycosylation can be altered to, for example,
increase the affinity of the antibody for antigen. Such ydrate modifications can be
accomplished by, for example, ng one or more sites of glycosylation within the
antibody sequence. For e, one or more amino acid substitutions can be made that
result in elimination of one or more variable region glycosylation sites to thereby
eliminate glycosylation at that site. Such sylation may increase the affinity of the
antibody for antigen. Such an approach is described in further detail in PCT Publication
016466A2, and US. Pat. Nos. 5,714,350 and 6,350,861, each of which is
incorporated herein by reference in its entirety.
Additionally or alternatively, a modified antibody of the invention can be made
that has an altered type of glycosylation, such as a hypofucosylated antibody having
reduced amounts of fucosyl es or an antibody having increased bisecting GlcNAc
structures. Such altered glycosylation patterns have been demonstrated to increase the
ADCC ability of dies. Such carbohydrate cations can be lished by,
for example, expressing the antibody in a host cell with altered glycosylation machinery.
Cells with altered glycosylation machinery have been described in the art and can be
used as host cells in which to express recombinant antibodies of the invention to thereby
produce an antibody with altered glycosylation. See, for example, s, R. L. et a1.
(2002) J. Biol. Chem. 277:26733-26740; Umana et al. (1999) Nat. Biotech. 17:176-1, as
well as, European Patent No: EP 1,176,195; PCT Publications WO 03/035835; WO
42 80, each of which is incorporated herein by reference in its ty.
Protein glycosylation depends on the amino acid sequence of the protein of
interest, as well as the host cell in which the protein is expressed. Different organisms
may produce different glycosylation enzymes (e.g., glycosyltransferases and
idases), and have different substrates (nucleotide sugars) ble. Due to such
factors, protein glycosylation pattern, and composition of glycosyl residues, may differ
depending on the host system in which the particular protein is expressed. Glycosyl
residues useful in the invention may include, but are not limited to, glucose, galactose,
mannose, fucose, n-acetylglucosamine and sialic acid. Preferably the glycosylated
binding protein comprises glycosyl residues such that the glycosylation pattern is
human.
It is known to those skilled in the art that differing protein glycosylation may
result in differing protein characteristics. For instance, the efficacy of a therapeutic
protein produced in a microorganism host, such as yeast, and glycosylated utilizing the
yeast endogenous pathway may be reduced ed to that of the same protein
expressed in a mammalian cell, such as a CHO cell line. Such roteins may also be
immunogenic in humans and show reduced ife in vivo after administration.
Specific receptors in humans and other animals may recognize specific glycosyl residues
and promote the rapid clearance of the protein from the bloodstream. Other adverse
effects may include changes in protein folding, solubility, tibility to proteases,
trafficking, transport, compartmentalization, secretion, recognition by other proteins or
factors, antigenicity, or allergenicity. ingly, a practitioner may prefer a
therapeutic n with a specific composition and pattern of glycosylation, for example
glycosylation composition and pattern identical, or at least similar, to that produced in
human cells or in the species-specific cells of the ed t animal.
sing glycosylated proteins different from that of a host cell may be
achieved by genetically modifying the host cell to express heterologous glycosylation
enzymes. Using techniques known in the art a practitioner may generate antibodies or
2O antigen-binding portions thereof exhibiting human protein glycosylation. For example,
yeast strains have been genetically modified to express turally ing
glycosylation enzymes such that glycosylated proteins (glycoproteins) produced in these
yeast strains exhibit protein glycosylation identical to that of animal cells, especially
human cells (U.S. patent applications 20040018590 and 20020137134 and PCT
publication WO2005100584 A2, the entire contents of each of which are incorporated
by reference ).
The methods and/or compositions of the present invention may also use an anti-
idiotypic (anti-Id) antibody specific for such binding proteins of the invention. An anti-
Id antibody is an antibody, which izes unique inants generally associated
with the antigen-binding region of another antibody. The anti-Id can be prepared by
immunizing an animal with the binding protein or a CDR containing region thereof. The
2012/045268
zed animal will recognize, and respond to the idiotypic determinants of the
zing antibody and produce an anti-Id antibody. The anti-Id antibody may also be
used as an "immunogen" to induce an immune response in yet another animal, producing
a so-called anti-anti-Id dy.
Further, it will be appreciated by one skilled in the art that a protein of st
may be expressed using a library of host cells genetically engineered to express various
ylation enzymes, such that member host cells of the y produce the protein of
interest with variant glycosylation patterns. A practitioner may then select and isolate the
protein of interest with particular novel glycosylation patterns. Preferably, the n
having a particularly selected novel glycosylation pattern exhibits improved or altered
ical properties.
11. Compositions of the Invention
The invention also provides compositions, e.g., pharmaceutical compositions,
comprising an antibody, or antigen-binding portion thereof, of the invention and a
ceutically acceptable carrier. The compositions of the invention comprise an
anti-IL-13 antibody, or antigen-binding n thereof, such that when administered
intravenously to a t at a dose of about 0.3 mg/kg, the antibody, or antigen-binding
portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of between
2O about 1,500 and about 2,700 ugh/ml; (b) a volume of distribution of between about 65
and 125 mL/kg; (c) a peak concentration (Cmax) of between about 5 and about 8 ug/ml;
and (d) a clearance rate of between about 0.1 and about 0.2 ml/h/kg.
In another aspect, the invention provides an isolated composition comprising an
anti-IL-13 dy, or antigen-binding portion thereof, such that, when administered
intravenously to a subject at a dose of about 3 mg/kg, the antibody, or antigen-binding
portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of between
about 21,000 and about 33,500 ugh/ml; (b) a volume of distribution of between about 55
and about 100 mL/kg; (c) a peak concentration (Cmax) of between about 55 and about 90
ug/ml; and (d) a clearance rate of between about 0.08 and about 0.15 ml/h/kg.
In another aspect, the invention provides an isolated composition comprising an
anti-IL-13 antibody, or antigen-binding n thereof, such that, when administered
enously to a subject at a dose of about 10 mg/kg, the antibody, or antigen-binding
portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of between
about 75 and about 100 ugh/ml; (b) a volume of distribution of between about 90 and
about130 mL/kg; (c) a peak concentration (Cmax) of between about 185 and about 250
ug/ml; and (d) a clearance rate of between about 0.1 and about 0.15 ml/h/kg.
In yet another aspect, the invention provides an isolated ition comprising
an anti-IL-13 antibody, or antigen-binding portion thereof, such that, when administered
subcutaneously to a subject at a dose of about 0.3 mg/kg, the antibody, or antigen-
binding portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of
n about 125 and about 800 ugh/ml; and (b) a peak concentration (Cmax) of
between about 1.0 and about 6.0 ug/ml.
In another aspect, the ion provides an isolated composition comprising an
anti-IL-13 antibody, or antigen-binding portion thereof, such that, when administered
subcutaneously to a subject at a dose of about 3 mg/kg, the antibody, or antigen-binding
portion thereof, is e of exhibiting: (a) an area under the curve (AUC) of between
about 1,100 and about 8,500 ugh/ml; and (b) a peak concentration (Cmax) of between
about 12 and about 60 ug/ml.
2O In another aspect, the invention es an isolated composition comprising an
anti-IL-13 antibody, or antigen-binding portion thereof, such that, when administered
intravenously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg,
the antibody, or n-binding portion thereof, is capable of exhibiting any of the
pharmacokinetic parameters set forth in the specification, Tables or Figures.
In another aspect, the invention provides an isolated composition comprising an
anti-IL-13 antibody, or antigen-binding n thereof, such that, when stered
subcutaneously to a subject at a dose of about 0.3 mg/kg, 1 mg/kg or 3 mg/kg, the
dy, or antigen-binding portion thereof, is capable of exhibiting any of the
pharmacokinetic ters set forth in the specification, Tables or Figures.
The pharmaceutical compositions comprising antibodies of the ion are for
use in, but not limited to, diagnosing, detecting, or monitoring a disorder, in preventing,
treating, managing, or ameliorating of a disorder or one or more symptoms thereof,
and/or in research. In a specific embodiment, a composition comprises one or more
antibodies of the invention. In another embodiment, the pharmaceutical composition
comprises one or more antibodies of the invention and one or more lactic or
therapeutic agents other than antibodies of the invention for treating a disorder in which
IL-l3 activity is detrimental, such as asthma. Preferably, the prophylactic or therapeutic
agents known to be useful for or having been or currently being used in the prevention,
treatment, management, or amelioration of a disorder or one or more symptoms thereof.
In accordance with these embodiments, the composition may further comprise of a
carrier, t or excipient.
lly, a pharmaceutical composition of the invention comprises an L-
13 antibody, or antigen-binding portion thereof, and a pharmaceutically acceptable
carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all
solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents, and the like that are physiologically compatible. Examples
of pharmaceutically acceptable carriers include one or more of water, saline, phosphate
buffered saline, dextrose, glycerol, l and the like, as well as combinations thereof.
In many cases, it will be preferable to e isotonic agents, for example, sugars,
polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
ceutically acceptable carriers may further comprise minor s of auxiliary
substances such as wetting or emulsifying agents, preservatives or buffers, which
enhance the shelf life or effectiveness of the antibody or antibody portion.
Various delivery s are known and can be used to administer one or more
antibodies of the invention or the combination of one or more antibodies of the invention
and a prophylactic agent or therapeutic agent useful for preventing, managing, ng,
or ameliorating a disorder or one or more symptoms thereof, e. g., encapsulation in
liposomes, articles, microcapsules, recombinant cells e of expressing the
antibody or antibody fragment, receptor-mediated endocytosis (see, e. g., Wu and Wu, J.
Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral
WO 09521
or other vector, etc. Methods of administering a prophylactic or therapeutic agent of the
invention e, but are not limited to, parenteral administration (e. g., intradermal,
uscular, intraperitoneal, intravenous and subcutaneous), epidurala administration,
intratumoral administration, and mucosal administration (e. g., asal and oral
routes). In addition, pulmonary administration can be employed, e. g., by use of an
inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Pat. Nos.
6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and
4,880,078; and PCT Publication Nos. W0 92/19244, WO 97/32572, WO 97/44013, WO
98/31346, and WO 99/66903, each of which is incorporated herein by reference their
entireties. In one embodiment, an antibody of the invention, ation therapy, or a
composition of the invention is administered using Alkermes AIRTM pulmonary drug
delivery technology mes, Inc., Cambridge, Mass.). In a specific ment,
prophylactic or therapeutic agents of the invention are administered intramuscularly,
intravenously, intratumorally, orally, intranasally, pulmonary, or subcutaneously. The
prophylactic or therapeutic agents may be administered by any convenient route, for
example by infusion or bolus injection, by absorption through epithelial or
mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be
administered together with other biologically active agents. Administration can be
systemic or local.
2O In a specific embodiment, it may be desirable to administer the compositions of
the ion locally to the area in need of treatment; this may be achieved by, for
example, and not by way of limitation, local infusion, by injection, or by means of an
implant, said implant being of a porous or non-porous material, including membranes
and matrices, such as sialastic membranes, polymers, fibrous matrices (e.g., TissuelTM),
or collagen matrices. In one embodiment, an ive amount of one or more dies
of the invention antagonists is administered locally to the ed area to a subject to
prevent, treat, manage, and/or ameliorate a disorder or a symptom thereof. In r
embodiment, an ive amount of one or more antibodies of the invention is
administered locally to the affected area in combination with an effective amount of one
or more therapies (e. g., one or more prophylactic or eutic agents) other than an
antibody of the ion of a subject to prevent, treat, manage, and/or ameliorate a
disorder or one or more ms thereof.
In another embodiment, the prophylactic or therapeutic agent of the invention
can be delivered in a controlled release or sustained e system. In one embodiment,
a pump may be used to achieve controlled or sustained release (see Langer, supra;
Sefton, 1987, CRC Crit. Ref. . Eng. 14:20; Buchwald et al., 1980, Surgery
88:507; Saudek et al., 1989, N. Engl. J. Med. 4). In another embodiment,
ric materials can be used to achieve controlled or sustained release of the
therapies of the invention (see e. g., l Applications of Controlled Release, Langer
and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability,
Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York
(1984); Ranger and Peppas, 1983, J., Macromol. Sci. Rev. Macromol. Chem. 23:61; see
also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. . 25:351;
Howard et al., 1989, J. Neurosurg. 7 1:105); US. Pat. No. 5,679,377; 5,916,597;
,912,015; 5,989,463; 5,128,326; PCT Publication No. WO 99/15154; and PCT
Publication No. WO 99/20253. Examples of rs used in sustained e
formulations include, but are not limited to, poly(2-hydroxy ethyl methacrylate),
poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate),
poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N-vinyl
pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene ), polylactides
2O (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In a preferred
embodiment, the polymer used in a sustained release formulation is inert, free of
leachable impurities, stable on storage, sterile, and biodegradable. In yet r
embodiment, a controlled or sustained release system can be placed in proximity of the
prophylactic or therapeutic target, thus requiring only a fraction of the systemic dose
(see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp.
115-138 (1984)).
Controlled release systems are discussed in the review by Langer (1990, Science
249: 1527-1533). Any technique known to one of skill in the art can be used to e
sustained e formulations comprising one or more therapeutic agents of the
invention. See, e.g., US. Pat. No. 4,526,938, PCT publication WO 91/05548, PCT
publication WO 96/20698, Ning et al., 1996, tumoral Radioimmunotheraphy of a
Human Colon Cancer Xenograft Using a Sustained-Release Gel," Radiotherapy
&Oncology 39: 179-189, Song et al., 1995, "Antibody Mediated Lung Targeting of
Long-Circulating Emulsions," PDA Journal of Pharmaceutical Science &Technology
50:372-397, Cleek et al., 1997, "Biodegradable Polymeric rs for a bFGF Antibody
for vascular Application," Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-
854, and Lam et al., 1997, "Microencapsulation of Recombinant Humanized
Monoclonal Antibody for Local Delivery," Proc. Int'l. Symp. Control Rel. Bioact. Mater.
-760, each of which is incorporated herein by reference in their entireties.
A pharmaceutical composition of the invention is formulated to be compatible
with its ed route of administration. Examples of routes of administration include,
but are not limited to, eral, e. g., intravenous, intradermal, aneous, oral,
intranasal (e.g., inhalation), transdermal (e.g., l), transmucosal, and rectal
administration. In a specific embodiment, the composition is formulated in accordance
with routine ures as a pharmaceutical ition adapted for intravenous,
subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings.
Typically, compositions for intravenous administration are ons in sterile isotonic
aqueous buffer. Where necessary, the composition may also include a solubilizing agent
and a local anesthetic such as lignocamne to ease pain at the site of the injection.
If the compositions of the invention are to be administered topically, the
compositions can be formulated in the form of an ointment, cream, transdermal patch,
, gel, shampoo, spray, aerosol, solution, on, or other form well-known to
one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences and Introduction
to Pharmaceutical Dosage Forms, 19th ed., Mack Pub. Co., Easton, Pa. (1995). For non-
sprayable topical dosage forms, viscous to semi-solid or solid forms comprising a carrier
or one or more excipients compatible with topical application and having a dynamic
viscosity preferably greater than water are typically employed. le ations
include, without limitation, solutions, suspensions, ons, creams, ointments,
powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with
auxiliary agents (e.g., preservatives, stabilizers, wetting agents, s, or salts) for
influencing various properties, such as, for example, osmotic pressure. Other suitable
topical dosage forms include sprayable aerosol preparations wherein the active
ingredient, preferably in combination with a solid or liquid inert carrier, is packaged in a
e with a rized volatile (e.g., a gaseous propellant, such as freon) or in a
squeeze bottle. Moisturizers or humectants can also be added to pharmaceutical
compositions and dosage forms if desired. Examples of such additional ingredients are
well known in the art.
For intranasal administration of a composition of the ion, the composition
can be formulated in an aerosol form, spray, mist or in the form of drops. In particular,
prophylactic or therapeutic agents for use according to the present invention can be
conveniently delivered in the form of an aerosol spray presentation from pressurized
packs or a nebuliser, with the use of a suitable propellant (e. g., dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
In the case of a pressurized aerosol the dosage unit may be determined by providing a
valve to deliver a metered amount. Capsules and cartridges (composed of, e. g., gelatin)
for use in an inhaler or insufflator may be formulated containing a powder mix of the
compound and a suitable powder base such as lactose or starch.
For oral stration, compositions of the invention can be ated orally
in the form of tablets, capsules, cachets, gelcaps, solutions, suspensions, and the like.
Tablets or capsules can be prepared by conventional means with pharmaceutically
able excipients such as binding agents (e. g., pregelatinised maize starch,
polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose,
rystalline cellulose, or calcium en phosphate); lubricants (e. g., magnesium
stearate, talc, or silica); disintegrants (e.g., potato starch or sodium starch ate); or
wetting agents (e. g., sodium lauryl sulphate). The tablets may be coated by s
well-known in the art. Liquid preparations for oral administration may take the form of,
but not d to, solutions, syrups or suspensions, or they may be presented as a dry
product for tution with water or other suitable vehicle before use. Such liquid
ations may be prepared by conventional means with pharmaceutically acceptable
additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or
hydrogenated edible fats); emulsifying agents (6. g., lecithin or acacia); non-aqueous
vehicles (e.g., almond oil, oily , ethyl alcohol, or fractionated vegetable oils); and
preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The
preparations may also n buffer salts, ng, coloring, and sweetening agents as
appropriate. Preparations for oral administration may be suitably formulated for slow
release, controlled release, or sustained release of a prophylactic or therapeutic agent(s).
The methods of the invention may se pulmonary administration, e.g., by
use of an inhaler or nebulizer, of a composition formulated with an aerosolizing agent.
See, e.g., U.S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064,
,855,913, 5,290,540, and 4,880,078; and PCT ation Nos. WO 92/19244, WO
97/32572, WO 97/44013, WO 98/31346, and WO 99/66903, each of which is
incorporated herein by reference their entireties. In a specific embodiment, an antibody
of the ion, combination therapy, and/or composition of the invention is
administered using Alkermes AIRTM pulmonary drug ry technology (Alkermes,
Inc., Cambridge, Mass.).
The methods of the invention may also comprise administration of a ition
ated for parenteral administration by injection (e. g., by bolus injection or
uous infusion). Formulations for injection may be presented in unit dosage form
(e.g., in ampoules or in multi-dose containers) with an added preservative. The
compositions may take such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and may n formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient may be in powder form for
2O constitution with a suitable e (e.g., sterile pyrogen-free water) before use.
The s of the invention may additionally comprise of administration of
compositions ated as depot preparations. Such long acting formulations may be
administered by implantation (e. g., subcutaneously or intramuscularly) or by
intramuscular injection. Thus, for example, the compositions may be formulated with
suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or
ion exchange resins, or as sparingly soluble derivatives (e.g., as a gly soluble salt).
The methods of the invention encompasses administration of compositions
formulated as l or salt forms. Pharmaceutically acceptable salts include those
formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic,
3O tartaric acids, etc., and those formed with cations such as those derived from sodium,
potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-
ethylamino ethanol, histidine, procaine, etc.
Generally, the ingredients of compositions are supplied either separately or
mixed together in unit dosage form, for example, as a dry lyophilized powder or water
free concentrate in a hermetically sealed container such as an e or sachette
indicating the quantity of active agent. Where the mode of stration is infusion,
composition can be dispensed with an infusion bottle containing sterile ceutical
grade water or . Where the mode of administration is by injection, an ampoule of
sterile water for injection or saline can be ed so that the ingredients may be mixed
prior to administration.
The compositions of the invention may be packaged in a hermetically sealed
container such as an ampoule or sachette indicating the ty of the agent. In one
embodiment, the compositions of the ion may be supplied as a dry sterilized
lyophilized powder or water free concentrate in a hermetically sealed container and can
be reconstituted (e. g., with water or ) to the appropriate concentration for
administration to a subject. Preferably, the compositions of the invention are supplied as
a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage of at
least 5 mg, more preferably at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg,
at least 45 mg, at least 50 mg, at least 75 mg, or at least 100 mg. The lyophilized
prophylactic or therapeutic agents or ceutical compositions of the invention
2O should be stored at between 2°C and 8°C in its original container and the prophylactic or
therapeutic agents, or pharmaceutical compositions of the invention should be
administered within 1 week, preferably within 5 days, within 72 hours, within 48 hours,
within 24 hours, within 12 hours, within 6 hours, within 5 hours, within 3 hours, or
within 1 hour after being reconstituted. In an alternative embodiment, one or more of the
prophylactic or therapeutic agents or pharmaceutical compositions of the invention is
supplied in liquid form in a hermetically sealed container indicating the quantity and
concentration of the agent. Preferably, the liquid form of the administered ition
is supplied in a hermetically sealed container at least 0.25 mg/ml, more preferably at
least 0.5 mg/ml, at least 1 mg/ml, at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml,
at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, at least 75
mg/ml or at least 100 mg/ml. The liquid form should be stored at between 2°C and 8°C
in its original container.
Compositions of the invention are preferably suitable for parenteral
stration. For example, the compositions of the invention may be prepared as an
inj ectable solution ning 0.1-250 mg/ml antibody. The injectable solution can be
ed of either a liquid or lyophilized dosage form in a flint or amber vial, ampule
or pre-filled syringe. The buffer can be L—histidine (l-50 mM), optimally 5-10 mM, at
pH 5.0 to 7.0 (optimally pH 6.0). Other suitable s e but are not limited to,
sodium succinate, sodium citrate, sodium phosphate or potassium phosphate. Sodium
chloride can be used to modify the toxicity of the solution at a concentration of 0-300
mM (optimally 150 mM for a liquid dosage form). Cryoprotectants can be included for a
lyophilized dosage form, principally 0-10% e (optimally ). Other suitable
cryoprotectants include trehalose and lactose. Bulking agents can be included for a
lyophilized dosage form, principally l-10% mannitol (optimally 24%). Stabilizers can
be used in both liquid and lyophilized dosage forms, principally l-50 mM L-Methionine
(optimally 5-10 mM). Other le bulking agents include glycine, arginine, can be
included as 0-0.05% polysorbate-80 (optimally 0.005-0.01%). Additional surfactants
include but are not limited to polysorbate 20 and BRIJ tants. The pharmaceutical
composition comprising the antibodies and antibody-portions of the invention prepared
as an inj ectable solution for parenteral administration, can further comprise an agent
useful as an adjuvant, such as those used to increase the absorption, or dispersion of a
therapeutic protein (e. g., antibody). A particularly useful adjuvant is hyaluronidase, such
as xTM (recombinant human hyaluronidase). Addition of hyaluronidase in the
inj ectable solution es human bioavailability following eral administration,
particularly subcutaneous administration. It also allows for greater injection site volumes
(Le. greater than 1 ml) with less pain and discomfort, and m incidence of
injection site ons. (see W02004078140, U82006104968 incorporated herein by
reference).
The compositions of this invention may be in a variety of forms. These include,
for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e. g.,
injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders,
liposomes and suppositories. The red form depends on the intended mode of
WO 09521
administration and therapeutic application. Typical preferred compositions are in the
form of inj ectable or infusible solutions, such as compositions similar to those used for
passive immunization of humans with other dies. The preferred mode of
administration is eral (e.g., intravenous, subcutaneous, intraperitoneal,
intramuscular). In a preferred embodiment, the antibody is administered by enous
infusion or injection. In another preferred embodiment, the dy is administered by
intramuscular or subcutaneous injection.
Therapeutic compositions typically must be sterile and stable under the
conditions of manufacture and e. The composition can be formulated as a solution,
microemulsion, dispersion, liposome, or other ordered structure suitable to high drug
concentration. Sterile injectable solutions can be prepared by incorporating the active
compound (i.e., antibody or antibody portion) in the required amount in an appropriate
solvent with one or a combination of ingredients enumerated above, as required,
followed by filtered sterilization. Generally, dispersions are prepared by incorporating
the active compound into a sterile vehicle that contains a basic dispersion medium and
the ed other ingredients from those enumerated above. In the case of sterile,
lyophilized powders for the preparation of sterile injectable solutions, the preferred
methods of preparation are vacuum drying and spray-drying that yields a powder of the
active ient plus any additional desired ingredient from a previously sterile-filtered
solution thereof. The proper fluidity of a solution can be maintained, for e, by the
use of a g such as lecithin, by the maintenance of the required particle size in the
case of dispersion and by the use of surfactants. Prolonged absorption of injectable
compositions can be brought about by including, in the composition, an agent that delays
absorption, for example, monostearate salts and gelatin.
The compositions of the present ion can be administered by a variety of
methods known in the art, although for many therapeutic applications, the preferred
route/mode of administration is subcutaneous injection, enous injection or
infusion. As will be appreciated by the skilled artisan, the route and/or mode of
administration will vary depending upon the desired results. In certain embodiments, the
active compound may be prepared with a carrier that will protect the compound t
rapid e, such as a controlled release formulation, including implants, transdermal
patches, and microencapsulated delivery systems. Biodegradable, biocompatible
polymers can be used, such as ethylene vinyl e, polyanhydrides, polyglycolic acid,
en, polyorthoesters, and polylactic acid. Many methods for the preparation of such
formulations are patented or lly known to those skilled in the art. See, e. g.,
Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel
Dekker, Inc., New York, 1978.
In certain embodiments, the compositions of the invention may be orally
administered, for example, with an inert diluent or an assimilable edible carrier. The
nd (and other ingredients, if desired) may also be enclosed in a hard or soft shell
gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
For oral therapeutic stration, the compounds may be incorporated with excipients
and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs,
suspensions, , wafers, and the like. To administer a compound of the invention by
other than parenteral stration, it may be necessary to coat the compound with, or
co-administer the compound with, a material to prevent its inactivation.
Supplementary active compounds can also be incorporated into the
compositions. In certain ments, an antibody or dy portion of the invention
is ulated with and/or coadministered with one or more additional therapeutic
agents that are useful for treating disorders in which IL-l3 activity is detrimental. For
e, an anti-IL—l3 antibody or antibody portion of the invention may be
coformulated and/or coadministered with one or more additional antibodies that bind
other targets (e.g., antibodies that bind other cytokines or that bind cell surface
molecules). rmore, one or more antibodies of the invention may be used in
combination with two or more of the foregoing therapeutic agents. Such combination
therapies may advantageously utilize lower dosages of the administered therapeutic
agents, thus avoiding possible toxicities or complications associated with the various
monotherapies.
In certain embodiments, an l-l3 antibody, or antigen-binding portion
thereof, is linked to a half-life extending e known in the art. Such vehicles include,
but are not limited to, the Fc domain, polyethylene glycol, and dextran. Such vehicles
are described, e.g., in US. application Ser. No. 09/428,082 and published PCT
WO 09521
Application No. WO 99/25044, which are hereby incorporated by reference for any
purpose.
The pharmaceutical itions of the ion may include a "therapeutically
effective amount" or a "prophylactically effective amount" of an antibody or antibody
portion of the ion. A "therapeutically effective amount" refers to an amount
effective, at dosages and for periods of time ary, to achieve the desired therapeutic
. A therapeutically effective amount of the antibody or antibody portion may be
determined by a person skilled in the art and may vary ing to factors such as the
disease state, age, sex, and weight of the individual, and the ability of the antibody or
antibody portion to elicit a d response in the individual. A therapeutically effective
amount is also one in which any toxic or detrimental effects of the antibody, or antibody
portion, are outweighed by the therapeutically beneficial effects. A "prophylactically
effective amount" refers to an amount effective, at dosages and for periods of time
necessary, to achieve the desired prophylactic result. lly, since a prophylactic
dose is used in subjects prior to or at an earlier stage of e, the prophylactically
effective amount will be less than the therapeutically effective amount.
Dosage regimens may be adjusted to e the optimum desired response (6. g.,
a therapeutic or prophylactic response). For example, a single bolus may be
administered, several divided doses may be administered over time or the dose may be
proportionally reduced or increased as indicated by the exigencies of the therapeutic
situation. It is especially advantageous to formulate parenteral compositions in dosage
unit form for ease of stration and uniformity of dosage. Dosage unit form as used
herein refers to physically discrete units suited as unitary dosages for the mammalian
subjects to be treated; each unit containing a predetermined quantity of active compound
calculated to produce the desired therapeutic effect in association with the required
pharmaceutical carrier. The specification for the dosage unit forms of the invention are
dictated by and directly dependent on (a) the unique characteristics of the active
compound and the particular therapeutic or prophylactic effect to be achieved, and (b)
the limitations inherent in the art of compounding such an active compound for the
treatment of sensitivity in individuals.
An ary, non-limiting range for a therapeutically or prophylactically
effective amount of an antibody or dy portion of the invention is 0.1-20 mg/kg,
more preferably 1-10 mg/kg. In one ment, a therapeutically or prophylactically
effective amount of the antibody, or antigen-binding portion thereof, is 0.3 mg/kg. In
another embodiment, a therapeutically or prophylactically effective amount of the
dy, or antigen-binding portion thereof, is 3 mg/kg. In another embodiment, a
therapeutically or prophylactically effective amount of the antibody, or antigen-binding
portion thereof, is 10 mg/kg. In yet another embodiment, a therapeutically or
prophylactically effective amount of the antibody, or antigen-binding portion thereof, is
0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8
mg/kg, 0.9 mg/kg, 1 mg/kg, 1.25 mg/kg, 1.5 mg/kg, 1.75 mg/kg, 2 mg/kg, 2.5 mg/kg, 3
mg/kg, 3.5 mg/kg, 4 mg/kg, 4.5 mg/kg, 5 mg/kg, 5.5 mg/kg, 6 mg/kg, 6.5 mg/kg, 7
mg/kg, 7.5 mg/kg, 8 mg/kg, 8.5 mg/kg, 9 mg/kg, 9.5 mg/kg, 10 mg/kg, 11 mg/kg, 12
mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg or 20
mg/kg. It is to be noted that dosage values may vary with the type and severity of the
condition to be ated. It is to be r understood that for any particular subject,
specific dosage regimens should be adjusted over time according to the dual need
and the professional judgment of the person administering or supervising the
administration of the compositions, and that dosage ranges set forth herein are
exemplary only and are not intended to limit the scope or practice of the claimed
2O composition.
III. Methods of the Invention
In r aspect, this application es a method of treating (e. g., curing,
suppressing, ameliorating, delaying or preventing the onset of, or preventing recurrence
or relapse of) or preventing an ILassociated disorder, such as asthma, in a subject.
The method includes: administering to the subject an IL—13 binding agent (particularly
an antagonist), e. g., an anti-IL-13 antibody or antigen-biding portion thereof as
described herein, in an amount sufficient to treat or prevent the ILassociated
disorder, such as asthma. The IL-13 antagonist, e.g., the anti-IL-13 dy or antigen-
binding portion thereof, can be administered to the subject, alone or in combination with
other therapeutic modalities as described herein.
In one embodiment, the subject is a , e. g., a human suffering from one or
more associated disorders, ing, e.g., respiratory disorders (e.g., asthma (e.g.,
allergic and nonallergic asthma or mild asthma, or moderate asthma), chronic
obstructive pulmonary disease (COPD), and other conditions involving airway
inflammation, eosinophilia, fibrosis and excess mucus tion; atopic disorders (e.g.,
atopic dermatitis and allergic rhinitis). Accordingly, the sure includes the use of an
IL-l3 binding agent (such as an anti-IL-l3 antibody or fragment thereof described
herein) for a treatment described herein and the use of an IL-l3 binding agent (such as
an L-l3 antibody or fragment thereof described herein) for ing a medicament
for a treatment described herein.
Examples of IL—l3-associated disorders include, but are not limited to, a disorder
chosen from one or more of: respiratory disorders, e. g., asthma (e. g., allergic and
nonallergic asthma (e.g., asthma due to ion with, e. g., respiratory syncytial virus
(RSV), e. g., in younger en)), chronic obstructive pulmonary disease , and
other ions involving airway inflammation, eosinophilia, fibrosis and excess mucus
tion, e. g., cystic fibrosis and pulmonary fibrosis.
In other embodiments, this application provides a method of treating (e.g.,
reducing, ameliorating) or preventing one or more symptoms associated with a
respiratory disorder, e.g., asthma (e.g., allergic and ergic asthma); allergies;
chronic obstructive pulmonary disease (COPD); a ion involving airway
inflammation, eosinophilia, fibrosis and excess mucus production, e.g., cystic fibrosis
and pulmonary fibrosis. For example, symptoms of asthma include, but are not limited
to, wheezing, shortness of breath, bronchoconstriction, airway eactivity, decreased
lung capacity, fibrosis, airway inflammation, and mucus production. The method
comprises administering to the subject an IL-l3 antagonist, e.g., an IL-l3 antibody or a
fragment thereof, in an amount sufficient to treat (e. g., reduce, ameliorate) or prevent
one or more symptoms. The IL-l3 dy can be administered therapeutically or
prophylactically, or both. The IL-l3 antagonist, e.g., the anti-IL-l3 antibody, or antigen-
binding portion thereof, can be administered to the subject, alone or in combination with
other therapeutic modalities as described herein. Preferably, the subject is a mammal,
e.g., a human suffering from an IL—l3-associated disorder, such as asthma, as described
herein.
In another aspect, this application provides a method for detecting the presence
of IL-13 in a sample in vitro (e.g., a biological sample, such as serum, plasma, tissue,
biopsy). The subject method can be used to diagnose a disorder, e.g., asthma, e.g., mild
or te asthma. The method includes: (i) contacting the sample or a l sample
with the anti-IL-l3 antibody or fragment f as described herein; and (ii) detecting
formation of a complex between the anti-IL-l3 dy or fragment thereof, and the
sample or the control sample, wherein a statistically significant change in the formation
of the complex in the sample relative to the control sample is indicative of the presence
of the IL-13 in the sample.
In yet another aspect, this application provides a method for detecting the
presence of IL-13 in vivo (e.g., in vivo imaging in a subject). The subject method can be
used to se a disorder, e.g., an IL-l3-associated er, e.g., asthma, e.g., mild or
moderate asthma. The method includes: (i) administering the L-l3 antibody or
fragment thereof as described herein to a subject or a control subject under conditions
that allow binding of the antibody or fragment to IL-l3; and (ii) detecting formation of a
complex between the antibody or fragment and IL-l3, wherein a statistically significant
change in the formation of the complex in the subject relative to the control subject is
indicative of the presence of IL-l3.
Antibodies of the invention, or antigen binding ns thereof can be used
alone or in combination to treat such diseases. It should be understood that the
antibodies of the invention or antigen binding portion f can be used alone or in
combination with an additional agent, e.g., a therapeutic agent, said additional agent
being selected by the skilled artisan for its intended purpose. For example, the onal
agent can be a therapeutic agent cognized as being useful to treat the disease or
condition being d by the antibody of the present invention. The additional agent
also can be an agent that imparts a beneficial attribute to the therapeutic composition
e.g., an agent which s the viscosity of the composition.
It should further be understood that the combinations which are to be included
within this ion are those ations useful for their intended purpose. The
agents set forth below are illustrative for purposes and not intended to be limited. The
combinations, which are part of this invention, can be the antibodies of the present
invention and at least one additional agent selected from the lists below. The
ation can also include more than one onal agent, e. g., two or three
additional agents if the combination is such that the formed composition can perform its
intended function.
The combination therapy can include one or more IL-l3 antagonists, e. g., anti-
IL-l3 antibodies or fragments thereof, coformulated with, and/or coadministered with,
one or more additional eutic agents, e. g., one or more cytokine and growth factor
inhibitors, immunosuppressants, anti-inflammatory agents (e.g., systemic anti-
inflammatory agents), anti-fibrotic agents, metabolic inhibitors, enzyme inhibitors,
and/or cytotoxic or cytostatic agents, as described in more herein.
Examples of preferred additional therapeutic agents that can be coadministered
and/or coformulated with one or more IL—l3 antagonists, e. g., L-l3 antibodies or
fragments thereof, include, but are not d to, one or more of: inhaled steroids; betaagonists
, e.g., short-acting or long-acting beta-agonists; antagonists of rienes or
leukotriene receptors; combination drugs such as ADVAIR; IgE inhibitors, e. g., anti-IgE
antibodies (e.g., XOLAIR); phosphodiesterase inhibitors (e. g., PDE4 tors);
xanthines; olinergic drugs; mast cell-stabilizing agents such as cromolyn; IL-4
inhibitors; IL-5 inhibitors; eotaxin/CCR3 inhibitors; antagonists of ine or its
receptors including H1, H2, H3, and H4, and antagonists of prostaglandin D or its
ors (DPl and . Such combinations can be used to treat asthma and other
respiratory disorders. Additional examples of therapeutic agents that can be
coadministered and/or coformulated with one or more L-l3 antibodies or
fragments thereof include one or more of: TNF antagonists (e. g., a soluble fragment of a
TNF receptor, e.g., p55 or p75 human TNF receptor or derivatives thereof, e.g., 75 kD
TNFR-IgG (75 kD TNF receptor-IgG fusion protein, ENBREL)); TNF enzyme
antagonists, e.g., TNF converting enzyme (TACE) inhibitors; muscarinic receptor
antagonists; TGF-beta antagonists; interferon gamma; perfenidone; chemotherapeutic
, e. g., methotrexate, leflunomide, or a sirolimus (rapamycin) or an analog thereof,
e.g., CCI—779; COX2 and cPLA2 inhibitors; NSAIDs; immunomodulators; p38
inhibitors, TPL-2, MK-2 and NFkB inhibitors, among others.
Other preferred combinations are cytokine suppressive anti-inflammatory drug(s)
(CSAIDs); antibodies to or antagonists of other human cytokines or growth factors, for
example, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, IL-21, IL-
31, interferons, EMAP-II, GM-CSF, FGF, EGF, PDGF, and edothelin-l, as well as the
receptors of these cytokines and growth factors. Antibodies of the invention, or antigen
binding portions thereof, can be combined with antibodies to cell surface molecules such
as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.l),
CD86 (B72), CD90, CTLA or their ligands including CD154 (gp39 or CD40L).
Preferred combinations of therapeutic agents may interfere at different points in
the inflammatory cascade; preferred examples include TNF nists like chimeric,
zed or human TNF antibodies, D2E7, (PCT Publication No. WO 97/29131), CA2
(RemicadeTM), CDP 571, and e p55 or p75 TNF receptors, derivatives, thereof,
FR1gG (EnbrelTM) or p55TNFR1gG (Lenercept), and also TNF converting
enzyme (TACE) inhibitors; similarly IL-l inhibitors (Interleukin-l-converting enzyme
inhibitors, IL-lRA etc.) may be effective for the same . Other preferred
ations include Interleukin 4. Yet r preferred combination are other key
players of the asthmatic response which may act parallel to, dependent on or in concert
with IL-13 function; especially preferred are IL—9 antagonists including IL-9 antibodies.
2O It has been shown that IL-13 and IL—9 have pping but distinct functions and a
combination of antagonists to both may be most effective. Yet another preferred
combination are anti-IL-5 antibodies. Yet other preferred combinations include
antagonists of chemokines including MCP-l, MCP-4, eotaXins, RANTES, MDC, CCL-
12 and CCL—17 (TARC) and ine ors ing CCR2, CCR3, CCR4, and
CXCR4. Yet combinations can include antagonists to asthma ors including acid
mammalian chitinase, CRHT2, e, SlPl, SlP2, Tyk2, ROCKII, Stat6, p38,
NFkB, phosphodiesterase 4 (PDE-4), mast cell trytase, NO, adenosine, IKK2, GATA3,
ICAM-l, VCAM-l, and ICOS.
As used herein, the term "a disorder in which IL-13 activity is detrimental" is
intended to include diseases and other disorders in which the presence of IL-13 in a
subject suffering from the disorder has been shown to be or is suspected of being either
responsible for the pathophysiology of the disorder or a factor that contributes to a
worsening of the disorder. In one embodiment, the disorder in which IL—l3 activity is
detrimental is asthma, e.g., mild asthma or moderate asthma. Accordingly, a disorder in
which IL-l3 ty is detrimental is a disorder in which reduction of IL-13 activity is
expected to alleviate the symptoms and/or progression of the disorder. Such disorders
may be evidenced, for example, by an se in the concentration of IL-13 in a
biological fluid of a subject suffering from the disorder (6. g., an increase in the
concentration of IL-13 in serum, plasma, synovial fluid, etc. of the subject), which can
be detected, for example, using an anti-IL—l3 dy as described above. miting
examples of disorders that can be treated with the antibodies of the invention include
asthma, e.g., mild or moderate asthma, as well as those disorders discussed in the section
below ning to pharmaceutical compositions of the antibodies of the invention.
IL-l3 has been implicated as having a l role in causing pathological
responses ated with . However other mediators of differential
immunological pathways are also involved in asthma pathogenesis, and blocking these
mediators, in addition to IL-l3, may offer additional therapeutic benefit. Thus, binding
proteins of the invention may be incorporated into DVD-lg proteins where in the DVD
is capable of binding target pairs including, but not limited to, IL-13 and a pro-
inflammatory cytokine, such as tumor necrosis factor-0t c). TNF—oc may amplify
the inflammatory response in asthma and may be linked to disease severity (McDonnell,
et (11., Progress in Respiratory Research (2001), 31(New Drugs for Asthma, Allergy and
COPD), 247-250). This ts that blocking both IL-13 and TNF-oc may have
cial effects, ularly in severe airway disease. In a preferred embodiment the
DVD-lg of the invention binds the targets IL-13 and TNFOt and is used for treating
asthma.
The present invention is further illustrated by the following examples which
should not be construed as limiting in any way. The contents of all cited references,
including literature references, issued patents, and published patent applications, as cited
throughout this application are hereby expressly incorporated herein by reference. It
should further be understood that the contents of all the figures and tables attached
hereto, as well as the entire contents of U.S. Patent No. 7,915,388 are expressly
incorporated herein by reference.
EXAMPLES
Introduction to Examples
Asthma is a chronic inflammatory disorder of the airways characterized by
wheezing, lessness, chest tightness, and cough. Asthma affects approximately 20
million people in the US, and about 75% of asthma patients are adults. Of the adult
asthma patients, approximately 60% of asthma patients have mild disease, about 20%
have moderate disease and the remaining 20% have severe disease.
Interleukin-l3 (IL-13) is thought to be pivotal in the pathogenesis of human
asthma, in that elevated levels of IL-13 are present in the lungs of asthma patients, and
these levels correlate with disease severity (Figure 1). Likewise, increased IL-13 is
present in both sputum and in lung es of patients with moderate to severe asthma
who are treated with inhaled corticosteroids (ICS) or systemic corticosteroids and
ue to be symptomatic. Moreover, human IL-l3 c polymorphisms are
associated with asthma and atopy (allergic hypersensitivity). IL-l3 binds to two
receptors, 0tl and IL-l3R0t2. IL-13 is a well-validated target for asthma as
2O cy has been demonstrated using various means of IL-13 antagonism in multiple,
pre-clinical models of asthma.
l3C5.5 is a zed recombinant immunoglobulin IgGl (IgGl, K) onal
antibody (mAb) specific for human wild-type and variant IL-l3. l3C5.5 recognizes a
unique epitope on IL-l3 that blocks its binding to both IL-l3 receptors ocl and 0t2
(Figure 2); other similar IL-l3-binding antibodies analyzed to date only block the ocl
receptor as determined by crystallography and biochemical terization. l3C5.5 is
selective for IL-l3, and does not recognize other nes. Two residues (L240A and
L241A) in the heavy chain were mutated to prevent Fc gamma receptor and complement
binding. Likewise, 13C5.5 does not bind or stimulate human whole blood cells to
release cytokines. The heavy and light chain variable regions are set forth above as SEQ
ID N02 and SEQ ID NO:3, respectively.
13C5.5 binds both human wild type and t IL-13 with high ty and
potency; this is important because variant IL-13 is present in ~20% of human
asthmatics. 13C5.5 does not cross-react with mouse, sheep, or dog IL-13. 13C5.5 does
cross-react with cynomolgus monkey rIL-13 with a 51 fold lower in vitro y and
with rat rIL-13 with a 155 fold lower in vitro potency compared to human rIL-13.
Although the affinity and potency of 13C5.5 is lower against cynomolgus and rat rIL-13
in vitro, 13C5.5 fully neutralizes cynomolgus monkey rIL-13 in vitro with a half
l inhibitory concentration (IC50) of 4.1 nM and rat IL-13 with an IC50 of 12.4
Initial pharmacokinetic analysis following single-dose administration of 13C5.5
was conducted in Sprague-Dawley rats and cynomolgus monkey (Figure 3). 13C5.5
generally exhibited low clearance, low volume of distribution, and high ilability.
The half-life varied from approximately 12 to 16 days in rats and 6 to 11 days in
monkeys. The pharmacokinetics of 13C5.5 was generally similar between female and
male monkeys and rats.
2O 13C5.5 was well tolerated in 4-week rat and 2-week monkey toxicology s
and had sufficient safety margins relative to the recommended starting dose for human
clinical trials. The no-observed-adverse-effect-levels (NOAELs) during the repeat dose
toxicology studies were 1500 mg/kg/dose via intravenous (IV) administration in rats and
lgus monkey and 200 mg/kg/dose via subcutaneous (SC) administration in
cynomologus monkey.
This study was a Phase 1 first-in-human study in adult subjects with or without
mild to te controlled asthma. This placebo-controlled study evaluated 4 single
escalating doses (0.3, 1.0, 3.0, and 10.0 mg/kg) of 13C5.5 administered IV and 2 doses
(0.3 and 3.0mg/kg) of 13C5.5 administered as 3 weekly SC doses.
2012/045268
A study of 13C5.5 conducted in healthy ts and subjects with
mild-to-moderate controlled asthma allowed for collection of standard data regarding
human pharmacokinetics and bioavailability of 13C5.5 as well as the tolerability, safety,
and immunogenicity with single- and multiple- escalating doses of 13C5.5 in the target
disease indication.
Experimental Protocol
This was a Phase 1, single and multiple escalating dose, placebo-controlled,
double-blind, ized, 3-part study which was conducted according to a tial
design. Adults in general good health (n = 20) and adults with mild to moderate
controlled asthma (n = 27) were selected to participate in the study according to the
selection criteria. No more than one subject was dosed per cohort per day.
Part 1 of the study consisted of four groups (Groups 1 through 4), with 5 subjects
in each group. For Part 1, after meeting the selection criteria, adults in general good
health (n = 20) were assigned to one of the following four single dose groups:
Group 1 (intravenous infusion of 0.3 mg/kg 13C5.5 or o),
Group 2 (intravenous infusion of 1.0 mg/kg 13C5.5 or placebo),
Group 3 (intravenous infusion of 3.0 mg/kg 13C5.5 or placebo), or
Group 4 (intravenous on of 10.0 mg/kg 13C5.5 or placebo).
Within each group, four subjects were randomized to receive 13C5.5 and one
subject was randomized to receive placebo. Dose escalation took place for a new cohort
after all subjects within a dose cohort had satisfactorily completed at least the minimum
one-week safety assessments.
Part 2 of the study ted of three groups (Groups 5 through 7), with
5 subjects randomized to each of Groups 5, 6 and 7. For Part 2, after meeting the
selection criteria, adult subjects with mild-to-moderate lled asthma (n = 15) were
assigned to one of three single dose groups:
Group 5 (intravenous infusion of 0.3 mg/kg 13C5.5 or placebo),
Group 6 (intravenous infusion of 3.0 mg/kg 13C5.5 or placebo), or
Group 7 venous infusion of 10.0 mg/kg 13C5.5 or placebo).
Within Groups 5, 6 and 7, four subjects were randomized to receive 13C5.5
and one subject was randomized to receive placebo.
As shown in Figure 4, dosing for a cohort in Part 2 was allowed to begin after all
ts of the same dose level in Part 1 and all lower dose levels in Part 2 had
satisfactorily completed at least the minimum one-week safety assessments after the last
dose.
Part 3 of the study consisted of two groups s 8 and 9), with 6 subjects
randomized to each of Groups 8 and 9. For Part 3, after meeting the selection criteria,
adult subjects with mild to moderate controlled asthma (n = 12) were ed to one of
two groups:
Group 8 taneous injection of 0.3 mg/kg 13C5.5 or placebo, three
weekly doses) or
Group 9 (subcutaneous injection of 3.0 mg/kg 13C5.5 or placebo, three
weekly doses).
2O Within Groups 8 and 9, four subjects were randomized to receive 13C5.5 and
two subjects were randomized to receive placebo.
Dosing for cohorts in Part 3 was allowed to begin after all subjects within the
same dose level in Part 2, and one dose level higher in Part 1 and all lower dose levels in
Part 3 had satisfactorily completed at least the minimum one-week safety assessments
after the last dose (Figure 4).
The study was conducted in a double-blind manner such that the investigators
and subjects were blinded to treatment assignments within each group. For evaluation
of safety, the medical monitor was unblinded to treatment assignments. A m of
the treatment groups is shown in Table l.
Table 1. Treatment Groups
Part Group Regimen Number of
Subjects
Part 1* Group 1 0.3 mg/kg 13C5.5 IV or 5 (4:1)
Healthy Subjects placebo
Group 2 1.0 mg/kg 13C5.5 IV or 5 (4:1)
placebo
Group 3 3.0 mg/kg 13C5.5 IV or 5 (4:1)
placebo
Group 4 10.0 mg/kg 13C5.5 IV or 5 (4:1)
placebo
Part 2” Group 5 0.3 mg/kg 13C5.5 IV or 5 (4:1)
Mild/Moderate placebo
Controlled
Asthma
Group 6 3.0 mg/kg 13C5.5 IV or 5 (4:1)
placebo
Group 7 10.0 mg/kg 13C5.5 IV or 5 (4:1)
placebo
Part 3 Group 8 0.3 mg/kg 13C5.5 SC or 6 (4:2)
oderate placebo,
Controlled 3 weekly doses
Asthma
Group 9 3.0 mg/kg 13C5.5 SC or 6 (4:2)
placebo,
3 weekly doses
* Dose escalation took place for a new cohort after all subjects within a cohort had
satisfactorily ted at least the minimum one-week safety assessments.
# Group 5 was dosed after completion of Group 1 and tion of adequate
safety for that dosing cohort (minimum one-week safety assessments). A similar
approach was taken with Group 6 after completion of Groups 3 and 5 and Group 7
after completion of Groups 4 and 6.
513 Group 8 was dosed after completion of Groups 2 and 5 and evaluation of
adequate safety for those dosing s and evaluation of adequate safety
(minimum one-week safety assessments). A similar approach was taken with Group
9 after completion of Groups 4, 6 and 8.
For Parts 1 and 2, study drug or o was stered on Study Day 1 for
each dose group. For Part 3, study drug or placebo was administered on Study Days 1,
8, and 15 for each dose group. Study drug administration on Study Days 8 and 15 may
have occurred within a 24-hour period of the scheduled dose in cohorts 8 and 9. A
minimum of one week separated the different dose levels.
Subjects were confined to the study site and supervised for approximately 4 to
6 days if they were in an IV dose group (Parts 1 and 2) or imately 6 to 8 days if
they were in an SC dose group (Part 3). ement began in the afternoon, of the
2O Baseline day which may have occurred anytime within a 3-day window (i.e., Study
Day —3 to Study Day —1) prior to dosing on Study Day 1, and ended after the collection
of the 48-hour blood samples (Study Day 3) for subject's enrolled in the IV dosing
groups, or after the collection of the 96-hour blood sample (Study Day 5) for subject's
enrolled in the SC dosing groups. Strenuous activity during confinement was not
permitted.
In addition, subjects in Part 3 were confined to the study site on Study Days 8
and 15 for 24 hours. During confinement subjects received an SC dose of either 13C5.5
2012/045268
or placebo and were evaluated for vital signs, safety assessments, laboratory
assessments, pharmacokinetics and ADA, Biomarker ng, ocardiograms
(ECGs), and pulmonary function tests .
Subjects received a standardized diet, providing approximately 30% of the daily
calories from fat, no more than 45% of daily calories from carbohydrates, and providing
approximately 1900 calories/day for all meals during confinement. The composition
(protein, fat, carbohydrate, and total calories) of all meals was determined by a dietician,
and a record was kept with the source documents. During confinement in each part of
the study, the subjects consumed only the scheduled meals provided in the study and
water to quench thirst. The subjects ned from all other food and beverage.
For Parts 1 and 2, no food or beverage, except for water to quench thirst, was
allowed on Study Day —1 from 8 hours prior to dosing until approximately 2 hours after
completion of the dosing.
For Part 3, no food or beverage, except for water to quench thirst, was allowed
on Study Days 1, 8, and 15 from 8 hours prior to dosing until approximately 2 hours
after completion of the dosing on Study Day 1.
Inclusion Criteria
A t was eligible for study participation if he/she met the following criteria:
1. Males or females and age was between 18 and 55 years, inclusive.
2. For Parts 2 and 3, a diagnosis of asthma for at least 6 months prior to Screening:
Mild to moderate controlled asthmatic ts as defined below
Use of prescribed short acting beta agonists for no more than 4 puffs/week
for symptomatic control of asthma
Long acting beta agonists (LABA) may have been taken as prescribed if
used concurrently with d corticosteroids (ICS). LABA was not
administered for 12 hours before the screening PFTs were med and
could resume at the completion of the testing
If on ICS, up to a medium dose may have been used (defined as the
equivalent of fluticasone MDS/HFA up to 440 mcg daily or fluticasone
DPT up to 500 mcg daily)
3. For Parts 2 and 3, forced expiratory volume 1 (FEVl) 270% at the Screening and
Baseline visits.
4. For Parts 2 and 3, if on an ICS, a stable ICS dose for 34 weeks before
Study Day 1 and dose was ed to remain stable throughout the study. Must
have used ICS for at least 4 weeks before the screening visit.
. For Parts 2 and 3, subjects with asthma had a positive methacholine challenge test
result available by history (within the past 12 months) or demonstrated airway
reversibility in pulmonary function measurements by trating at least 12%
increase in FEV1 from best effort when tested at least 30 minutes after two to four
tions of inhaled albuterol or nebulized albuterol (or equivalent short acting
beta agonist). Up to 2 attempts could have been made at any one session to
demonstrate ibility. Subjects may have returned on another day for repeat
testing if necessary. Reversibility or methacholine challenge test confirming
reversibility may have been documented by medical record if performed within
the past 12 . A positive methacholine challenge was defined as a PCZO at a
dose of holine of $8.0 mg/mL using American Thoracic Society standards
for pulmonary function testing (see Guidelines for Methacholine and Exercise
Challenge Testing 1999. Am J. Respir. Crit. Care Med., Vol. 161, pp. 309-329,
2000).
6. For Parts 2 and 3, subjects had well-controlled asthma for at least 4 weeks prior to
Study Day 1, as defined by:
Asthma ms 32 days/week (i.e., cough, wheezing, shortness of breath)
Nighttime awakenings 32 times during the prior 4-week period
No interference with normal activity
No more than 4 inhalations/week of a short acting beta agonists for asthma
symptom control (excluding the prophylactic use for the prevention of
exercise induced bronchospasm).
7. If female, the subject met one of the following criteria:
Postmenopausal for at least two years,
Surgically sterile eral oophorectomy, bilateral tubal ligation, or
ectomy). Females who had undergone tubal ligation were required to
agree to use a second form of contraception starting on the first day of
confinement until 160 days after study drug treatment which ed:
Intrauterine (IUD) devices
Barrier methods (diaphragm with spermicide, or condom with spermicide)
Injected, oral, transdermal, vaginal, or implanted methods of al
contraceptives
8. s had negative results for pregnancy tests performed:
At Screening on a serum specimen obtained within 28 days prior to Study
Day 1 and at Baseline, which may have occurred anytime within a 3 day
window (i.e., Study Day —3 to Study Day —1) prior to dosing Study Day 1.
9. If male, the subject was surgically sterile or practicing at least 1 of the following
s of birth control during the study and for 160 days after last study drug
administration:
Subject used condom and partner(s) used an IUD
Subject used condom and partner(s) used oral, injected, or ted methods
of hormonal contraceptives
Subject used s and partner(s) used barrier method aceptive
, diaphragm, or vaginal ring with spermicidal jellies or creams)
Additionally, male subjects agreed to not donate sperm during the study and for
160 days after the last dose of study drug.
. For Part 1, Body Mass Index (BMI) was 18 to 29, inclusive. For Parts 2 and 3,
BMI was 18 to 34, ive. BMI was calculated as weight in kg d by
square of height in meters. Body weight did not exceed 120 kg.
11. A condition of general good health (other than mild-moderate controlled asthma
and associated medical conditions such as mild-moderate allergic rhinitis, atopic
dermatitis, and gastroesophageal reflux disease) based upon the results of a
medical history, physical examination, vital signs, laboratory profile and a 12-
lead electrocardiogram (ECG).
l2. Voluntarily signed and dated an informed consent approved by an IRB, prior to
the conduct of any screening or study-specific procedures.
Exclusion Criteria
A subject was not eligible for study participation if he/she met any of the
following criteria:
1. Subjects was using LABA therapy without concurrent use of ICS.
2. For Parts 2 and 3, asthma exacerbation within 8 weeks of Study Day 1.
3. For Parts 2 and 3, upper atory tract infection within 4 weeks of Study Day 1.
4. For Parts 2 and 3, asthma exacerbation requiring systemic osteroids or any
other reason for requiring systemic corticosteroids Within 6 months of Study
Day 1.
. For Parts 2 and 3, asthma exacerbation requiring emergency room (ER) visit,
hospitalization, or medical intervention Within 6 months of Study Day 1.
6. History of ally significant allergic reaction Le. anaphylaxis (per the
investigator) to any drug, biologic, food or e.
7. y of major immunologic reaction to any IgG containing agent.
8. y of atopic dermatitis involving 210% of body surface area or requiring
l treatment other than use of low to medium potency topical
corticosteroids or over-the-counter emollients Within 6 months of Study Day 1.
9. History of diabetes (Type I or Type II) or a fasting serum glucose level suggestive
of diabetes (fasting serum glucose 2126 mg/dL) at Screening.
. History of an allergic reaction or significant sensitivity to constituents of study
drug.
11. History of tuberculosis (TB) or iosis.
12. History of persistent chronic or active infections which required hospitalization or
treatment with IV antibiotics, IV antivirals or IV antifungals Within 30 days of
Screening or oral antibiotics/antivirals Within 14 days prior to Study Day 1.
13. Subjects were evaluated for latent TB infections. Subjects demonstrated e
of TB infection or exposure as evidenced by a ve chest X-ray and negative
purified protein derivative (PPD) skin test.
14. Positive test result for hepatitis B surface antigen (HB sAg), hepatitis C virus
antibody (HCV Ab), or HIV antibodies (HIV Ab).
. Positive test result on schistosomiasis serology.
16. History of unexplained diarrhea or abdominal pain of greater than 2 weeks
duration.
17. History of untreated parasitic infections.
18. History of genetic or ed immune deficiency.
19. For Parts 2 and 3, use of any non-essential medications, vitamins and/or herbal
supplements within the 2-week period prior to study drug administration. For
Part 1, used any prescription, over-the-counter medications or herbal supplements
within 2 weeks prior to study drug administration.
20. For Parts 2 and 3, subject had taken ® within 5 months of Study Day 1.
21. For Parts 2 and 3, subject had a change in immunotherapy dose in the 3 months
prior to Baseline.
22. Received any drug by injection within 30 days or 5 half-lives (whichever was
) prior to study drug administration.
23. Received any investigational product within 30 days or 5 half-lives (whichever
was longer) prior to study drug administration.
24. History of cancer or lymphoproliferative disease other than a successfully treated
tastatic ous squamous cell or basal cell carcinoma.
. History of epilepsy, any clinically significant cardiac, respiratory t mild to
2O moderate asthma), renal, hepatic, gastrointestinal, hematologic, rheumatologic, or
psychiatric e or disorder, non-healing wounds or recurrent poor wound
healing, or any uncontrolled medical illness. In addition the following were
excluded:
Chronic obstructive pulmonary disease (COPD), congestive heart failure,
pulmonary sm, pulmonary infiltration with eosinophilia, current cough
secondary to drugs, vocal cord dysfunctions.
26. History of cardiopulmonary Sudden Death in any first-degree relative.
27. nt or breast-feeding female.
28. Recent (6-month) history of drug or alcohol abuse.
29. Received of any live vaccine Within 3 months prior to study drug administration.
. Positive screen for drugs of abuse, alcohol, or cotinine at ing or on
admission.
31. Chest X-ray at Screening indicating any clinically significant abnormality
(including calcified granuloma and/or pleural scarring) as assessed by appropriate
medical personnel.
32. Febrile illness Within 14 days prior to dosing.
33. Subjects with ne QTc interval by Friderica tion (QTcF) > 450 msec
for females and > 430 msec for males.
34. Donated or lost a significant blood volume (including pheresis) or received
a transfusion of any blood product Within 8 weeks prior to study drug
administration.
. Subject was a smoker, or had a history of smoking Within the 6-month period
2O preceding study drug administration.
36. Current enrollment in another al study.
37. Previous enrollment in this study.
38. ered by the investigator or medical monitor, for any reason, to be an
unsuitable candidate to e 13C5.5.
Treatments Administered
For Parts 1 and 2, a single dose of 13C5.5 or 13C5.5 placebo (0.3, 1.0, 3.0, or
.0 mg/kg) was stered intravenously to each subject in the morning on
Study Day 1. For Part 3, a total of 3 doses of 13C5.5 or 13C5.5 placebo (0.3 or
3.0 mg/kg) were administered subcutaneously in the morning on Study Days 1, 8, and
. For the IV infusion, an ling catheter was inserted into a vein prior to dosing
and was flushed with 1 mL of 13C5.5 placebo. 13C5.5 or 13C5.5 placebo was
administered intravenously by continuous infusion over approximately 120 minutes with
the subjects in a supine position. Following the infusion, a 1 mL 13C5.5 o flush
was administered, and the line was maintained for a minimum of 2 hours following the
completion of the infusion with a 0.9% isotonic saline solution. Subjects remained in a
supine position for at least 5 minutes before infusion and until 30 minutes after the end
of infusion.
For the SC dose, the study drug was administered subcutaneously into the left
upper quadrant of the abdomen, ng any blood vessels, thickening or tenderness of
skin, scars, fibrous tissue, stretch marks, ng, redness, nevi, or other skin
2O imperfections. The subject remained in a supine position for at least 30 minutes
following each injection.
Subjects were assigned to one of nine dose groups (Table 2). Within each IV
infusion group, four subjects were randomized to receive 13C5.5 and one subject
received placebo. Within each SC group, four subjects received 13C5.5 and two
received placebo. Dose escalation took place for a new cohort only after all subjects
within a dose cohort had satisfactorily completed the m one-week safety
assessments.
Table 2. Investigational Product: 13C5.5
Formulation
13C5.5 13C5.5 Placebo
Dosage Form Parenteral Parenteral
Solution for injection in PPS Solution for injection in
ation
Strength (mg) 100 mg per 1.0 mL N/A
Mode of Administration IV Infusion or SC injection IV Infusion or SC injection
Bulk Product Lot Number 09-023042 09-023043
Manufacturing Site Germany Germany
Finishing lot 09-024016 09-024017
Retest Date 31 January 2011 31 January 2011
PFS = pre-filled syringe; N/A = Not applicable.
For IV , study medication in the PPS was further diluted with 13C5.5
placebo and mixed in an injection syringe for administration. For SC dosing, no dilution
was required, however material was transferred to ion es for stration.
The study drug was stored at 20 to SOC/36O to 46oF, protected from light, and was not
frozen.
Method ofAssigning Subjects to Treatment Groups
As they were enrolled in the study, healthy subjects in Part 1 of the study were
assigned unique consecutive numbers beginning with 1101, 1201, 1301 and 1401 for
Groups 1, 2, 3, and 4, respectively. Subjects with mild to moderate controlled asthma in
Part 2 were assigned unique consecutive numbers beginning with 2501, 2601 and 2701
for Groups 5, 6 and 7, respectively. Subjects with mild to te controlled asthma
in Part 3 were assigned unique consecutive numbers beginning with 3801 and 3901 for
Groups 8 and 9, respectively. The subjects were randomly assigned to receive 13C5.5 or
placebo. The randomization schedule was computer-generated before the start of the
study.
Selection ofDoses in the Study
The maximum recommended starting dose (MRSD) for the first-in-human (FIH)
trial was calculated according to the US Food and Drug Administration (FDA) Guidance
for Industry ating the safe starting dose in the clinical trials for therapeutics in
adult healthy volunteers." Per the guidance, MRSD for proteins with molecular weight
(MW) > 0 daltons that are stered IV, should be estimated by normalizing
across s in mg/kg, rather than using body surface area scaling. Additionally, the
2O 13C5.5 in vitro and in vivo data for human versus cynomolgus monkey rIL-13 or rat
rIL-13 demonstrate a ~8fold potency shift, respectively which was included in the
final MRSD estimates.
Based on the no adverse event effect level (NOAEL) from the 2-week repeat
dose lgus monkey study, a safety factor of 10, and a 8-fold potency shift
between monkey and human rIL—13 from in vivo pharmacology data, the MRSD was
determined to be 19 mg/kg. Similarly based on the NOAEL from the 4 week repeat
dose rat study, a safety factor of 10, and a d potency shift between rat and human
WO 09521
rIL-l3 from in vivo pharmacology data, the MRSD was ined to be 3 mg/kg.
Furthermore, when a potency shift of 155-fold using the in vitro pharmacology data is
used, the human MRSD was determined to be 1 mg/kg.
A range of doses were evaluated in this trial to establish dose-linearity, with the
low dose selected to allow for an appropriate safety margin while minimizing the
likelihood of immunogenicity. The high dose was chosen to evaluate the safety margin
of high doses in both a healthy and controlled asthma population prior to proceeding into
Phase 2 to enable appropriate dose ranging design in the proof-of-concept study. Safety
and tolerability were established following single escalating doses prior to proceeding to
multiple dosing. Subcutaneous multiple dosing was ant for assessing
bioavailability, potential exposure-response relationships in the tic population,
and immunogenicity.
Prior and Concomitant Therapy
For Part 1, concomitant medications were not to be permitted throughout the
study.
For Parts 2 and 3, short acting beta agonist use as rescue therapy was permitted
during the study. Low to medium dose ICS use, and nasal corticosteroid use was
permitted during the study. Long-acting beta agonist use was allowed for patients as
prescribed if LABA was being used concurrently with ICS at Screening. There should
have been no plan to change asthma medications for the duration of the study.
Systemic corticosteroid use was permitted if needed for control of an asthma
exacerbation but subjects were to be discontinued from any r treatment with
l3C5.5. Subjects who ed use of systemic corticosteroids were to remain in the
study and followed for safety assessments.
Only essential medications needed for the treatment of existing medical
conditions were allowed during the study. These included lipid-lowering agents, anti-
hypertensives, antacids, histamine-2 receptor antagonists, proton pump inhibitors, and
pain relievers such as aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).
Antihistamine use, over-the-counter ent use, and/or low to medium potency
topical osteroid (Class IV, V, VI or VII) use was permitted in ts with atopic
dermatitis meeting entry criteria. Nasal corticosteroid use was permitted in subjects with
allergic rhinitis. Subjects were on stable doses of permitted medications for a minimum
of 8 weeks prior to Study Day 1 and remained on stable doses throughout the study. Use
of acetaminophen of 2 g or less per day was allowed on an intermittent basis at the
tion of the investigator.
Use of non-essential medications was discouraged but if a subject reported taking
any over-the-counter or prescription medications, vitamins and/or herbal supplements or
if administration of any medication became necessary from 30 days prior to study drug
administration through the end of the study, the name of the medication, dosage
information including dose and frequency, date(s) of administration ing start and
end dates, and reason for use were recorded, and the l monitor was notified.
13C5.5 andADA Assay
Blood samples for l3C5.5 assay and anti-drug antibody (ADA) were obtained
throughout the study, as indicated in Table 3. The time that each blood sample was
collected was recorded to the nearest minute in the source document and on the
appropriate electronic case report form (eCRF). The timing of blood collections took
priority over all other scheduled study activities except for dosing.
Additional blood s for drug measurement may have been collected from
subjects if they were discontinued due to adverse ; the clock time, and date the
sample was taken were to be recorded.
Samples were to be collected Within i 5 minutes of the scheduled times on Study
Day 1, Within i 1 hour of the scheduled times on Study Days 2 h 6, and Within i
3 hours of the scheduled times on Study Days 7 through 127.
Table 3. Serum Volume (mL) for Each Sample
IV Doses
Hour
3, 4, 6, 10, 14, 24, 1344,
48, 33 50 2016,
0 2 72, 96, 120, 168 6 4 672 1008 2688
13C5.5 (MSD) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
ADA (screening 1.5 1.5 1.5 1.5
assay)
ADA 2.0 2.0 2.0 2.0
(neutralizing
assay)
SC Doses
Hour
672, 1008,
8, 24, 48, 72, 360, 384, 408, 1344, 2016,
0 96, 120, 168, 336 432, 456, 504 2352, 3024
13C5.5 (MSD) 1.5 1.5 1.5 1.5 1.5
ADA ning 1.5 1.5 1.5
assay)
ADA (neutralizing 2.0 2.0 2.0
assay)
MSD = Meso—scale-discovery assay.
Results from MSD assay for 13C5.5 and screening assay for ADA were
reported for this study.
Blood samples for the 13C5.5 assay were collected by venipuncture into
riately labeled evacuated serum collection tubes without gel separator. For IV
study drug administration (Parts 1 and 2), samples for 13C5.5 assay were collected at
0 hour (pre-dose) and at 2, 3, 4, 6, 10, 14, 24, 48, 72, 96, 120, 168, 336, 504, 672, 1008,
1344, 2016, and 2688 hours following the onset of study drug administration on Study
Day 1. For SC study drug administration (Part 3), s for 13C5.5 assay were
collected at 0 hour (pre-dose) and at 8, 24, 48, 72, 96, 120, 168, 336, 360, 384, 408, 432,
456, 504, 672, 1008, 1344, 2016, 2352 and 3024 hours following study drug
administration on Study Day 1. The samples for hours 168 and 336 were collected
immediately prior to dosing on Study Days 8 and 15, respectively. A blood sample for
13C5.5 assay was obtained at the early termination visit, if applicable. The serum
volume needed for each sample is listed in Table 3. Blood was d to clot for
minutes at room temperature before fugation.
Blood samples for ADA assay were collected by venipuncture into appropriately
labeled evacuated serum collection tubes without gel separator. For IV study drug
2O administration, blood samples for ADA assay were collected on Study Day 1 at 0 hour
(pre-dose) and on Study Days 15, 29, 57, 85 and 113. For SC study drug administration,
blood samples for ADA assay were collected on Study Days 1 and 15 at 0 hour
(pre-dose) and on Study Days 29, 43, 57, 85, 99 and 127. A blood sample for ADA
assay was also obtained at the early termination visit, if able. The serum volume
needed for each sample is listed in Table 3. Blood was allowed to clot for 30 minutes at
room temperature before centrifugation.
Pharmacokinetic Variables
Values for the pharmacokinetic parameters of 13C5.5 after IV dosing were
estimated using partmental methods.
The maximum observed serum concentration (Cmax) and the time to Cmax (peak
time, Tmax) were determined directly from the serum concentration-time data.
The value of the apparent terminal phase ation rate constant (B, Beta) was
obtained from the slope of the least squares linear regression of the logarithms of the
serum concentration versus time data from the terminal log-linear phase of the profile.
The terminal log-linear phase was identified using PhoenixTM WinNonlin® Version 6.1
(Pharsight Corporation, Mountain View, CA) and visual inspection. A m of
three concentration-time data points was used to determine B. The actual times used for
each subject may be found in the tables of the calculated pharmacokinetic ters.
The terminal phase ation half-life (ti/2) was calculated as ln(2)/B.
The area under the plasma concentration-time curve (AUC) from time 0 to the
time of the last measurable concentration (AUCt) was calculated by the linear
trapezoidal rule. The AUC was extrapolated to te time by dividing the last
measurable plasma concentration (Ct) by B. Denoting the extrapolated n of the
AUC by AUCext, the AUC from time 0 to infinite time (AUCOO, AUCinf) was calculated
as follows:
AUC00 = AUC: + AUCext
The percentage of the contribution of the extrapolated AUC (AUCext) to the
overall AUC00 was calculated by dividing the AUCext by the AUC00 and multiplying this
quotient by 100.
The clearance value (CL) was calculated by dividing the administered dose by
the AUCOO. The volume of distribution (Vdfi, VDB) value was calculated by dividing the
CL by B. An estimate of the volume of distribution at steady state (VSS) was also
presented.
2012/045268
Dose-normalized Cmax, AUC, and AUC00 were also calculated for all groups in
Parts 1 and 2.
For the SC dose groups in Part 3, Cmax, Tmax, and AUC from 0 to 168 hours post-
dose (AUC0_168) were estimated after the first and third doses. Beta and tl/2 were
estimated following the third SC dose. Additionally, dose-normalized Cmax and AUC0_
168 were calculated for Groups 8 and 9 in Part 3. The accumulation ratio (Rac) for the
AUC0_168 for Study Day 15 relative to the AUC0_168 for Study Day 1 was also calculated.
Pharmacokinetics
For each of Parts 1, 2 and 3, serum trations of 13C5.5 and ADA and
pharmacokinetic parameter values were ted for each subject and each dose group,
and summary statistics were computed for each sampling time and each parameter.
For all the 13C5.5 single-dose regimens (groups) in healthy subjects (Part 1),
analyses were performed on dose-normalized Cmax, dose-normalized AUC, Tmax and B to
address the issue of linear pharmacokinetics and dose tionality. The thmic
transformation was employed for Cmax and AUC. For each parameter, a one-way
is of variance (ANOVA) was performed. Subjects were classified by dose level.
Body weight or another measure of size was to be included as a covariate in the model
for Cmx and AUC if the regression coefficient was tically significant at level of
0.10. Within the framework of the final model, the highest dose was compared to the
lowest dose. For the logarithms of Cmax and AUC, a 95% confidence interval, as well as
a point estimate, were provided for the ratio of the central value of the highest dose
relative to that of the lowest dose. The point estimate and the 95% confidence interval
were obtained by exponentiation of the corresponding estimate and confidence limits for
the ence of logarithm means. If at least four 13C5.5 dose levels were studied, a
test was also performed at significance level 0.05 on a contrast in the dose level means,
with the contrast chosen to be sensitive to an approximately linear trend with the
logarithm of dose.
ANOVAs were also ted for the single dose regimens in ts with mild
to moderate controlled asthma (Part 2). Within the framework of the model, the
hypothesis of no difference between the highest and lowest doses was tested. The
analyses could or could not have been performed jointly (analyses were not performed
jointly) for the two populations (healthy subjects and subjects with mild to moderate
controlled asthma). If es had been performed jointly for the two populations, then
only data from the dose levels that the two populations had in common, were to be
included. In this case, the model would have had effects for population, dose level and
the interaction of population by dose level. Body weight or r measure of size
could have been included in the model for Cmax and AUC. If the tic on population-
dose interaction had been significant at level of 0.10, then estimates and other inferences
would have been provided for each population separately. Otherwise, estimates and
other inferences were to have been based on the dose level main effects.
ANOVA was also performed for the multiple-dose regimens (Part 3) for
pharmacokinetic parameters corresponding to those of the single-dose regimens. The
decision on whether to e a measure of size as a ate was based in part on the
results for Parts 1 and 2. For Cmax and AUC, point estimates and 95% confidence
intervals were provided for the ratio of the central values of the two doses, as ned
for Part 1.
Missing Values and Model Violations
If there had been missing values due to premature discontinuations that were
possibly related to study drug, the possibility of bias as a result of the missing values
would have been considered.
Values of pharmacokinetic variables (Cmax, AUC, etc.) are normally determined
without replacing missing individual tration values, simply using the available
data, and, if necessary, performing the analysis with some missing values for a
pharmacokinetic variable. However, missing concentration values for isolated
2012/045268
dual serum samples could have been replaced (imputed) if such might have
affected study conclusions or meaningfully affected point estimates.
If the probability distribution of a variable had non-symmetry to the degree that
sions from the ANOVA (ANOVAs were med for all parts rather than
ANCOVAs) might have been affected or point estimates were misleading, then a
transformation (an alternative to the logarithm in the case of Cmax and AUC) that yielded
an approximately symmetric distribution was to have been sought. If a satisfactory
transformation could not have been found or if it appeared that both tails of the
probability distribution were quite long, a nonparametric analysis could have been
performed. If the dose levels had unequal variances to the extent that conclusions might
have been affected, then approximate methods that allowed for unequal ces would
have been used.
Example 1: Escalating Single Doses in Healthy and Asthma Subjects (Groups 1
through 7)
The mean i standard deviation (SD) serum concentration-time profiles after a
single IV infusion of 0.3 mg/kg to 10 mg/kg l3C5.5 to y subjects (Groups 1
through 4) are presented in Figures 5 and 6 on linear and log-linear scales, respectively.
The mean i SD serum concentration-time profiles after a single IV infusion of
0.3 mg/kg, 3.0 mg/kg orlO mg/kg l3C5.5 to healthy subjects and subjects with mild to
moderate asthma (Groups 1, 3 through 7) are ted in Figures 7 and 8 on linear and
log-linear , respectively.
The mean i SD pharmacokinetic parameters of l3C5.5 after a single IV infusion
of l3C5.5 to healthy and asthma subjects are shown in Table 4.
Table 4. Mean 1 SD Pharmacokinetic ters of 13C5.5 Following a
Single IV Infusion of 13C5.5 in Healthy Subjects and Asthma Subjects
Group Group Group
Group Group 2 3 Group Group 7
1 5 1.0 3.0 6 4 10
0.3 0.3 mg/kg mg/kg 3.0 10 mg/kg
mg/kg mg/kg (N = (N = mg/kg mg/kg (N = 4)
(N=4) (N=4) 3)# 3)# (N=4) (N=4)
Health Mild/ Health Health Mild/ Health Mild/
PK y Mod y y Mod y Mod
Parame Volunt Asthm Volunt Volunt Asthm Volunt Asthm
ter Unit eer a eer eer a eer a
Cmax ug/mL 6.881 6.721 20.65J_r 80.15J_r 68.554; 214.50 292.00
0.49 0.91 2.43 6.11 10.46 $27.77 $19.88
AUCtT ugOhr/mL 2102i 1999i 6490i 26214 24580 82527 92307
495 450 1192 i5519 i2578 i8957 i9810
AUCOOT nghr/mL 2264i 2123i 6649i 27180 25037 87342
94917
394 544 1362 i 6051 i 2913 i
i 9276
10966
t1/2¢ day 17.35 i 17.24 i 18.83 i 22.64 i 16.37 i 26.66 i 23.50 i
3.34 8.24 4.83 4.26 6.35 4.52 4.45
0.135i 0.148i 0.154i 0.114i 0.121i 0.116i 0.106i
CLT mL/hr/kg
0.022 0.035 0.028 0.027 0.013 0.015 0.010
82.4 i 96.6 i 102.0 i 89.2 i 72.8 i 108.9 i 89.0 i
leg,T mL/kg
12.6 25.9 11.9 7.6 16.7 18.1 19.7
VSST mL/kg 80.3 i 90.0 i 95.1 i 83.1 i 75.9 i 97.7 i 69.7 i
4.5 20.0 7.3 7.0 15.9 13.8 7.8
Cmax/Do ug/mL/(mg/k 22.93i 22.41i 20.65i 26.72i 22.85i 21.45i 29.20i
se g) 1.65 3.02 2.43 2.04 3.49 2.78 1.99
AUCt/D ugOhr/mL/(m 7007i 6664i 6490i 8738i 8193i 8253i 9231 i
ose g/kg) 1650 1501 1192 1840 859 896 981
D ugOhr/mL/(m 7546i 7076i 6649i 9060i 8346i 8734i 9492i
ose g/kg) 1315 1812 1362 2017 971 1097 928
# N = 4 for Cmax and Cmax/Dose for Groups 2 and 3.
¢ Harmonic mean i pseudo-standard deviation; evaluations of tl/2 were
based on statistical tests for B.
T Parameter was not tested statistically.
VSS: Estimate of volume of distribution at steady state.
ing IV administration, the exposures, as determined by AUC and Cmax,
appeared to increase in a dose dependent manner over the 0.3 mg/kg to 10 mg/kg range.
Exposures (AUC and Cmax) to 13C5.5 in healthy and asthma subjects were similar at the
tested doses (0.3 mg/kg, 3.0 mg/kg, and 10.0 mg/kg IV). The pharmacokinetics of
13C5.5 were similar to that of a typical globulin G1 (IgGl) with a small volume
of distribution and long half-life. Harmonic mean i pseduo SD half-lives of 13C5.5
ranged from 16.4 i 6.35 days to 26.7 i 4.52 days, and mean Vdp, ranged from 72.8 to
108.9 mL/kg following IV infusions over the 0.3 mg/kg to 10.0 mg/kg dose range.
The total variabilities in Cmax, AUC: and AUC00 for 13C5.5 expressed as percent
CV for escalating 13C5.5 single IV ons in healthy and asthma subjects are shown
in Table 5.
2012/045268
Table 5. Total Variability for Pharmacokinetic Parameters (Parts 1 and 2)
Variability (% CV)
Group 1 Group 2 Group 3 Group 4
Paramet 0.3 mg/kg 1.0 mg/kg 3.0 mg/kg 10 mg/kg
er (Units) (N = 4) (N = 3)# (N = 3)# (N = 4)
Healthy Subjects
Cmax ug/mL 7.2 11.8 7.6 12.9
AUC: Hg'hr/mL 23.5 18.4 21.1 10.9
AUCOO HgOhI/mL 17.4 20.5 22.3 12.6
Mild to Moderate Asthma Subjects
Group 5 Group 6 Group 7
0.3 mg/kg 3.0 mg/kg 10 mg/kg
(N=4) (N=4) (N=4)
Cmax pg/mL 13.5 15.3 6.8
AUCt nghr/mL 22.5 10.5 10.6
AUCOO HgOhI/mL 25.6 11.6 9.8
# N = 4 for Cmax for Groups 2 and 3.
Example 2: Dose Proportionality and Pharmacokinetic Linearity in Healthy and
Asthma Subjects (Parts 1 and 2)
The mean i SD dose-normalized Cmax and AUC00 values for 13C5.5 following
administration of single IV infusions of 13C5.5 over the 0.3 to 10 mg/kg dose range are
presented in Table 4. The mean i SD dose-normalized Cmax and AUC00 values of
13C5.5 versus dose level are presented in Figure 9.
To address the issues of pharmacokinetic linearity and dose proportionality in
healthy subjects and subjects with mild to te asthma, an ANOVA was performed
on the pharmacokinetic parameters. Subjects were classified by treatment group
en).
In healthy subjects, 13C5.5 cokinetics were dose linear in Cmax and AUC.
The mean Cmax, AUC: or AUC00 values were similar between the highest dose (10
mg/kg) and the lowest dose (0.3 mg/kg). There were no statistically significant trends (p
> 0.05) for changes in 13C5.5 dose-normalized Cmax, or ormalized AUC over the
dose range (0.3 to 10 mg/kg). However, the power of the tests was low due to small
number of ts in each of the dose groups. Based on statistical tests for B, the tl/2
value for the highest dose (26.7 i 4.52 days, 10 mg/kg) was statistically significantly
longer than the value of 17.4 i 3.34 days for the lowest dose of 0.3 mg/kg (Table 4).
2O The results also indicated that there were tically icant trends (p < 0.05) for
increases in 13C5.5 tl/2 across the 0.3 to 10 mg/kg dose range.
In subjects with mild to moderate asthma, the dose-normalized Cmax of the
highest dose (10 mg/kg) was statistically significantly higher than that for the lowest
dose of 0.3 mg/kg. The dose-normalized AUCt and AUC00 values of the highest dose
were statistically significantly greater (p < 0.05) than those of the lowest dose.
However, the observed departure from dose proportionality was small with an estimate
of the ratio of central values of 1.3 for Cmax and 1.4 for AUC over a 33-fold range of
doses.
Example 3: Three Weekly SC Injections in Asthma Subjects (Groups 8 and 9)
The mean i SD serum concentration versus time es of 13C5.5 following
3 weekly SC doses of 13C5.5 for Group 8 (0.3 mg/kg) and Group 9 (3.0 mg/kg) are
presented in Figure 10 on linear and log-linear scales.
The mean i SD pharmacokinetic parameters of 13C5.5 following three weekly
doses of 0.3 mg/kg or 3.0 mg/kg 13C5.5 SC are shown in Table 6. The accumulation
following 3 weekly doses of 13C5.5 s to be linear as the Cmax and AUC values are
approximately 3-fold greater following three 0.3 mg/kg or 3.0 mg/kg weekly doses of
. Tmax appears to be similar following the first and third 0.3 and 3.0 mg/kg doses
of 13C5.5. The harmonic mean i pseudo-SD half-life for 13C5.5 was 27.29 i 3.33 and
24.30 i 1.23 days after SC administration of 0.3 and 3.0 mg/kg for three days,
respectively. Using simultaneous pharmacokinetic modeling of IV and SC data, the
estimated bioavailability of 13C5.5 was approximately 70%.
amoem H 3m -- 3m -- -- -- --
omon
38.3% a
9:30 wfiws a a“ H $2 I m? w; w:
9:53 u Hmd 32 H H H
H E;
3 359 zv 8.:
3% we 83 32 Noam
Wmofl fins a a“ 3m $8 I 84 6m
358 u H H E $2 -- H H
.3 3 8.: gm we 3m a?
88: .wE-OOD<
8 amoem H
583 H 3m -- 3m -- -- -- -- \QQ
amon— 8
m w
.3 9:30 “was a a“ 8.0 2: I mm.m mam mmm wovoOD<
359 u H H 03 as H H H
zv 3? 3% 8.8 2
2 who Hm mam ENG
Wmofl Ho
“flue 2: I
.3 Q a“ N; OE mmm 0:3
358 u H H E;
29:52am £8 -- H H 05
2. 92 0% we 26 g mm
633528
23:28355 :5 dug
as? £83.? E 5 A3358? ?
H soufisasoo<
:82 Noam
28? 2358355 $3528 Eu $-63 way m3 38an 383.63
WO 09521
ASBExS: .Qm
I 8:8:
SEEESV H
:2on 0:0:me
m u
The total variabilities in Cmax and AUC0_168 for 13C5.5 expressed as percent CV
following administration of three weekly SC doses of 13C5.5 in subjects with mild to
moderate asthma are shown in Table 7.
Table 7. Total Variability for Pharmacokinetic Parameters (Part 3)
Variability (%CV), Mild to Moderate Asthma ts
Group 8 Group 9
0.3 mg/kg SC 3.0 mg/kg SC
(N = 4) (N = 4)
Parameter (Units) Day 1 Day 15 Day 1 Day 15
Cmax ug/mL 39.9 19.9 33.0 26.6
68 ug-hr/mL 44.8 15.7 47.6 19.5
Example 4: Dose Proportionality and Pharmacokinetic Linearity (Part 3)
The mean i SD dose-normalized Cmax and AUCoo values for 13C5.5 ing
stration of 3 weekly SC doses of 13C5.5 0.3 or 3.0 mg/kg are presented in Table
6. The mean i SD dose-normalized Cmax and AUCoo values of 13C5.5 versus dose level
are presented in Figures 11 and 12, respectively.
To address the issues of pharmacokinetic ity and dose proportionality an
ANOVA was performed on the pharmacokinetic parameters. Subjects were classified
by treatment group (regimen).
In subjects with mild to moderate asthma administered 3 weekly SC doses,
13C5.5 pharmacokinetics were dose linear in Cmax and AUC. The mean Tmax, Cmax and
AUC0_168 values were similar between the highest dose (3.0 mg/kg) and the lowest dose
WO 09521
(0.3 mg/kg) on both Day 1 and Day 15. Of note, the power of the tests was low due to
small number of subjects in each of the dose groups.
Statistics/Analysis for Examples 1-4
Adjustments for covariates were not med.
Subjects 1202 and 1304 prematurely discontinued from the study and their last
assay blood samples were collected at Hour 672 and Hour 96, respectively. For these
two subjects, pharmacokinetic parameters were not calculated except for Cmax and Tmax.
Subject 1103 prematurely discontinued from the study and his last assay blood sample
was collected at imately 894 hours post dose. For this subject, pharmacokinetic
parameters were ated. The few cases of a missing concentration for an individual
sampling time did not prevent a determination of values of the cokinetic
parameters in which there is confidence.
Subjects whose available data warranted determination of values for the
pharmacokinetic parameters were included in the statistical analysis. This study was
conducted at a single study center; therefore, no considerations for a plurality of centers
were necessary.
Conclusion for Examples 1-4
2O The pharmacokinetics of 13C5.5 after single dose administration were consistent
with that of a IgGl with a long half-life and small volume of distribution. For subjects
administered a single IV infusion of 13C5.5, the systemic re (AUC and Cmax) to
13C5.5 increased in a dose proportional manner over the dose range of 0.3 to 10 mg/kg
for healthy subjects; however, for ts with mild to moderate controlled asthma,
AUC and Cmax increased in a slightly more (30 to 40%) than dose proportional manner
over the same 33-fold dose range. For subjects with mild to moderate asthma
administered 3 weekly SC doses, 13C5.5 pharmacokinetics were dose linear in both
AUC and Cmax between the 0.3 and 3.0 mg/kg doses. The accumulation of 13C5.5 was
as expected about 3-fold following three weekly SC doses.
WO 09521
During the study, 13C5.5 was well tolerated and safe when administered as a
single dose up to 10 mg/kg IV or as multiple doses of 0.3 and 3 mg/kg SC. The adverse
event profile in healthy adults was similar to that observed in subjects with asthma. No
dose-related increases or administration-specific trends in treatment-emergent adverse
events were appreciated. In each part of the study, the proportion of subjects reporting
an upper respiratory tract infection or viral upper atory tract infection was r
among those receiving 13C5.5 compared to those receiving placebo. All of these events
were of mild or moderate severity, and none were judged by the investigator to be
possibly or probably related to study drug. However, the incidence of respiratory
infections will continue to be monitored closely in future studies. Multiple events of
blood CPK increased were reported including in one placebo t; these events
occurred following the l confinement at the study site and were associated in each
case with transient ions in CPK and a history of increased physical activity.
One subject in the 13C5.5 0.3 mg/kg treatment group experienced a serious
adverse event of alization for bunionectomy that was assessed by the investigator
as not related to study drug stration. No subjects discontinued study drug due to a
treatment-emergent adverse event. Other than a report of infusion site pain in one
subject, there were no adverse events of infusion-related reactions reported, and a review
of events that could represent deterioration in asthma and spirometry data did not
suggest a worsening of underlying disease in asthma subjects.
No clinically significant trends were detected in other safety analyses including
vital signs, ECG variables and laboratory ements.
E UIVALENTS
Those d in the art will recognize, or be able to ascertain using no more than
routine experimentation, many equivalents to the specific ments of the invention
described herein. Such equivalents are intended to be encompassed by the following
claims.
WE
Claims (53)
1. Use of an isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating asthma in a human subject by intravenous administration of the antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein, the dy, or antigen-binding portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of between about 1,500 and about 2,700 µgh/ml; (b) a volume of distribution of between about 65 and 125 mL/kg; (c) a peak concentration (Cmax) of between about 5 and about 8 µg/ml; and (d) a clearance rate of between about 0.1 and about 0.2 ml/h/kg.
2. Use of an isolated composition comprising an anti-IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for ng asthma in a human subject by intravenous stration of the antibody, or antigen-binding portion thereof, at a dose of about 3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, ses the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and n the antibody, or antigen-binding portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of n about 21,000 and about 33,500 µgh/ml; (b) a volume of bution of between about 55 and about 100 mL/kg; (c) a peak concentration (Cmax) of between about 55 and about 90 µg/ml; and (d) a clearance rate of between about 0.08 and about 0.15 g.
3. Use of an isolated composition comprising an anti-IL-13 antibody, or antigen-binding n thereof, in the preparation of a medicament for treating asthma in a human subject by intravenous administration of the antibody, or antigen-binding portion thereof, at a dose of about 10 mg/kg, wherein the anti-IL-13 antibody, or antigen g portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein the dy, or antigen-binding portion thereof, is e of exhibiting: (a) an area under the curve (AUC) of between about 75 and about 100 µgh/ml; AH26(11205451_1):JJC (b) a volume of distribution of between about 90 and about130 mL/kg; (c) a peak concentration (Cmax) of between about 185 and about 250 µg/ml; and (d) a clearance rate of between about 0.1 and about 0.15 ml/h/kg.
4. Use of an ed composition comprising an anti-IL-13 dy, or antigen-binding portion thereof, in the preparation of a medicament for ng asthma in a human subject by subcutaneous administration of the antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein the antibody, or antigen-binding portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of between about 125 and about 800 µgh/ml; and (b) a peak concentration (Cmax) of between about 1.0 and about 6.0 µg/ml.
5. Use of an isolated composition comprising an L-13 antibody, or n-binding portion thereof, in the preparation of a medicament for treating asthma in a human subject by subcutaneous administration of the antibody, or antigen-binding portion f, at a dose of about 3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, ses the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein the antibody, or antigen-binding portion thereof, is capable of exhibiting: (a) an area under the curve (AUC) of between about 1,100 and about 8,500 ; and (b) a peak concentration (Cmax) of between about 12 and about 60 µg/ml.
6. The use of any one of claims 1-5, wherein the anti-IL-13 dy, or antigen-binding portion thereof, is 13C5.5, or an antigen-binding n thereof.
7. The use of any one of claims 1-5, wherein the composition is a pharmaceutical composition.
8. The use of any one of claims 1 to 7, wherein in said treating, the medicament is administered once.
9. The use of any one of claims 1 to 7, wherein in said treating, the medicament is stered weekly. AH26(11205451_1):JJC
10. The use of claim 9, wherein in said treating, the medicament is administered for about 3 weeks.
11. The use of any one of claims 1 to 7, wherein the asthma is mild to moderate asthma.
12. The use of any one of claims 1 to 7, wherein said treating further comprises administering an additional agent to said subject.
13. The use of claim 12, wherein said additional agent is selected from the group consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a mulation le blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof; methotrexate, a cyclosporin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an heumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug ), an analgesic, an anesthetic, a ve, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an ic d, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.
14. Use of an anti-IL-13 antibody, or n-binding portion f, in the preparation of a medicament for treating asthma in a human subject by intravenous administration of the antibody, or antigen-binding portion thereof, at a dose of about 0.3 mg/kg, wherein the anti-IL- 13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one pharmacokinetic characteristic selected from the group consisting of: (a) a maximum serum concentration (Cmax) of between about 5 and about 235 µg/mL, (b) an area under the serum concentration-time curve (AUC) of n about 1,500 and about 98,000 µgh/mL, is achieved following administration of the dy, or antigen-binding n thereof to said subject.
15. The use of claim 14, wherein the Cmax is between about 5 and about 10 µg/mL. AH26(11269199_1):JJC
16. The use of claim 14, wherein the AUC is n about 1,500 and about 2,700 µgh/mL.
17. Use of an L-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating asthma in a human subject by intravenous administration of the antibody, or antigen-binding portion thereof, at a dose of about 3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one pharmacokinetic characteristic selected from the group consisting of: (a) a maximum serum concentration (Cmax) of n about 5 and about 235 µg/mL, and (b) an area under the serum tration-time curve (AUC) of between about 1,500 and about 98,000 µgh/mL, is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.
18. The use of claim 17, wherein the Cmax is between about 55 and about 90 µg/mL.
19. The use of claim 17, wherein the AUC is between about 20,000 and about 34,000 µgh/mL.
20. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the ation of a ment for treating asthma in a human subject by intravenous administration of the antibody, or antigen-binding portion thereof, at a dose of about 10 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one cokinetic characteristic selected from the group consisting of: (a) a maximum serum concentration (Cmax) of n about 5 and about 235 µg/mL, and (b) an area under the serum concentration-time curve (AUC) of between about 1,500 and about 98,000 µgh/mL, is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.
21. The use of claim 20, wherein the Cmax is between about 190 and about 235 µg/mL.
22. The use of claim 20, wherein the AUC is n about 75,000 and about 100,000 µgh/mL. AH26(11269199_1):JJC
23. The use of claim 14, wherein the Cmax value is between about 20 and about 30 (µg/mL)/(mg/kg) after dose normalization.
24. The use of claim 14, wherein the AUC is between about 6,000 and about 10,000 (µgh/mL)/(mg/kg) after dose normalization.
25. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the ation of a medicament for treating asthma in a human subject by subcutaneous administration at a dose of about 0.3 mg/kg, wherein the anti-IL-13 antibody, or antigen g portion f, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, wherein at least one pharmacokinetic teristic selected from the group consisting of: (a) a m serum concentration (Cmax) of between about 1 and about 60 µg/mL, (b) an area under the serum concentration-time curve (AUC) of between about 125 and about 8,100 µgh/mL, is achieved following administration of the antibody, or antigen-binding portion f to said subject.
26. The use of claim 25, wherein the Cmax is between about 1 and about 6 µg/mL.
27. The use of claim 25, wherein the AUC is between about 100 and about 800 µgh/mL.
28. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the preparation of a ment for treating asthma in a human subject by subcutaneous administration at a dose of about 3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain le region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, wherein at least one pharmacokinetic characteristic selected from the group consisting of: (a) a maximum serum concentration (Cmax) of n about 1 and about 60 µg/mL, and (b) an area under the serum concentration-time curve (AUC) of between about 125 and about 8,100 µgh/mL, is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.
29. The use of claim 28, wherein the Cmax is between about 12 and about 60 µg/mL. AH26(11269199_1):JJC
30. The use of claim 28, wherein the AUC is between about 1,100 and about 8,100 µgh/mL.
31. The use of any one of claims 14, 17, 20, 25 or 28, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is 13C5.5, or an antigen-binding portion thereof.
32. The use of any one of claims 14, 17, 20, 25 or 28, wherein in said treating, the medicament is administered once.
33. The use of any one of claims 14, 17, 20, 25 or 28, wherein in said treating, the medicament is administered weekly.
34. The use of claim 33, wherein in said treating, the medicament is administered for three weeks.
35. The use of any one of claims 14, 17, 20, 25 or 28, wherein said asthma is mild to moderate asthma.
36. The use of any one of claims 14, 17, 20, 25 or 28, wherein said ng further comprises the administration of an additional agent.
37. The use of claim 36, wherein said additional agent is selected from the group consisting of: a therapeutic agent, an g agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule r, an anti-cytokine antibody or functional fragment thereof; methotrexate, a cyclosporin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an anti-rheumatic, a muscle nt, a ic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a uscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an opoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone ement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a ant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an epinephrine or analog, a cytokine, and a cytokine nist.
38. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the ation of a medicament for treating asthma in a human subject by subcutaneous administration at a dose of about 0.3 mg/kg, n the anti-IL-13 antibody, or antigen binding portion thereof, comprises AH26(11269199_1):JJC the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, n at least one pharmacokinetic characteristic selected from the group consisting of: (a) a half-life of between about 24 and 31 days; (b) a Tmax of between about 3 and about 5 days; and (c) a bioavailability of at least about 60% is achieved following administration of the antibody, or antigen-binding portion f to said t.
39. The use of claim 38, wherein the bioavailability is at least about 70%.
40. Use of an anti-IL-13 antibody, or n-binding portion thereof, in the preparation of a medicament for treating asthma in a human t by subcutaneous administration at a dose of about 3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding n thereof, comprises the heavy chain le region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one pharmacokinetic characteristic selected from the group consisting of: (a) a half-life of between about 23 and 26 days; (b) a Tmax of less than or equal to about 5 days; and (c) a bioavailability of at least about 60% is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.
41. The use of claim 40, wherein the bioavailability is at least about 70%.
42. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating asthma in a human subject by intravenous administration at a dose of about 0.3 mg/kg, wherein the anti-IL-13 antibody, or antigen g portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one pharmacokinetic characteristic selected from the group consisting of: (a) a clearance rate of between about 0.11 to about 0.19 mL/hr/kg; and (b) a volume of distribution of between about 70 to about 130 mL/kg AH26(11269199_1):JJC is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.
43. Use of an L-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating asthma in a human subject by intravenous stration at a dose of about 3 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain le region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one pharmacokinetic characteristic selected from the group ting of: (a) a nce rate of between about 0.08 to about 0.14 mL/hr/kg; and (b) a volume of distribution of between about 55 to about 100 mL/kg is achieved following administration of the antibody, or antigen-binding n thereof to said subject.
44. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the ation of a medicament for treating asthma in a human subject by intravenous administration at a dose of about 10 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one pharmacokinetic characteristic selected from the group consisting of: (a) a clearance rate of between about 0.09 to about 0.13 mL/hr/kg; and (b) a volume of distribution of between about 85 to about 130 mL/kg is achieved following administration of the antibody, or antigen-binding portion thereof to said subject.
45. The use of any one of claims 38-44, wherein the anti-IL-13 antibody, or antigen-binding portion thereof, is , or an antigen-binding portion thereof.
46. The use of any one of claims 38-44, wherein in said treating, the medicament is administered once.
47. The use of any one of claims 38-44, wherein in said treating, the medicament is administered weekly.
48. The use of claim 47, n in said treating, the medicament is administered for 3 weeks. AH26(11269199_1):JJC
49. The use of any one of claims 38-44, wherein said asthma is mild to moderate asthma.
50. The use of any one of claims 38-44, wherein said treating further comprises administering an additional agent to said subject.
51. The use of claim 50, wherein said additional agent is selected from the group consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof; rexate, a cyclosporin, a rapamycin, an FK506, a detectable label or reporter, a TNF antagonist, an anti-rheumatic, a muscle relaxant, a narcotic, a non-steroid nflammatory drug (NSAID), an analgesic, an anesthetic, a ve, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a e replacement drug, a radiopharmaceutical, an pressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an oral steroid, an epinephrine or analog, a ne, and a cytokine antagonist.
52. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating asthma in a human subject by intravenous administration at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg, wherein the anti-IL-13 antibody, or antigen binding n thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain le region of SEQ ID NO:3, and wherein at least one of the pharmacokinetic teristics set forth in the specification, Tables or s is achieved following administration of the antibody, or n-binding portion thereof, to said subject.
53. Use of an anti-IL-13 antibody, or antigen-binding portion thereof, in the preparation of a medicament for treating asthma in a human t by subcutaneous administration at a dose of about 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg, wherein the anti-IL-13 antibody, or antigen binding portion thereof, comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable region of SEQ ID NO:3, and wherein at least one of the pharmacokinetic characteristics set forth in the specification, Tables or
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161507347P | 2011-07-13 | 2011-07-13 | |
US61/507,347 | 2011-07-13 | ||
PCT/US2012/045268 WO2013009521A2 (en) | 2011-07-13 | 2012-07-02 | Methods and compositions for treating asthma using anti-il-13 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ619873A NZ619873A (en) | 2016-05-27 |
NZ619873B2 true NZ619873B2 (en) | 2016-08-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10919961B2 (en) | Methods and compositions for treating asthma using anti-IL-13 antibodies | |
US20220289858A1 (en) | Anti-cd40 antibodies and uses thereof | |
RU2650767C2 (en) | Interleukin-13-binding proteins | |
US8624002B2 (en) | Prostaglandin E2 binding proteins and uses thereof | |
JP2012516153A (en) | IL-1 binding protein | |
AU2021203358B2 (en) | Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies | |
US20150203592A1 (en) | Compositions and methods for treating osteoarthritis | |
NZ619873B2 (en) | Methods and compositions for treating asthma using anti-il-13 antibodies |